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Organic synthesis is a powerful tool for molecular construction with notable 
applications to material sciences,[1] natural product syntheses[2] and life-saving 
pharmaceuticals.[3] In light of these transformative advantages, tremendous 
efforts have been devoted to the development of novel methods for molecular 
syntheses, which has resulted in diverse applications with countless benefits 
for society.[4] However, despite indisputable progress, organic syntheses, which 
has been dominated by the transformation of functional groups,[5] continues to 
be perceived as a polluting science due to inter alia waste generation, resource 
and energy consumption, and the use of often toxic and dangerous chemicals. 
In 1988, Warner and Anastas included catalysis as one of the “12 Principles of 
Green Chemistry”.[6] During the past century, catalysis has been recognized as 
a foundation of the chemical industries with significant achievements in 
developing economically, environmentally and technologically beneficial 
transformations.[7] 
A significant stimulus in organic synthesis was made by the emergence of direct 
functionalizations of omnipresent C–H bonds.[8] C–H functionalizations are 
environmentally-benign and economically-attractive, since they prevent lengthy 
synthetic operations and reduce waste generation by activating the inert C–H 
bonds directly instead of using pre-functionalized substrates (Scheme 1). 
 
Scheme 1 Traditional functional group interconversion versus C–H functionalization. 
                     1. Introduction 
2 
 
1.1 Transition Metal-Catalyzed C–H Activation 
1.1.1 The Concept of Transition Metal-Catalyzed C–H Activation 
Transition metal-catalyzed C–H activation involves the transformation of 
otherwise inert C–H bonds into C–Met bonds.[9] In this concept, the formation 
of an organometallic complex through C–H coordination of the inner-sphere of 
a metal is often important.[10] The intermediate produced by C–H activation can 
further undergo subsequent reactions to afford the functionalized products 
(Scheme 1.1). 
 
Scheme 1.1 C–H activation. 
1.1.2 Advantages of Transition Metal-Catalyzed C–H Activation 
Transition metal-catalyzed cross-couplings, such as the Suzuki-Miyaura, 
Negishi and Mizoroki-Heck reactions, are an important tool in organic synthesis 
for the formation of C–C bonds, which have been awarded the 2010 Nobel Prize 
in chemistry.[11] However, despite indisputable progress, cross-coupling 
reactions continue to be severely limited, due to inter alia the requirement of 
pre-functionalized substrates and organometallic compounds, which 
signifycantly decrease the user-friendliness, sustainability and step-economy. 
From this point of view, the direct activation of omnipresent C–H bonds would 
be a highly desirable alternative to conventional cross-couplings due to the 
avoidance of pre-functionalized substrates (Scheme 1.2). 




Scheme 1.2 Comparison of cross-coupling and C–H functionalization. 
In order to achieve an efficient direct C–H functionalization, a transition metal 
catalyst, which can directly react with a C–H bond to generate a C–M bond 
under mild conditions, is highly desirable. Partially, due to the high dissociation 
energy of C–H bonds (~110 kcal mol−1 for C(aryl)–H and ~ 105 kcal mol−1 for 
alkanes),[12] harsh conditions would be required to cleave the bond directly, thus 
resulting in a narrow substrate scope.[13] Additionally, the metallated 
intermediates can easily react with a number of different chemicals thereby 
allowing for a range of applications.[14]  
The fact that C–H bonds are omnipresent in organic molecules and have 
comparable dissociation energies represents a challenge for controlling the 
selectivity in direct C–H activation. To tackle this issue, various strategies have 
been developed based on the transition metal catalyst’s mode of action, for 
example 1) electronic bias,[15] 2) steric control,[16] and 3) directing group-
assisted C–H activation[17] (Scheme 1.3a). Since approaches based on 
electronic and steric biases highly depend on the nature of the substrates, this 
strategy is typically limited in terms of viable scope. In sharp contrast, by a 
directing group (DG) which coordinates to the metal center of the catalyst and 
directs the catalyst to a proximal position, selective C–H activation could be 
achieved with a broad variety of substrates. Furthermore, considerable 
attention has been devoted to the development of weakly coordinating,[18] 
removable[19, 17c] or transient[20] directing groups (Scheme 1.3b). 




Scheme 1.3 Positional selectivity in C–H activation. 
1.1.3 Mechanisms of Transition Metal-Catalyzed C–H Activation 
As a better understanding of the elementary C–H cleavage step would allow for 
the design of more efficient catalytic C–H functionalizations, intensive studies 
have been devoted to elucidate various C–H activation modes.[21] Depending 
on the metal fragment, C–H metalation can proceed via several distinct reaction 
pathways:[21a] a) oxidative addition with electron-rich, low-valent complexes of 
late transition metals, b) electrophilic substitution with late transition metals in 
higher oxidation states where the metal acts as a Lewis acid, c) σ-bond 
metathesis with early transition metals, typically involving an alkyl- or hydride-
metal complex, as well as lanthanides and actinides,[21b] d) 1,2-addition with 
unsaturated M=X bonds, such as metal imido, oxo and alkylidene complexes, 
and e) base-assisted metalation most commonly with carboxylate ligands 
(Scheme 1.4).[21a]  




Scheme 1.4 Viable modes of organometallic C–H activation. 
Over the past few years, several transition states of base-assisted C–H 
metalation were proposed (Scheme 1.5).[21a] The concerted metalation-
deprotonation (CMD)[22] describes the synergistic interaction between the metal 
center, the carboxylate-ligand and the C–H bond via a six-membered transition 
state. For the ambiphilic metal-ligand activation (AMLA),[23] a similar transition 
state has been proposed. Both transition states are characterized by a 
preference for kinetically C–H-acidic substrates. As an explanation for the 
preference of electron-rich substrates in several catalytic transformations, the 
concept of base-assisted internal electrophilic substitution (BIES) has been 
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proposed by Ackermann.[24] In contrast to the six-membered transition states, 
the term internal electrophilic substitution (IES)[25] which was proposed for the 
reaction involving alkoxide bases featured a transition state with a highly 
strained four-membered ring, basically a σ-bond metathesis. Based on 
Ackermann’s BIES, Carrow coined this mechanistic manifold very recently as 
e-CMD.[26]  
 
Scheme 1.5 Proposed transition states for base-assisted C–H metalations. 
1.2 Iron-Catalyzed C–H Activation  
Transition metal-catalyzed C–H functionalization has been recognized as a 
powerful tool for molecular syntheses. [9, 14, 17a] Thus far, C–H functionalizations 
were often achieved with precious transition metal catalysts, for instance, 
palladium, iridium, rhodium and ruthenium. However, these noble late transition 
metals normally feature high costs,[27] a low natural abundance[28] and a high 
toxicity,[29] which highly decreases the sustainability and economic efficiency of 
the approach. As a direct consequence, the development of transformations 
under 3d transition metal catalysis,[30] and especially iron,[31] has attracted 
considerable attention due to their high Earth-abundance, cost-efficiency, and 
low toxicity.[32]  
Owing to the electron configuration of iron, iron catalysts can access various 
oxidation from −2 to +6 and spin states and can easily undergo single electron 
transfer (SET) processes. These properties enable iron catalysts to be 
employed in a wide range of transformations.[33]  
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In general, iron in low oxidation states exhibits nucleophilic properties, which 
enables a number of organic transformations, such as nucleophilic 
substitutions, reductions, cycloisomerizations, or cross coupling reactions,[34] 
while in higher oxidation states, iron behaves as a Lewis acid, thus activating 
unsaturated bonds.[35]  
Inspired by early studies of catalytic C–C bond formations,[36] the scientific 
community focused their attention on the development of efficient iron catalysts 
systems for sustainable C–H activation strategies. Indeed, low-valent iron 
species were found to be effective for the activation of C(sp2)–H as well as 
C(sp3)–H bonds under mild reaction conditions, providing an environmentally 
benign and atom-economical alternative for the construction of novel C–C and 
C–Het bonds.[31] 
1.2.1 Early Reports on Iron-Catalyzed C–H Activation 
In 1968, an early example of stoichiometric organometallic C–H activation was 
reported, in which an ortho-C–H bond was oxidatively added to an iron(0) 
center to form the hydride ferracycle complex 2 through irradiation of the 
[Fe(dppe)2·C2H4] complex 1 (Scheme 1.6).[37]  
 
Scheme 1.6 Stoichiometric organometallic C–H activation. 
Stoichiometric cyclometallations of organic compounds with iron complexes 
were subsequently described.[38] A representative example is the stoichiometric 
cyclometallation of aryl imines with Fe(PMe3)4 or FeMe2(PMe3)4, which was 
reported by Klein.[39] C–H activation of benzaldimine 3a by FeMe2(PMe3)4 
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proceeds via σ-bond metathesis, while cyclometallation was proposed to 
proceed via nitrogen-assisted C–H oxidative addition when Fe(PMe3)4 and 
ketimine 3b were employed (Scheme 1.7). 
 
Scheme 1.7 Directed stoichiometric C–H activation. 
Two notable aspects of this stoichiometric C–H activation are: 1) Nitrogen-
directed C(sp2)–H activation is possible, ideally with iron(0) through oxidative 
addition or with a methyliron(II) species via σ-bond metathesis, and 2) the 
iron(0) complex displayed a higher reactivity towards C–H bond activation as 
compare to N–H bond cleavage.  
In 1987, Jones disclosed the first example of iron-catalyzed C–H 
functionalization.[40] The catalyst 8 generated from Fe(PMe3)4 and isocyanide 7 
enable the successful transformation of aldimine 9 from benzene 6 (Scheme 
1.8). The key to success in this reaction was the low concentration to avoid 
substrate inhibition and the use of UV irradiation for the generation of active 
iron species. 
 
Scheme 1.8 Iron-catalyzed C–H functionalization of benzene. 
In 2006, Nakamura disclosed an example of iron-catalyzed direct C–H 
activation was disclosed by through a serendipitous observation during iron-
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catalyzed cross-coupling reactions (Scheme 1.9).[41] Here, a C–H 
functionalized product, 2-biphenylpyridine 12, was observed in the cross-
coupling of 2-bromopyridine 10 and a phenylzinc reagent. In order to develop 
an efficient iron-catalyzed C–H activation system, the authors analyzed the 
reaction, which resulted in a number of significant observations: 1) an oxidant 
is necessary for catalyst turnover, 2) a nitrogen-based ligand is crucial for this 
transformation, and 3) the coupling partner is an in situ formed organic zinc 
reagent rather than the Grignard reagent. 
 
Scheme 1.9 Iron-catalyzed C–H arylation. 
Two years later, Nakamura reported an iron-catalyzed direct C–H activation 
with phenanthroline 14 as the ligand and dichloroisobutane 15 (DCIB) as the 
oxidant of choice (Scheme 1.10).[42]  
 
Scheme 1.10 Iron-catalyzed direct C–H activation.  
Subsequent studies using monodentate directing groups,[43] such as imines, 
amides, ketones, esters, and pyridines, led to major advancement in the field of 
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iron-catalyzed C(sp2)–H arylations and alkylations. A breakthrough in iron-
catalyzed C–H functionalization was represented by the application of 
bidentate[9a, 9g] directing groups, which not only provided an access to 
unprecedented C(sp3)–H activations, but also significantly diversified possible 
transformations. Major progress in the field of bidentate directing group-
assisted iron-catalyzed C–H functionalizations was achieved by Nakamura[31a] 
with 8-aminoquinoline (Q) group and by Ackermann[31b] with the easily 
accessible triazolyldimethylmethyl (TAM) group. 
1.2.2 Iron-Catalyzed C–H Activation with Organometallic Reagents 
At an early stage, major progress in this research field was achieved by the 
development of direct arylations of C(sp2)–H bonds using monodentate 
directing groups, including: 1) functionalizations of olefinic C(sp2)–H bonds,[43g] 
2) without zinc additives,[43h] 3) replacing Grignard reagents with metallic 
magnesium,[43e] and 4) the use of synthetically useful imines[43c, 43h, 43j] and 
amides[43f] as the directing group.  
C(sp3)–H functionalizations were realized by bidentate directing group 
assistance through low-valent iron catalysis. In this context, Nakamura reported 
on 8-aminoquinoline group-assisted direct arylations of aliphatic amides 17 with 
in situ generated aryl zinc reagents (Scheme 1.11a).[44] In contrast, Ackermann 
developed a powerful method employing the TAM group, a highly effective 
bidentate directing group, for the direct arylation of aromatic and aliphatic 
amides 20 and 23 (Scheme 1.11b).[45] It is worth noting that a bidentate 
phosphine ligand, such as dppbz 18 or dppe 21, was necessary for these 
transformations, whereas nitrogen-based ligands turned out to be ineffective. 
Recently, Ackermann successfully used environmental friendly electricity as 
oxidant instead of DCIB for the iron-catalyzed C–H arylation.[46] 




Scheme 1.11 Bidentate directing group-assisted iron-catalyzed C–H arylation. 
In addition, lithium borate salts 26 proved to be a viable alternative to Grignard 
reagents for the low-valent iron-catalyzed C–H alkenylation (Scheme 1.12a).[47] 
Since various alkenylboronates are easily available and the corresponding 
magnesium reagents are usually difficult to prepare, this transformation shows 
a broader substrate scope as compared to the approach using 
alkenylmagnesium bromide 28 (Scheme 1.12b).[48]  




Scheme 1.12 Iron-catalyzed C–H alkenylation. 
Apart from arylations and alkenylations, considerable achievements were also 
accomplished in iron-catalyzed C–H alkylations using alkyl aluminium 
reagents[49] or in situ alkyl formed zinc reagents.[48, 50] 
1.2.3 Iron-Catalyzed C–H Activation with Organic Electrophiles 
Despite indisputable progress in iron-catalyzed C–H activations with 
nucleophilic coupling partners, in most of the cases, stoichiometric amounts of 
expensive and toxic DCIB is needed as an oxidant to guarantee an efficient 
transformation (Scheme 1.13, path a). Recently, a major advancement in iron-
catalyzed C–H activation was represented by reacting the in situ generated iron 
species with various organic electrophiles, thus avoiding the use of external 
oxidants (scheme 1.13, path b). In this context, C–H transformations including 
alkylation,[51] allylation[51a, 52] and alkynylation[53] were accomplished, employing 
electrophiles in bidentate directing group-assisted low-valent iron catalysis. 




Scheme 1.13 Bidentate directing group assisted iron-catalyzed C–H arylation. 
Nakamura reported iron-catalyzed C–H allylations with allyl phenyl ethers 30 
as the organic electrophiles (Scheme 1.14a).[52] The fact that allyl phenyl ether 
30 could be used as the electrophile in iron-catalyzed C–H functionalizations, 
was serendipitously discovered during their optimization of oxidants for iron-
catalyzed arylations of N-phenylpyrazole with diarylzinc. In this approach, C–H 
methylations and arylations in the presence of organozinc reagents, such as 
Me2Zn or Ph2Zn, was observed, suggesting that an appropriate organometallic 
base was crucial for the transformation. To further gain insights into the 
catalyst’s mode of action, deuterated allyl phenyl ether [D]2-30 was subjected 
 
Scheme 1.14 Iron-catalyzed C–H allylations with allyl phenyl ethers. 
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to the reaction. Selectively γ,γ-deuterated-product [D]2-31 was observed,   
providing strong support for a SN2-type mechanism (Scheme 1.14b). 
In a report by Ackermann, a widely applicable method for C–H allylations 
employing the user-friendly TAM group was disclosed.[51a] Various aromatic, 
heteroaromatic and olefinic benzamides 32 were found to be applicable in the 
transformation (Scheme 1.15a). Notably, the branched allylated product 
34e/34f was formed with comparable levels of regioselectivity with (E)-crotyl 
chloride 33a or the secondary allyl chloride 33b, providing support for the 
formation of a η3-allyl intermediate (Scheme 1.15b).[54] 
 
Scheme 1.15 Iron-catalyzed C–H allylation with allyl halides. 
The concept was further expanded to iron-catalyzed C–H alkylation and 
benzylation using alkyl and benzyl electrophiles. 
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For the alkylation reported by Nakamura, an excess of NaI was crucial for 
suppressing the undesired C–H arylation, thereby allowing for an efficient 
transformation (Scheme 1.16).[51c] Interestingly, the diastereochemical 
information was partially deteriorated in 36a when using diastereochemically 
well-defined trans-4-tert-butylcyclohexyl tosylate 35a. In addition, the catalytic 
activity was completely inhibited when the radical scavenger TEMPO was 
added. These observations highlight the radical character of the C–O cleavage 
process.[55] 
 
Scheme 1.16 Iron-catalyzed C–H alkylation with tosylates. 
In a contribution by Cook, alkyl and benzyl halides were employed for 
alkylations and benzylations in which NaI or zinc salt as additives were not 
necessary (Scheme 1.17a).[51b] The key to success in this reaction was the slow 
addition of the Grignard reagent and the use of BHT in the transformation of 
secondary alky halides 38. In addition, based on the slow addition procedure 
and the short reaction time, the authors proposed that a phenyliron species 
formed by transmetallation from PhMgBr, which immediately undergoes 
turnover-limiting coordination of the amide substrate, followed by rapid, 
irreversible C–H cleavage. Furthermore, Ackermann described an approach for 
methylation, alkylation and benzylation utilizing the modular click-triazole-
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based TAM as the directing group (Scheme 1.17b).[51a] This powerful procedure 
enabled the C–H alkylations with alkyl iodides, bromides, and even chlorides 
as the electrophile. Detailed studies revealed the reaction to proceed via a SET-
induced C–Hal cleavage. 
 
Scheme 1.17 Iron-catalyzed alkylation and benzylation of amides with halides. 
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1.2.4 Iron-Catalyzed C–H Annulation Reactions 
Apart from their application to C–H alkylation, arylation and allylation reactions, 
low-valent iron species, which can be coordinated by the π-systems of 
alkynes,[56] can promote C–H annulation reactions. 
Thus, Nakamura reported the iron-catalyzed oxidative [4 + 2] annulation of 2-
biaryl Grignard reagents 42 with alkynes 43 for the synthesis of phenanthrene 
derivatives 44 (Scheme 1.18a).[57] Notably, not only internal alkynes but also 
terminal alkynes could be transformed. In addition, a similar approach for iron-
catalyzed oxidative [2 + 2 + 2] annulations of aryl Grignard reagents 45 with two 
molecules of an internal alkyne 43a was achieved by the authors.[58] 
Mechanistically, the reaction was proposed to proceed through iron-catalyzed 
carbometalation of the alkyne 43a with the aryl Grignard reagent 45, 
subsequent with intramolecular C–H activation to form the five-membered 
ferracycle 46. Then insertion of a second molecule of alkyne 43a takes place 
to form intermediate 48, which undergoes reductive elimination and oxidation 
to afford the final product 49 and regenerate the active iron species (Scheme 
1.18b). Furthermore, a combination of arylindium reagents with alkyl Grignard 
reagents was found to be a viable alternative for the synthesis of phenanthrene 
derivatives under redox-neutral conditions.[59] 
 




Scheme 1.18 Iron-catalyzed annulation of alkynes with aryl Grignard reagents. 
Nakamura[60] and Ackermann[61] reported iron-catalyzed formations of pyridone 
50 and isoquinolone derivatives 52 by assistance of the well-established Q and 
the modular triazolylmethyl (TAH) groups, respectively (Scheme 1.19). In 
contrast to iron-catalyzed transformations using organometallic reagents[45] or 
organic electrophiles,[51a] which prefer the bulky TAM group, the TAH group was 
shown to be more suitable for oxidative annulations. 




Scheme 1.19 Iron-catalyzed C–H annulations. 
Inspired by the work of Reed on iron(0)-mediated imine cyclometallations,[62] 
Wang developed Fe3(CO)12 catalyzed redox-neutral cyclizations of internal 
alkynes 43 with imines 53 for the synthesis of 3,4‐dihydroisoquinolines 54 
(Scheme 1.20).[63] Despite this transformation featured neat reaction conditions, 
the coupling partners were limited in diarylethynes and poor regio-selectivity 
was observed when asymmetric alkyne was employed.  
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Scheme 1.20 Iron-catalyzed C–H redox-neutral [4+2] cyclization. 
Despite considerable progress, iron-catalyzed C–H annulation reactions, thus 
far limited to alkynes as coupling partners, employing unsaturated coupling 
partners such as allenes and BCPs have not been developed. 
Allenes have been recognized as increasingly useful building blocks in modern 
synthetic chemistry,[64] due to inter alia their transformative utility,[65] and various 
bioactive compounds and functional materials containing an allene moiety.[66] 
However, compared to alkyne and alkene transformations,[67] the application of 
allenes in catalyzed C–H activation remains underdeveloped, and thus far 
dominated by precious 4d and 5d transition metals.[68] 
Bicyclopropylidenes (BCPs) featuring two cyclopropane rings were identified as 
a useful structural motif for six membered ring formation.[69] However, their 
applications in C–H activation are narrow with three ruthenium-catalyzed C–H 
hydroarylations being reported, in which the cyclopropane rings are 
conserved.[70]   
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1.3 Transition Metal-Catalyzed C–H/C–C Activation 
Transition metal-catalyzed C–H activation has gained significant attention for 
efficient C–C and C–Het formations. The past decade has witnessed the 
emergence of selective C–C cleavages as a powerful tool for the construction 
of increasingly complex molecules,[71] despite C–C bonds usually being less 
sterically accessible and having less favorable orbital interactions with 
transition metal catalyst compared to C–H bonds.[72] Significant progress in this 
field was recently made by merging C–H activation with challenging C–C 
activation,[73] which provided a new strategy for overcoming synthetic 
challenges and a method for the convenient preparation of novel molecules 
(Scheme 1.21). 
Scheme 1.21 Merging C–H activation with C–C activation. 
To date, several mode of actions have been suggested for this novel strategy 
depending on the different kinds of substrates, including mainly: 1) combination 
of decarboxylation and C–H activation,[74] 2) merging decarbonylation with C–
H activation,[75] and 3) functionalization of strained carbocycles[76] (Scheme 
1.22). The tandem reactions of decarboxylation and concomitant C–H 
activation is highly desirable, due to the abundance and availability of aromatic 
carboxylic acids. For a successful transformation, a fine-tuning of the 
experimental conditions is required to avoid protodecarboxylation without C–H 
activation as well as C–H bond activation without decarboxylation (Scheme 
1.22a). The decarbonylation of aldehydes through dual C–H and C–C activation 
became attractive to the scientific community after Wilkinson’s catalyst was 
found to be effective for this transformation.[75a, 75d–75f] Typically, the 
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decarbonylation includes two elementary steps. First, C–H activation of the 
aldehyde occurs, followed by C–C cleavage and CO extrusion (Scheme 1.22b). 
The strain-release of highly strained carbocycles enabled C–C cleavages by 
the assistance of transition metals (Scheme 1.22c),[77] which provided access 
to novel molecules.[78] 
 
 
Scheme 1.22 Manifolds of merging C–H activation and C–C cleavage.  
The first example of this dual activation mode was reported by Bergman during 
a study on the mechanism of the formation of rhodacyclobutane 58 (Scheme 
1.23).[79] The C–H bond of 1,1-dimethylcyclopropane 55 was activated by the 
rhodium species 56 at low temperature. Subsequently, by warming up the 
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reaction mixture, C–C bond insertion took place to give the 
thermodynamic product 58. 
 
Scheme 1.23 Dual activation of C–H and C–C bonds.  
Inspired by the pioneering work of Bergman, strained ring systems for C–H and 
C–C dual activations have thus been intensively studied.[80] In 2000, Shair 
reported the rhodium-catalyzed intramolecular C–H activation and C–C 
cleavage for the formation of cyclooctenone 63.[81] The C–H activation of the 
aldehyde moiety in 59 takes place first, then intermediate 60 undergoes 
intramolecular hydrometallation to form intermediate 61. After ring opening and 
reductive elimination, the final product 63 is obtained (Scheme 1.24). In order 
to avoid decarbonylation and guarantee high yields ethylene was necessary. 
 
Scheme 1.24 Synthesis of cyclooctenone through dual C–H and C–C activation. 
In 2011, Orellana disclosed the synthesis of benzodiquinanes 65 through 
palladium-catalyzed oxidative ring expansion of 1-vinyl-1-cyclobutanols 64 
(Scheme 1.25).[82] The generally moderate yields observed in this 
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transformation suggested the existence of other pathways, which led to several 
byproducts.  
 
Scheme 1.25 Palladium-catalyzed oxidative ring expansion reaction. 
The dual activation strategy was also viable for intermolecular reactions using 
rhodium or ruthenium catalysts.[83] An early example of a dual activation 
manifold for intermolecular reactions was disclosed by Ackermann during their 
research on ruthenium-catalyzed hydroarylations of methylenecyclopropanes  
 
Scheme 1.26 Ruthenium-catalyzed hydroarylation reactions. 




67 (Scheme 1.26a).[70b, 70c] It is worth noting that in the reactions with 
methylenecyclopropanes 67 or bicyclopropylidenes 70, the strained rings were 
conserved (Scheme 1.26a and 1.26b), while in the hydroarylation with 
benzhydrylidenecyclopropane 72 C–C cleavage occurred (Scheme 1.26c). 
In 2013, Wu developed an intermolecular tandem C–H and C–C activation 
during their research on rhodium-catalyzed C–H annulations of benzamide with 
methylenecyclopropanes (Scheme 1.27).[84] From a mechanism perspective, 
C–H activation proceeds through a concerted metalation-deprotonation 
sequence, followed by coordination and insertion of methylenecyclopropane 67 
to furnish 75, the arylrhodium intermediate 76 then undergoes β-C-elimination 
and reductive elimination to yield product 77.  
 
Scheme 1.27 Intermolecular tandem C–H and C–C activation. 
During the past years, 3d metal catalysis was proven to be an ideal alternative 
for tandem C–H and C–C activations.[24c, 85] In 2016, Ackermann disclosed the 
first example of cobalt-catalyzed C–H activation and C–C cleavage (Scheme 
1.28a).[85d] The reaction featured a high catalytic efficacy at room temperature. 
In addition, this transformation resulted in an unprecedented 
diastereoselectivity affording the thermodynamically less stable Z-alkenes 81 
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as the product. One year later, Ackermann reported the formation of tetracyclic 
compounds 84 through manganese-catalyzed stereoselective C–H/C–C 
activation with methylenecyclopropane 83 (Scheme 1.28b).[24c] Excellent levels 
of positional selectivity as well as diastereoselectivity were achieved in this 
transformation. 
 
Scheme 1.28 3d metal-catalyzed tandem C–H and C–C activation. 
Tandem C–H activation/C–C cleavage reactions can also occur under 
assistance of bidentate directing groups, using cobalt acetate as the catalyst 
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(Scheme 1.29).[85a] Instead of a reductive elimination to form a C–N bond, which 
is observed in the rhodium-catalyzed annulation of alkylidenecyclopropanes 
annulations,[84] a second C–H activation occurred to form the ring opening 
product 87 under cobalt catalysis.  
 
Scheme 1.29 Cobalt-catalyzed C–H/C–C/C–H activation. 
  




Transition metal-catalyzed C–H activations have emerged as a powerful 
platform for efficient and sustainable C–C and C–Het bond formations. While 
most transformations were accomplished with precious and toxic 4d and 5d 
metal catalysts, sustainable catalytic manifolds by 3d metal catalysis,[30]  and 
especially iron-catalyzed C–H transformations,[31, 33, 86] have attracted 
significant attention due to their Earth-abundance, cost-efficiency, and low 
toxicity.[32]  
Despite considerable progress, iron-catalyzed C–H annulation reactions[57–61, 63] 
continue to be challenging transformation with major limitations in: 1) types of 
coupling partners with only alkynes were reported thus far, 2) the requirement 
of an excess of DCIB as an external oxidant, 3) lack of product diversity, due to 
a narrow substrate scope in some cases, 4) not fully elucidated reaction 
mechanism, and 5) absence of efficient protocols for removal of the TAH group. 
Therefore, it is highly desirable to establish a novel approach for low-valent iron-
catalyzed C–H annulations with allenes under redox-neutral conditions 
(Scheme 2.1). 
 
Scheme 2.1 Iron-catalyzed redox-neutral annulation with allenes. 
Remaining limitations in iron-catalyzed C–H alkyne annulation, such as the lack 
of detailed mechanistic studies and efficient procedures to remove the TAH 
group, promoted us to develop iron-catalyzed C–H annulations with propargyl 
acetates with the main purpose to shed light on the mechanism of iron-
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catalyzed redox-neutral annulations with alkynes and the removal of TAH group 
(Scheme 2.2). 
 
Scheme 2.2 Iron-catalyzed redox-neutral annulation with alkynes. 
A significant stimulus in C–H activation chemistry was recently gained by 
merging C–H activation with challenging C–C cleavages.[71, 73] While 
considerable progress has been achieved, this methodology was still limited by 
1) the requirement of precious metals,[83–84] 2) activated 
vinylcyclopropanes,[24c, 85b-85d] and 3) harsh oxidative conditions.[85a] Thus, a 
protocol to overcome these limitations would be highly desirable.  
To combine C–H activation with challenging C–C activation under iron catalysis 
as well as to further diversify the application of BCPs in C–H activation, the 
application of bicyclopropylidene derivatives in iron-catalyzed C–H/C–C 
activation should prove highly valuable (Scheme 2.3). 




Scheme 2.3 Iron-catalyzed C–H/C–C activation with BCPs. 
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3. Results and Discussion 
3.1 Iron-Catalyzed C–H/N–H Allene Annulation 
Iron-catalyzed C–H oxidative annulations have emerged as a powerful tool for 
N-heterocycle constructions. While these strategies were limited to alkynes as 
the coupling partners and highlighted the requirement of an excess of DCIB as 
the external oxidant, a study of iron-catalyzed C–H oxidative annulations with 
alternative coupling partners under redox-neutral conditions would be highly 
considerable.  
3.1.1 Optimization Studies 
The optimization studies began by probing various reaction conditions for the 
envisioned iron-catalyzed C–H functionalization of benzamide 51a with allene 
88a (Table 3.1). The investigation on the amount of solvent and the addition 
order of allenes (see general procedure GPA’) indicated that a high 
concentration of Grignard reagent and zinc salts was required for the formation 
of the active iron catalyst (entries 1–3). In addition, the use of biomass-derived 
solvent[87] 2-MeTHF delivered product 89aa in moderate yield (entry 4). iPrMgBr 
proved to be the additive of choice (entries 5 and 6). The allene annulation 
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Table 3.1 Optimization of iron-catalyzed C–H activation with allenes 88a.  
 
Entry X mol % Grignard reagent Solvent (y mL) Yield/% 
1 15 iPrMgBr THF (1.0) 44[b] 
2 15 iPrMgBr THF (0.4) 91 
3 15 iPrMgBr THF (0.4)  46[c] 
4 15 iPrMgBr 2-MeTHF (0.4)  59[b] 
5 15 MeMgBr THF (0.4) 71 
6 15 iPrMgCl THF (0.4) 64 
7     15 iPrMgBr THF (0.4) 66[d] 
8 1 iPrMgBr THF (0.4) 38 
9 5 iPrMgBr THF (0.4) 35 
10 10 iPrMgBr THF (0.4) 82 
[a] Reaction conditions: 51a (0.30 mmol), 88a (3 equiv), Fe(acac)3 (x mol %), dppe (15 mol %), 
ZnBr2·TMEDA (2 equiv), Grignard reagent (3.0 M, 3 equiv), Solvent (y mL), 65 °C, 16 h; yields 
of isolated products. [b] used 51a (0.15 mmol) [c] adding 88a at the same time with catalyst. [d] 
25 °C. 
To further optimize the reaction, different types of catalyst, ligand and leaving 
group were tested in the transformation (Table 3.2). The unique power of the 
iron catalysis regime was reflected by cobalt, manganese and nickel catalysts 
falling short in providing the desired product 89aa (entries 1–5). Various simple 
phosphine and nitrogen-based ligand were also tested, but failed to provide the 
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desired product 89aa in synthetically useful yields (entries 6–12). The 
investigation on different leaving groups revealed allenyl acetate 88a to be 
optimal for an external-oxidant-free C–H annulation (entries 13–17). 
Table 3.2 Optimization of iron-catalyzed C–H activation with allenes 88.  
 
Entry [TM] Ligand LG Yield [%] 
1 --- dppe OAc (88a) --- 
2 CoCl2 dppe OAc (88a) --- 
3 MnCl2 dppe OAc (88a) --- 
4 Ni(acac)2 dppe OAc (88a) --- 
5 Fe(acac)3 dppe OAc (88a) 91 
6 Fe(acac)3 dppen OAc (88a) 25 
7 Fe(acac)3 dppz OAc (88a) trace 
8 Fe(acac)3 PPh3 OAc (88a) --- 
9 Fe(acac)3 dppp OAc (88a) --- 
10 Fe(acac)3 Xantphos OAc (88a) --- 
11 Fe(acac)3 phen OAc (88a) --- 
12 Fe(acac)3 2,2’-bipyridine OAc (88a) --- 
13 Fe(acac)3 dppe Cl (88b) 16 
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14 Fe(acac)3 dppe OP(O)(OEt)2 (88c) 16 
15 Fe(acac)3 dppe OC(O)Ph (88d) 30 
16 Fe(acac)3 dppe OC(O)OMe (88e) 35 
17 Fe(acac)3 dppe OH (88f) --- 
[a] Reaction conditions: 51a (0.30 mmol), 88 (0.90 mmol), [TM] (15 mol %), Ligand (15 mol %), 
ZnBr2·TMEDA (0.60 mmol), iPrMgBr (3.0 M, 0.90 mmol), THF (0.40 mL), 65 °C, 16 h; yields of 
isolated products.  
 
3.1.2. Impact of Directing Group on C–H Functionalization 
With the optimized condition in hand, we further tested the impact of various 
bidentate directing group on this transformation (Table 3.3). Thus, a variety of 
methylene-tethered triazoles TAH delivered the desired isoquinolones 89aa–
89da in high yields (entries 1–4), tolerating among others a reactive alkyl 
chloride 51d without any cross-coupling products being observed. In addition, 
the modular nature of the triazole group further enabled the synthesis of the 
non-aromatic exo-methylene dihydroisoquinolines 90 through the judicious 
choice of the TAM group which was proved to be invalid for iron-catalyzed C–
H annulation with alkynes[61] (entries 5–7). However, other bulky groups at the 
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Table 3.3 Impact of directing group on C–H functionalization.  
 
 












































































































[a] Reaction conditions: 51/32 (0.30 mmol), 88a (0.90 mmol), Fe(acac)3 (15 mol %), dppe 
(15 mol %), ZnBr2·TMEDA (0.60 mmol), iPrMgBr (3 M, 0.90 mmol), THF (0.40 mL), 65 °C, 16 
h; yields of isolated products. 
 
No transformation was observed when employing bidentate directing groups 
which were otherwise widely used in 3d transition metal catalyzed system 
(Scheme 3.1). These observations suggested that the structure as well as the 
electronic properties of the directing group are crucial to achieve successful C–
H activation catalyzed by the in situ generated low-valent iron species. 
 




Scheme 3.1 Limitations on directing group.[a]  
3.1.3. Substrate Scope and Limitations 
Under the optimized iron-catalyzed C–H activation conditions, we next explored 
its versatility with a range of substituted TAH-benzamides 51 (Table 3.4). With 
regard to para-substituted TAH-benzamides 51e–51j, the corresponding 
isoquinolone products 89ea–89ja were obtained in moderate to high yields, 
(entries 2–7). Likewise, chloro at the para-position 51j were efficiently 
converted to synthetically useful isoquinolones without any dehalogenation 
product being observed (entrie 7). Di-substituted benzamides 51k and 51l 
yielded the corresponding products 89ka and 89la in good regioselectivity 
(entries 8 and 9). Furthermore, thiophenyl-derived benzamide 51m furnishing 
the desired products 89ma in moderate yield, while furanyl-derived benzamide 
51n proved to be unsuitable for the transformation (entries 10 and 11). 
Unfortunately, the olefinic C(sp2)–H and aliphatic C(sp3)–H bond were 
incompatible for this transformation (entries 12–14). 
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Table 3.4 Substrate scope of TAH benzamide 51. 
 
























































































































[a] Reaction conditions: 51 (0.30 mmol), 88a (0.90 mmol), Fe(acac)3 (15 mol %), dppe 
(15 mol %), ZnBr2·TMEDA (0.60 mmol), iPrMgBr (3.0 M, 0.90 mmol), THF (0.40 mL), 65 °C, 
16 h; yields of isolated products.  
The modular nature of the triazole group TAM provided an access to various 
exo-methylene isoquinolines 90 with ample scope (Table 3.5). Differently 
decorated aromatic amides delivered the desired products 90fa–90ja with high 
levels of positional selectivity control, with the reaction occurring at the less 
sterically congested site (entries 1–6). However, other types of C(sp2)–H bond, 
such as in furanyl-, naphthyl-, olefinic and C(sp3)–H bonds fell short in the 
envisioned iron-catalyzed annulations (entries 7–11). 
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Table 3.5 Substrate scope of TAM benzamide. 
 
Entry 32 90 Yield [%] 
 
1 






































































[a] Reaction conditions: 32 (0.30 mmol), 88a (0.90 mmol), Fe(acac)3 (15 mol %), dppe 
(15 mol %), ZnBr2·TMEDA (0.60 mmol), iPrMgBr (3.0 M, 0.90 mmol), THF (0.40 mL), 65 °C, 
16 h; yields of isolated products.  
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Furthermore, the versatile iron catalyst further enabled the efficient conversion 
of decorated allenes 88 and TAM-benzamide 32a to furnish the corresponding 
exo-methylene isoquinolines 90 with moderate to high yields (Table 3.6). Allenyl 
acetates bearing alkyl groups with different chain-lengths and functional group 
were efficiently converted (entries 1–4). Allenes with aromatic substituted at the 
α-position of acetate group or the di-substituted allene failed to give the product 
(entries 5–7).  
Table 3.6 Substrate scope of TAM substrate 32a with various allenes 88. 
 













































[a] Reaction conditions: 32a (0.30 mmol), 88 (0.90 mmol), Fe(acac)3 (15 mol %), dppe 
(15 mol %), ZnBr2·TMEDA (0.60 mmol), iPrMgBr (3.0 M, 0.90 mmol), THF (0.40 mL), 65 °C, 16 
h; yields of isolated products.  
3.1.4 Traceless Removal of TAM Group 
The TAM directing group was tracelessly removed in a user-friendly one-pot 
fashion further illustrate the synthetic utility of the iron-catalyzed redox-neutral 
C–H annulation with allenes (Scheme 3.2).  
 
Scheme 3.2 Traceless removal of TAM group.  
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Crystals suitable for X-ray diffraction were then grown by slow evaporation, 
unambiguously confirming the connectivity of product 89la (Scheme 3.3). 
 
Scheme 3.3 Molecular structure of 89la with thermal ellipoids at 50% probability level. 
The crystal structure was measured and solved by Dr. Christopher Golz. 
3.1.5 Mechanistic Studies 
Given the unique features of the developed iron-catalyzed C–H annulation, we 
became intrigued by studying its mode of action. Mechanistic approaches 
including experiment, Mössbauer spectroscopy and DFT computation were 
carefully conducted to reveal the detail mechanism. 
Competition Experiment 
Intermolecular competition experiments revealed an inherent higher reactivity 
of electron-deficient arenes 51h (Scheme 3.4), indicating a ligand-to-ligand 
hydrogen transfer (LLHT)[24d, 46, 88] mechanism which prefer a kinetically C–H-
acidic substrates to be operative for the C–H activation. Different from σ-bond 
metathesis with early transition metals and base-assisted metalation most 
commonly with carboxylate ligands, the LLHT was reported in the cases with 
late transition metals and normally with nitrogen ligands. 
 




Scheme 3.4 Competition reaction of iron-catalyzed C–H/N–H annulation.  
Reactions with Isotopically-labelled Substrates 
A C–D functionalization with the isotopically labelled substrate [D]5-51a either 
by independent reactions using in situ React-IR measurement (Scheme 3.5a) 
or an intermolecular KIE measurement through a one-pot reaction fashion 
(Scheme 3.5b), showed no significant kinetic isotope effect (kH/kD = 1.2 or 1.5), 
providing support for a facile C–H cleavage which is not the rate-determining 
step of the overall reaction.  
 
Scheme 3.5 KIE studies of iron-catalyzed C–H annulation with allenes 88a.  
No deuterium scrambling was observed when isotopically labelled substrate 
[D]5-51a was employed (Scheme 3.6a). Furthermore, deuterium scrambling 
was not observed when using deuterium-labelled solvent (Scheme 3.6b) or 
isotopically labelled substrate [D]1-51a (Scheme 3.6c). In contrast, the 
                     3. Results and Discussion 
47 
 
specifically deuterium-labelled allene [D]2-88a resulted in the site-selective 
deuterium incorporation in the products [D]2-90aa (Scheme 3.6d), highlighting 
the key role of the C–O/C–H cleavage within an external oxidant-free allene 
annulation process. In addition, the same result was deuterium scrambling was 
observed in the product, when TAH benzamide 51a was reacted with [D]2-88a, 
which was performed by Dr. T. Müller.[89] 
 
Scheme 3.6 Experiments with isotopically-labelled substrates.  
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To further unveil the role of the acetate leaving group, two control experiment 
were conducted, one was employing alkyl allene 88n under the standard 
condition, which was performed by Dr. T. Müller (Scheme 3.7a), the other one 
was using the standard allene 88a but adding DCIB as an additional oxidant 
(Scheme 3.7b). To the end, the reaction under otherwise identical reaction 
conditions led to the corresponding hydroarylation product 103, while the 
reaction in the presence of DCIB gave the standard product 89aa. These 
observations highlighted an oxidation-induced reductive elimination occurring 
during the annulation process. 
 
Scheme 3.7 Role of leaving groups in iron-catalyzed C–H annulation. 
 
Mössbauer Spectroscopic Studies 
As to the catalyst’s mode of action, detailed step-to-step Mössbauer 
spectroscopic studies were conducted to unveil the oxidation and spin states of 
the iron intermediate species (Table 3.7). In order to avoid the influence of iron-
catalyzed β-H-elimination of Grinard reagent, MeMgBr was used instead of 
iPrMgBr for the Mössbauer measurement. As the amount of Grignard reacgent 
and zinc salts was largely excess comparing with iron catalyst in the standard 
condition, 9 equivalent of MeMgBr and 6 equivalent of ZnBr2·TMEDA were used 
here to create similar reduce environment for iron catalyst. To this end, the 
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presence of high-spin iron(II) intermediate species were supported by these 
observations.[90] This research was performed in collaboration with the research 
group of Prof. Dr. F. Meyer. After sample preparation, the data was recorded 
and interpreted by Dr. S. Demeshko.  
Table 3.7 Mössbauer parameters of reaction mixtures. 









1 57FeCl2 + THF +2HS 1.26 3.05 100 
2 Entry 1 + MeMgBr +1.4[91] 0.29 0.88 100 
























































[a] n.a. = not assigned. The data were recorded and interpreted by Dr. S. Demeshko.  
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3.1.6 Proposed Mechanism 
Based on the mechanistic findings, the iron-catalyzed allene annulation is 
proposed to be initiated by facile C–H metalation via LLHT, along with allene 
migratory insertion (Scheme 3.8). Thereafter, oxidation-induced reductive 
elimination takes place to generate the iron allyl complex 107. Based on the 
selective deuterium transposition, the iron allyl complex 107 was proposed to 
undergo a unique intramolecular C–H activation by 1,4-iron migration[92] which 
was considered as the key step to generate the stabilized allylic-benzylic iron 
intermediate 108. Proto-demetallation with the amide motif of the substrate 
51/32 delivers the intermediate 109 or the final product 90. The intermediate 
109 finally undergoes isomerization to furnish the corresponding isoquinolone 
89. The crucial 1,4 iron migration was further supported by computational 
studies that were conducted by Dr. J. C. A. Oliveira.[89] 
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3.2 Iron-Catalyzed C–H/N–H Propargyl Acetate Annulation 
While a previous report on iron-catalyzed alkyne annulations[61] showed 
limitations in substrate scope and a procedure to remove the TAH group was 
not available, it was valuable to investigate the reactivity of propargyl acetates 
in iron-catalyzed C–H annulations.  
3.2.1 Optimization Study and Substrate Scope 
Under the standard reaction condition for the allene annulations (Chapter 3.1.1), 
a similar reactivity was accomplished with propargyl acetates 91a, the reaction 
was found by Dr. T. Müller. The yield increased to 60% when using Fe(acac)2 
instead of Fe(acac)3. This finding suggested that an iron(II) catalyst may be 
more reactive than iron(III) catalysts (Scheme 3.9). 
 
Scheme 3.9 Test reaction of propargyl acetate 91a. 
For consistency and reproducibility, the optimization studies and the substrate 
scope were performed by Dr. T. Müller.[93]  
These experiments showed that: As in the allene annulation reactions (Chapter 
3.1.1), dppe proved to be the ligand of choice and FeCl2 showed higher activity 
in the catalytic reaction. The propargyl acetate annulation required more solvent 
and a lower reaction temperature. Furthermore, the propargyl acetate 
annulations with the TAH-substrates showed similar reactivity as was observed 
with the allenes. However, the TAM-substrates, which were compatible for 
allene annulations, fell short in providing the target products here. The 
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inherently decreased reactivity of the TAM-substrate can be partially attributed 
to the increased steric bulk of propargyl acetates as compared to the allenes.  
3.2.2 Traceless Electrochemical Removal of TAH Group 
Efforts first have been made to chemically remove the TAH group. 
Unfortunately, all attempts failed to deliver the target product 93aa (Table 3.8).  





1) LDA (2 equiv) /THF, −78 °C, 5 min 
2) O2, −78 °C,  
3) 10 min 
4) NH4Cl/H2O, −78–23 °C, 1 h 
2 1) BBr3 (5.3 equiv), DCM, 0–23 °C, 16 h 
2) PhI(TFA)2, MeCN/THF/H2O, 0 °C, 2 h 
3 BF3 Et2O (1.5 equiv), dry MeOH, 130 °C, 16 h 
4 NOBF4 (2.0 equiv), MeCN, 50 °C, 16 h 
5 H2O2 (5 mL), CF3COOH (4 mL), 40 °C, 18 h 
6 Conc. aq. HCl (1 mL), THF, 130 °C, 16 h 
7 Conc. aq. HCl (1 mL), THF, 130 °C, 16 h 
8 H2SO4 (1 mL), THF, 130 °C, 16 h 
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9 sat. NaOH (1 mL), THF, 130 °C, 16 h 
 
The TAH group of product 92aa could be removed in a traceless manner 
through electro-oxidative cleavage (Table 3.9). The corresponding 
isoquinolone 93aa was obtained in good yield using two equivalents of zinc salt 
and three equivalents of iPrMgBr (entry 1). The yield decreased with increasing 
amounts of iPrMgBr (entries 2–4). In addition, when only the Grignard reagent 
was present, the transformation was achieved in a low yield, while the sole use 
of zinc or magnesium salts fell short in giving the product (entries 5–8). 
Furthermore, nBu4NBF4, H2O as well as aqueous NH4Cl were tested as 
additives, significant product formation was not detected (entries 9–11). These 
observations suggested that the combination of ZnBr2·TMEDA and Grignard 
reagent was crucial for an efficient transformation. 
Table 3.9 Optimization of traceless removal of the TAH group.
 
Entry Additive 1 (x equiv) Additive 2 (y equiv) Yield [%] 
1 ZnBr·TMEDA (2) iPrMgBr (3) 73 
2 ZnBr·TMEDA (2) iPrMgBr (6) 72 
3 ZnBr·TMEDA (2) iPrMgBr (9) 63 
4 ZnBr·TMEDA (3) iPrMgBr (9) 40 
5 iPrMgBr (9) --- 38 
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6 MgBr2 (10) --- n.r. 
7 ZnBr·TMEDA (10) --- n.r. 
8 ZnBr2 (10) --- n.r. 
9 nBu4NBF4 (4) --- n.r. 
10[b] H2O  --- n.r.  
11[b] aq. NH4Cl  --- n.r. 
[a] Reaction conditions: 92aa (0.30 mmol), additive 1 (x equiv), additive (y equiv), THF (2 mL), 
60 °C, 16 h; yields of isolated products. [b] 2 mL of additive 1 was used. 
3.2.3 Mechanistic Studies 
Mechanistic experiments were performed by Dr. T. Müller[93] including 1) 
intermolecular competition experiments, 2) reactions with the isotopically-
labelled substrates, and 3) Hammett-plot analysis of the initial rates of the iron 
catalyzed C–H activation with a range of propargyl acetates. 
These experiments showed that a LLHT mechanism could be possible and that 
the C–H activation event is not the rate-determining step. Furthermore, no 
deuterium was incorporated into the product 92aa by using various isotopically-
labelled substrates, such as [D5]-benzamide, [D]-benzamide, [D6]-iPrMgBr, 
[D20]-dppe. A change in the rate-determining step could exist. 
Furthermore, when the standard reaction was conducted in the presence of  
 
Scheme 3.10 Reaction with isotopically-labelled solvent. 
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isotopically-labelled solvent, no deuterium was incorporated into the product 
(Scheme 3.10).  
While no deuterium incorporation in product 92aa was obsedved in the reaction 
with [D5]-51a (Scheme 3.11a, performed by Dr. T. Müller), the following 
experiments were conducted to understand where the proton at the ortho-
position of the benzamide 51a was ending in. H2 was detected by headspace 
GC analysis in the standard catalytic reaction (Scheme 3.11b). In addition, the 
proton of amide in the substrate 51a can be deprotonated by PhZnCl (Scheme 
3.11c). Thus, H2 could be formed through β-hydride elimination of the Fe-alkyl 
complex 111 (Scheme 3.13) or by-reaction of iron reacting with Grignard 
reagent. To further confirm, a DFT calculation was conducted by Dr. J. C. A. 
Oliveira. These results showed that the formation of H2 through β-hydride 
elimination of iron-alkyl complex 111 is less possible during the C–H activation 
event (Scheme 3.13). Based on these findings, we proposed that the proton of 
benzamide 51a which participate in C–H activation would be transfered to the 
isopropyl group in complex 111 then form propane gas (Scheme 3.13). 
 
Scheme 3.11 Detection of H2 and deprotonation of benzamide 51a. 
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In order to capture the intermediate, a reaction with di-phenyl substituted 
propargyl acetate 91b was performed (Scheme 3.12). Unfortunately, no 
transformation was observed under the standard conditions. 
 
Scheme 3.12 Reaction with di-phenyl substituted propargyl acetate 91b. 
Mössbauer Spectroscopy Studies 
To further gain insights into the catalyst’s mode of action, Mössbauer 
spectroscopic studies were conducted to unveil the oxidation and spin states of 
the iron intermediate species (Table 3.10). In order to avoid the influence of 
iron-catalyzed β-H-elimination of Grinard reagent, MeMgBr was used instead 
of iPrMgBr for the Mössbauer measurement. As the amount of Grignard 
reacgent and zinc salts was largely excess comparing with iron catalyst in the 
standard condition, 9 equivalent of MeMgBr and 6 equivalent of ZnBr2·TMEDA 
were used here to creat similar reduce environment for the iron catalyst. Our 
observations provided strong support for the presence of high-spin iron(II) 
intermediate species.[90] This research work was performed in collaboration with 
the research group of Prof. Dr. F. Meyer. After sample preparation, the data 
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Table 3.10 Mössbauer parameters of reaction mixtures. 









1 57FeCl2 + THF +2HS 1.26 3.05 100 
2 Entry 1 + MeMgBr +1.4[91] 0.29 0.88 100 
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3.2.4 Proposed Mechanism 
Based on our studies, a plausible catalytic cycle was proposed (Scheme 3.13). 
The catalytic cycle consists of: a) a reversible, facile C–H activation via LLHT, 
b) alkyne migratory insertion, c) exergonic β-O-elimination, d) allene migratory 
insertion, and e) proto-demetallation to deliver the desired isoquinolone product 
92 and regenerate the active iron species 111. 
 
Scheme 3.13 Proposed mechanism for the iron-catalyzed annulation with 91. 
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3.3 Iron-Catalyzed C–H/C–C Activation with 
Bicyclopropylidenes 
In recent years, the merger of C–H activation with challenging C–C cleavages 
has been developed for the construction of novel molecules. Despite 
considerable achievements, this approach was largely thus far restricted to 
precious metal catalysts,[83–84] activated vinylcyclopropanes,[24c, 85b–85d] as well 
as harsh oxidative conditions.[85a]  
3.3.1 Optimization Studies 
A series of BCP derivatives were tested under the standard reaction conditions 
of the iron-catalyzed C–H oxidative annulation with allenes. To our delight, 
when substrate 94a was used as the coupling partner, bispiro-fused product 
96aa was obtained in 45% yield (Scheme 3.14).  
 
Scheme 3.14 Test reactions with bicyclopropylidenes. 
Thereafter, considerable efforts were devoted to improve the yield of the 
structurally interesting product (Table 3.11). We initiated our optimization by 
testing different iron catalysts, and Fe(acac)3 delivered the best results among 
the tested catalysts (entries 1–4). In addition, various Grignard reagents are 
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probed, and iPrMgBr proved to be the best (entries 5–10). Other etheric 
solvents turned out to be less effective than THF (entries 11–15). Increasing 
the concentration of iPrMgBr did not facilitate the reaction (entries 16 and 17). 
Adding the BCP substrate 94a dropwise instead of in one portion showed a 
comparable reactivity (entry 18). The yield dropped to 26% when the reaction 
was run at 80 °C, while further decreasing the temperature to 23 °C almost shut 
down the reaction (entries 19 and 20). As the use of acetate as the leaving 
group was mandatory to achieve reasonable conversion in the iron-catalyzed 
annulation of allenyl acetates, we reinvestigated the role of the leaving group. 
When acetate or carbonate was installed on the BCP, the isoquinolone 95aa 
could be obtained as main product. In contrast, with alkoxy as the leaving group, 
product 96aa was obtained (entries 21–26). The yield of product 95aa 
decreased when FeCl2 was used instead of Fe(acac)3, and a higher 
concentration of Grignard reagent was employed (entries 27–29). Interestingly, 
biomass-derived solvent 2-MeTHF also enabled the isoquinolone 95aa 
transformation, while it proved to be inefficient for the reaction using methoxy 
as the leaving group (entries 15 and 30). Furthermore, the isoquinolone 95aa 
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1 Fe(acac)2 iPrMgBr (3) THF OMe 25 --- 
2 FeCl3 iPrMgBr (3) THF OMe  25 --- 
3 Fe(dbm)3 iPrMgBr (3) THF OMe 21 --- 
4 Fe(acac)3 iPrMgBr (3) THF OMe 45 --- 
5 Fe(acac)3 MeMgBr (3) THF OMe 42 --- 
6 Fe(acac)3 tBuMgCl (2) THF OMe 40 --- 
7 Fe(acac)3 CyMgCl (2) THF OMe 24 --- 
8 Fe(acac)3 TMSCH2MgCl (2.5) THF OMe --- --- 
9 Fe(acac)3 iPrMgCl (1) THF OMe 23 --- 
10 Fe(acac)3 cycloproplyMgBr (1) THF OMe 14 --- 
11b Fe(acac)3 iPrMgBr (3) Et2O OMe 21 --- 
12 Fe(acac)3 iPrMgBr (3) DME OMe --- --- 
13 Fe(acac)3 iPrMgBr (3) dioxane OMe --- --- 
14 Fe(acac)3 iPrMgBr (3) (nBu)2O OMe --- --- 
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15 Fe(acac)3 iPrMgBr (3) 2-MeTHF OMe --- --- 
16c Fe(acac)3 iPrMgBr (3) THF OMe 26 --- 
17 Fe(acac)3 iPrMgBr (4.3) THF OMe --- --- 
18d Fe(acac)3 iPrMgBr (3) THF OMe 40 --- 
19e Fe(acac)3 iPrMgBr (3) THF OMe trace --- 
20f Fe(acac)3 iPrMgBr (3) THF OMe 26 --- 
21 Fe(acac)3 iPrMgBr (3) THF OEt 35 --- 
22 Fe(acac)3 iPrMgBr (3) THF OBn trace --- 
23 Fe(acac)3 iPrMgBr (3) THF OPh  --- --- 
24 Fe(acac)3 iPrMgBr (3) THF   94e 30 15 
25 Fe(acac)3 iPrMgBr (3) THF   94f --- 70 
26 Fe(acac)3 iPrMgBr (3) THF OAc  --- 80 
27 FeCl2 iPrMgBr (3) THF OAc --- 53 
28 Fe(acac)3 iPrMgBr (4.28) THF OAc  --- 47 
29c Fe(acac)3 iPrMgBr (3) THF OAc  --- 53 
30 Fe(acac)3 iPrMgBr (3) 2-MeTHF OAc  --- 70 
31e Fe(acac)3 iPrMgBr (3) 2-MeTHF OAc  --- 64 
[a] Reaction conditions: 51a (0.30 mmol), 94 (0.90 mmol), [TM] (15 mol %), dppe (15 mol %), 
ZnBr2·TMEDA (0.60 mmol), Grignard reagent (0.90 mmol), THF (0.40 mL), 65 °C, 16 h; yields 
of isolated products. [b] at 40 °C. [c] 0.2 mL solvent was used. [d] dropwise addition of 94a over 
1 h. [e] at 23 °C. [f] at 80 °C.  
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3.3.2 Impact of the N-Substituent on the C–H/C–C Activation 
The iron-catalyzed C–H/C–C activation with different TAH groups provided 
various isoquinolones in moderate to good yields (Table 3.12). Among them, 
methylene-tethered TAH triazoles delivered the desired isoquinolones 95 in 
good yields (entries 1–4), tolerating among others a reactive alkyl chloride 51d 
without any cross-coupling products being observed (entry 5).  
Table 3.12 Impact of different TAH groups on the C–H/C–C activation. 
 





























[a] Reaction conditions: 51 (0.30 mmol), 94g (0.90 mmol), Fe(acac)3 (15 mol %), dppe 
(15 mol %), ZnBr2·TMEDA (0.60 mmol), iPrMgBr (3.0 M, 0.90 mmol), THF (0.40 mL), 65 °C, 
16 h; yields of isolated products.  
Notably, when TAM benzamide 32a was used, the triazole group was directly 
removed in situ, leading to the products of free isoquinolone 97 and triazole 
substituted alkene 119 (Scheme 3.15). Employing tetrahydropyranyl as the 
leaving group on the BCP (94e), the yield of the free isoquinolone 97 was 
increased to 52%. While previous studies on iron-catalyzed C–H annulation 
always needed an additional step for TAM group removal, this finding provided 
an alternative way to synthesize the NH-free isoquinolone. However, no product  
 
Scheme 3.15 Impact of different TAM groups on the C–H/C–C activation. 
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formation was observed when other bulky groups were introduced on the TAM 
group (Scheme 3.15). 
3.3.3 Substrate Scope and Limitations 
Next, the reactivity of various substituted TAH substrates and BCP acetates 
was investigated (Table 3.13). This transformation tolerated various functional 
groups, such as thioether (51s) and chloro (51j) (entries 1–6). For the para-
methyl substituted TAH substrate 51e, under the standard condition only 16% 
of the product 95eg were obtained. By prolonging the reaction time and 
lowering the reaction temperature, the yield was improved to 60% (entry 2). 
meta-Substituted TAH substrates, such as methyl, chloro or bromo, were 
efficiently converted to the desired isoquinolones 95tg–95wg with high chemo- 
and regio-selectivities (entries 7–10).  
Table 3.13 Substrate scope of TAH benzamide 51.
 
Entry 51 95 Yield [%] 
 
1 
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[a] Reaction conditions: 51 (0.30 mmol), 94g (0.90 mmol), Fe(acac)3 (15 mol %), dppe 
(15 mol %), ZnBr2·TMEDA (0.60 mmol), iPrMgBr (3.0 M, 0.90 mmol), THF (0.40 mL), 65 °C, 
16 h; yields of isolated products. 
A rare selective C–F/C–H activation could be induced when the para-CF3 
substituted TAH-substrate 51h was used, providing the C–H/C–C/C–F/C–H 
functionalized product 95hg’ (Scheme 3.16a). Additionally, meta-CF3 
substituted TAH-substrate 51x afforded the by-product 95xg’ with conservation 
of one cyclopropane ring (Scheme 3.16b). These findings strongly supported a 
β-O elimination or β-C elimination mechanism to be responsible for the ring 
opening of the cyclopropanes. For the para-CF3 substituted TAM-substrate 32g, 
the C–F/C–H functionalization product 97gg’ was here not observed (Scheme 
3.16c), which is suggestive of the C–N bond cleavage taking place 
preferentially over the C–C cleavage of the second cyclopropane ring during 
the formation of the free isoquinolone products 97 (Scheme 3.21, pathway C). 




Scheme 3.16 Impact of CF3-substitution of benzamide. 
Pre-installed long alkyl chain or phenyl group at the α-position of the BCP 
acetate significantly decreased the efficiency of the transformation (Table 3.14, 
entries 1 and 2). It is also worth to mention that the two cyclopropane rings of 
the BCP derivative are necessary for this C–H annulation reaction. The 
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Table 3.14 Substrate scope of BCP 94. 
 
Entry 94 95 Yield [%] 
 
1 









































[a] Reaction conditions: 51a (0.30 mmol), 94 (0.90 mmol), Fe(acac)3 (15 mol %), dppe 
(15 mol %), ZnBr2·TMEDA (0.60 mmol), iPrMgBr (3.0 M, 0.90 mmol), THF (0.40 mL), 65 °C, 
16 h; yields of isolated products. 
Efforts also have been made to extend the scope of the bispiro-fused product 
96. Unfortunately, BCPs bearing methoxy as the leaving group only afforded 
the corresponding products in low yields when reacted with different TAH 
substrates 51 (Table 3.15, entries 1–9). TAM substrates 32 were tested as well, 
however, no target product formation was observed (entries 10–12).  
Table 3.15 Substrate scope of bispiro-fused isoquinolone 96 formation.
 





















































































[a] Reaction conditions: 51/32 (0.30 mmol), 88a (0.90 mmol), Fe(acac)3 (15 mol %), dppe 
(15 mol %), ZnBr2·TMEDA (0.60 mmol), iPrMgBr (3.0 M, 0.90 mmol), THF (0.40 mL), 65 °C, 
16 h; yields of isolated products. 
 
3.3.4 Removal of TAH Group  
The TAH group of the bispiro-fused isoquinolone 96aa was removed in an 
electro-oxidative fashion without breaking the strained rings (Scheme 3.17).   
 





Scheme 3.17 Traceless electrochemical removal of the TAH group. 
Crystals suitable for X-ray diffraction were then grown by slow evaporation, 
unambiguously confirming the connectivity of product 120 (Scheme 3.18). 
 
Scheme 3.18 Molecular structure of 120 with thermal ellipoids at 50% probability level. 
The crystal structure was measured and solved by Dr. Christopher Golz. 
3.3.5 Mechanistic Studies 
In order to shed light on the reaction mechanism, experimental and Mössbauer 
spectroscopic studies were conducted. 
Experimental Studies 
A comparable reactivity between electron-deficient benzamide 51h and 
electron-rich benzamide 51e was observed (Scheme 3.19a). A C–D/N–H 
functionalization with the isotopically labelled substrates [D]5-51r or [D]5-51a, 
either by independent reactions or an intermolecular KIE measurement in a 
one-pot fashion, showed a very minor kinetic isotope effect (kH/kD = 1.2), 
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providing support for a facile C–H cleavage which is not the rate-determining 
step of the overall reaction (Scheme 3.19b and 3.19c). 
 
Scheme 3.19 Competition reaction and KIE studies. 
The deuterium-labelled substrate [D5]-51a resulted in site selective deuterium 
incorporation of the product [Dn]-95ag or [Dn]-96aa, being indicative of a LLHT 
mechanism (Scheme 3.20a and 3.20b). Interestingly, deuterium incorporation 
was position-selective for the corresponding products (Scheme 3.20c and 
3.20d), which indicates an iron-catalyzed C–C cleavage occurring during the 
catalytic reaction. The partial deuterium incorporation of the products [D]-95ag 
and [D]-96aa (Scheme 3.20c and 3.20d) indicates that intermediates 125 and 
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126 could be the resting states for the corresponding pathways A and B 
(Scheme 3.21). In addition, diastereo-selective deuterium incorporation in the 
products [Dn]-96aa and [D]-96aa was observed, (Scheme 3.20b and 3.20d) 
which suggests a migratory insertion taking place for the formation of 
intermediate 126 (Scheme 3.21, pathway B). 
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Mössbauer spectroscopy studies 
For further understanding the iron’s oxidation and spin states in the reaction, 
detailed Mössbauer spectroscopic studies were conducted. In order to avoid 
the influence of iron-catalyzed β-H-elimination of Grinard reagent, MeMgBr was 
used instead of iPrMgBr for the Mössbauer measurement. Overall, the 
presence of high-spin iron(II) intermediates were support by our 
observations.[90] These studies were performed in collaboration with the 
research group of Prof. Dr. F. Meyer. After sample preparation, the data were 
recorded and interpreted by Dr. S. Demeshko.  
Table 3.16 Mössbauer parameters of reaction mixtures. 
Entry Reaction 








1 57FeCl2 + THF +2HS 1.26 3.05 100 
2 Entry 1 + MeMgBr +1.4[91] 0.29 0.88 100 
3 





































































                     3. Results and Discussion 
78 
 
The data were recorded and interpreted by Dr. S. Demeshko.  
3.3.6 Proposed Mechanism 
Based on experimental studies and previous findings,[94] we propose a novel 
iron-catalyzed C–H/C–C activation sequence, involving three pathways can 
lead to three different product formations (Scheme 3.21).  
The catalytic cycle is initiated by a reversible C–H activation via LLHT to 
generate the cyclometalated iron species 121, which can undergo coordination 
and migratory insertion to deliver complex 123. After oxidation-induced 
reductive elimination[46, 94] and β-elimination of intermediate 123, intermediate 
124 is formed. From intermediate 124, depending on the combination of leaving 
group and N-substituent, three pathways can lead to three different products. 
In pathway A, intermediate 124 undergoes β-C-elimination to give intermediate 
125, subsequent with proto-demetallation to yield product 95ag and regenerate 
the active iron species 121. In pathway B, migratory insertion of the alkene 
takes place to form the intermediate 126. After proto-demetallation, product 
96aa is provided. Finally, in pathway C, a β-C-elimination occurs at the N–C 
bond which connects the directing group and benzamide moiety, thus forming 
the intermediates 127 and 128. Intermediate 128 undergoes β-H-elimination to 
release the alkene 119a and generate iron hydride species which reduces the 
intermediate 127 to generate intermediate 129. After β-C-elimination and proto-
demetallation, intermediate 129 yields the final product 97ag and releases the 
active iron species 121.  
8 
 


















Scheme 3.21 Proposed catalytic cycle for iron-catalyzed C–H/C–C activations. 
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4. Summary and Outlook 
The last decades have witnessed considerable progress in iron-catalyzed C–H 
functionalizations for a sustainable and economically-efficient access to C–C 
and C–Het bonds. Despite considerable progress, several limitations in iron-
catalyzed C–H annulation reactions need to be overcame. First, the types of 
viable coupling partners for this methodology are severly restricted, only 
alkynes were reported thus far. Next, an excess of DCIB as an external oxidant 
was requied for an efficient annulation. In addition, a narrow substrate scope 
was presented in several cases. Then, the reaction mechanism was not fully 
elucidated. Last, efficient protocols for the removal of the TAH group are 
missing.  
In the first project, iron-catalyzed C–H annulations with allenes 88 were 
disclosed (Scheme 4.1).[89] The notable achievements feature 1) a novel iron-
catalyzed annulation reaction with allenes, 2) C–H activation at room 
temperature, 3) external-oxidant-free conditions, 4) not only TAH benzamides 
51, TAM benzamides 32 can be compatible for this novel transformation, and 









Scheme 4.1 Iron-catalyzed C–H/N–H redox-neutral annulations with allenes 88. 
Within the second project, the synthesis of 3,4-disubstituted isoquinolones 92 
through iron-catalyzed C–H annulations with propargyl acetates 91 was 
realized (Scheme 4.2).[93] Notably, the TAH group, whose removal proved to be 
difficult, can be tracelessly removed in an electrochemical fashion. 
 
Scheme 4.2 Iron-catalyzed C–H/N–H redox-neutral annulations with alkynes 91. 
 
In the third project, the merger of C–H activation and C–C cleavage by iron 
catalysis was achieved by the application of BCPs 94 (Scheme 4.3). Salient 
features of this novel transformation include 1) first iron-catalyzed C–H/C–C 
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functionalizations, 2) the use of BCP derivatives 94 as coupling partners, 3) 
oxidant-free catalysis avoiding harsh conditions, 4) selective C‒C cleavage 
enable divers product formation, and 5) a mono-selective C‒F/C‒H activation 
sequence of trifluoromethylarenes. 
Scheme 4.3 Iron-catalyzed C–H/C–C activation with BCPs 94. 
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5. Experimental Part  
5.1 General Remarks  
All reactions involving moisture- or air-sensitive reagents or products were 
performed under an inert atmosphere of nitrogen using pre-dried glassware and 
standard Schlenk techniques. If not otherwise noted yields refer to isolated 
compounds, estimated to be >95% pure as determined by 1H NMR and GC 
analysis.  
Vacuum  
A Vacuubrand RZ 6 vacuum pump was used throughout the course of this 
thesis. The pressure was measured to be 0.7 mbar (uncorrected value).  
Melting Points  
Melting points were measured on a Stuart® Melting Point Apparatus SMP3 
from Barloworld Scientific. Values are uncorrected.  
Chromatography  
Analytical thin layer chromatography (TLC) was performed on silica gel 60 F254 
aluminum sheets from MERCK. Plates were either visualized under irradiation 
at 254 nm or 365 nm or developed by treatment with a potassium 
permanganate solution followed by careful warming. Chromatographic 
purification was accomplished by flash column chromatography on MERCK 
Geduran® silica gel, grade 60 (40–63 μm, 70–230 mesh ASTM).  
Gas Chromatography  
Monitoring of reaction process via gas chromatography or coupled gas 
chromatography-mass spectrometry was performed using a 7890 GC-system 
with/without mass detector 5975C (Triple-Axis-Detector) or a 7890B GC-
system coupled with a 5977A mass detector, both from Agilent Technologies®. 
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Infrared Spectroscopy  
Infrared (IR) spectra were recorded using a Bruker® Alpha-P ATR 
spectrometer. Liquid samples were measured as film and solid samples neat. 
Spectra were recorded in the range from 4000 to 400 cm−1. Analysis of the 
spectral data were carried out using Opus 6. Absorption is given in wave 
numbers (cm−1).  
Nuclear Magnetic Resonance Spectroscopy  
Nuclear magnetic resonance (NMR) spectra were recorded on Mercury Plus 
300, VNMRS 300, Inova 500 and 600 from Varian®, or Avance 300, Avance III 
300 and 400, Avance III HD 400 and 500 from Bruker®. Chemical shifts are 
reported in δ-values in ppm relative to the residual proton peak or carbon peak 
of the deuterated solvent. 
 
Solvent 1H NMR 13C NMR 
CDCl3  7.26 77.16 
C6D6  7.16 128.06 
 
The following abbreviations are used to describe the observed multiplicities: s 
(singlet), d (doublet), t (triplet), q (quartet), p (pentet), h (hexet), hept (heptet), 
m (multiplet) or analogous representations. The coupling constants J are 
reported in Hertz (Hz). Analysis of the recorded spectra was carried out using 
MestReNova 10 software. 
Mass Spectrometry  
Electron ionization (EI) and EI high resolution mass spectra (HRMS) were 
measured on a time-of-flight mass spectrometer AccuTOF from JOEL. 
Electrospray ionization (ESI) mass spectra were recorded on an Io-Trap mass 
spectrometer LCQ from Finnigan, a quadropole time-of-flight maXis from 
Bruker Daltonic or on a time-of-flight mass spectrometer microTOF from Bruker 
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Daltonic. ESI-HRMS spectra were recorded on a Bruker Apex IV or Bruker 
Daltonic 7T, fourier transform ion cyclotron resonance (FTICR) mass 
spectrometer. The ratios of mass to charge (m/z) are indicated, intensities 
relative to the base peak (I = 100) are given in parentheses. 
Electrocatalysis  
Electrocatalysis was conducted using an AXIOMET AX-3003P potentiostat in 
constant current mode. 
Mössbauer Spectroscopy 
Mößbauer spectra were recorded with a 57Co source in a Rh matrix using an 
alternating constant acceleration Wissel Mössbauer spectrometer operated in 
the transmission mode and equipped with a Janis closed-cycle helium cryostat. 
Isomer shifts are given relative to iron metal at ambient temperature. Simulation 
of the experimental data was performed with the Mfit program[95] using 
Lorentzian line doublets. 
Solvents  
Solvents for column chromatography were purified via distillation under 
reduced pressure prior to their use. All solvents for reactions involving moisture-
sensitive reagents were dried, distilled and stored under inert atmosphere (Ar 
or N2) according to following standard procedures:  
Purified by solvent purification system (SPS-800, M. Braun): CH2Cl2, toluene, 
tetrahydrofurane, dimethylformamide, diethylether.  
Dried and distilled over sodium/benzophenone: 1,4-dioxane, DME, 2-MeTHF.  
Dried and distilled over CaH2: 1,2-dichloroethane 
Chemicals  
Chemicals obtained from commercial sources with a purity >95% were used as 
received without further purification. Stainless steel electrodes (Type 304, 
10 mm × 15 mm × 0.25 mm; obtained from abcr, Germany) and RVC 
electrodes (5 mm × 10 mm × 6 mm, SIGRACELL® GFA 6 EA, obtained from 
SGL Carbon, Wiesbaden, Germany) were connected using stainless steel 
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adapters. The following compounds were known from the literature and were 
synthesized according to the previously known methods:  
TAH- and TAM- benzamides 51 and 32,[45, 53, 61] allenyl acetates 88,[96] 
57FeCl2,[97] propargyl acetates 91,[98] cyclopropylidenecyclohexane 117,[99] 
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5.2 General Procedures  
General Procedure A (GPA): Iron-Catalyzed C–H/N–H Allene Annulation  
To a stirred solution of 51/32 (0.30 mmol), ZnBr2∙TMEDA (206 mg, 0.60 mmol) 
and dppe (17.9 mg, 15 mol %) in THF (0.20 mL), iPrMgBr (3.0 M in 2-MeTHF, 
300 μL, 0.90 mmol) was added in one portion and the reaction mixture was 
stirred for 5 min at ambient temperature. Fe(acac)3 (15.9 mg, 15 mol %) was 
added in a single portion. After stirring the solution for additional 5 min, allene 
88 (0.90 mmol, 3.0 equiv) was added as a solution in THF (0.20 mL) in one 
portion. The mixture was placed in a pre-heated oil bath at 65 °C. After stirring 
for 16 h, sat. aqueous NH4Cl (2.0 mL) was added to the reaction mixture, which 
was then extracted with CH2Cl2 (3  15 mL). The combined organic extracts 
were dried over Na2SO4, filtered and concentrated. The crude product was 
purified by column chromatography on silica gel to afford the desired product 
89/90. 
General Procedure A’ (GPA’): Iron-Catalyzed C–H/N–H Allene Annulation  
To a stirred solution of 51/32 (0.30 mmol), ZnBr2∙TMEDA (206 mg, 0.60 mmol) 
and dppe (17.9 mg, 15 mol %) in THF (0.20 mL), iPrMgBr (3.0 M in 2-MeTHF, 
300 μL, 0.90 mmol) was added in one portion and the reaction mixture was 
stirred for 5 min at ambient temperature. Fe(acac)3 (15.9 mg, 15 mol %), THF 
(0.20 mL), allene 88 (0.90 mmol, 3.0 equiv) was added to the mixture at the 
same time. The resulting mixture was placed in a pre-heated oil bath at 65 °C. 
After stirring for 16 h, sat. aqueous NH4Cl (2.0 mL) was added to the reaction 
mixture, which was then extracted with CH2Cl2 (3  15 mL). The combined 
organic extracts were dried over Na2SO4, filtered and concentrated. The crude 
product was purified by column chromatography on silica gel to afford the 
desired product 89/90. 
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General Procedure B (GPB): Iron-Catalyzed C–H/N–H Alkyne Annulation 
To a stirred solution of 51 (0.30 mmol), ZnBr2∙TMEDA (205 mg, 0.60 mmol) and 
dppe (17.9 mg, 15 mol %) in THF (0.40 mL), iPrMgBr (3.0 M in 2-MeTHF, 300 
μL, 0.90 mmol) was added in one portion and the reaction mixture was stirred 
for 5 min at ambient temperature. Then, Fe(acac)2 (5.7 mg, 15 mol %) was 
added in a single portion. After stirring the solution for additional 5 min, alkyne 
91 (0.90 mmol, 3.0 equiv) was added as a solution in THF (0.40 mL). Then, the 
mixture was stirred at ambient temperature. After stirring for 16 h, sat. aqueous 
NH4Cl (3.0 mL) was added to the reaction mixture, which was extracted with 
CH2Cl2 (3  15 mL). The combined organic extracts were dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude product was 
purified by column chromatography on silica gel to afford the desired product 
92. 
General Procedure C (GPC): Iron-Catalyzed C–H/C–C Activation  
To a stirred solution of 51/32 (0.30 mmol), ZnBr2∙TMEDA (206 mg, 0.60 mmol) 
and dppe (17.9 mg, 15 mol %) in THF (0.20 mL), iPrMgBr (3.0 M in 2-MeTHF, 
300 μL, 0.90 mmol) was added in one portion and the reaction mixture was 
stirred for 5 min at ambient temperature. Fe(acac)3 (15.9 mg, 15 mol %) was 
added in a single portion. After stirring the solution for additional 5 min, BCP 94 
(0.90 mmol, 3.0 equiv) was added as a solution in THF (0.20 mL) in one portion. 
The mixture was placed in a pre-heated oil bath at 65 °C. After stirring for 16 h, 
sat. aqueous NH4Cl (2.0 mL) was added to the reaction mixture, which was 
then extracted with CH2Cl2 (3  15 mL). The combined organic extracts were 
dried over Na2SO4, filtered and concentrated. The crude product was purified 
by column chromatography on silica gel to afford the desired product 95/96/97. 
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General Procedure D (GPD): Electrochemical Removal of TAH Group  
The electrochemical removal of the TAH group was carried out in an undivided 
cell with RVC anode (10 mm × 5 mm × 6 mm) and a steel cathode 
(20 mm × 10 mm × 0.25 mm). To a stirred solution of isoquinolone 92/96 
(0.3 mmol) and ZnBr2∙TMEDA (150 mg, 0.44 mmol) in THF (2.0 mL), iPrMgBr 
(3.0 M in 2-MeTHF, 220 µL, 0.66 mmol) was added in one portion. The 
electrocatalysis was performed at 60 °C with a constant current of 10.0 mA 
maintained for 15 h. Then, the mixture was allowed to cool to ambient 
temperature, and saturated aq. NH4Cl (3.0 mL) was added. The RVC anode 
was washed with CH2Cl2 (3 × 10 mL) in an ultrasonic bath. The combined 
aqueous phases were extracted with CH2Cl2 (3  15 mL), dried over Na2SO4, 
filtered and concentrated under reduced pressure. Purification by column 
chromatography (nhexane/EtOAc = 3/2) yielded 93/120. 
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5.3 Iron-Catalyzed C–H/N–H Annulation with Allenes 




                         
The general procedure GPA was followed using 51a (85.9 mg, 0.30 mmol) and 
allene 88a (164 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 4/1) yielded 89aa (112 mg, 91%) as white solid.  
M.p. = 76–78 °C. 1H NMR (600 MHz, CDCl3): δ = 8.35 (d, J = 8.0 Hz, 1H), 7.70 
(s, 1H), 7.60–7.56 (m, 1H), 7.43–7.38 (m, 2H), 6.34 (s, 1H), 5.38 (s, 2H), 4.24 
(t, J = 7.3 Hz, 2H), 2.98 (t, J = 7.7 Hz, 2H), 1.86–1.80 (m, 2H), 1.71 (dt, 
J = 15.4, 7.7 Hz, 2H), 1.48 (dt, J = 15.4, 7.3 Hz, 2H), 1.40–1.34 (m, 2H), 1.32–
1.23 (m, 10H), 0.89 (t, J = 6.9 Hz, 3H), 0.83 (t, J = 7.0 Hz, 3H). 13C NMR 
(126 MHz, CDCl3): δ = 163.3 (Cq), 144.1 (Cq), 143.6 (Cq), 136.9 (Cq), 132.3 
(CH), 127.7 (CH), 125.9 (CH), 125.4 (CH), 124.3 (Cq), 123.8 (CH), 105.2 (CH), 
50.5 (CH2), 39.2 (CH2), 33.2 (CH2), 31.9 (CH2), 31.3 (CH2), 30.3 (CH2), 29.4 
(CH2), 29.3 (CH2), 28.9 (CH2), 26.3 (CH2), 22.8 (CH2), 22.6 (CH2), 14.3 (CH3), 
14.1 (CH3). IR (ATR): 2926, 2853, 1643, 1618, 1593, 1413, 1052, 801, 756, 
690 cm−1. MS (EI) m/z (relative intensity): 408 (70) [M]+, 337 (53), 324 (47), 295 
(63), 242 (48), 172 (39), 159 (91), 43 (100). HR-MS (EI) m/z calcd for 
C25H36N4O [M]+ 408.2889, found 408.2879. 
 





                           
The general procedure GPA was followed using 51b (94.3 mg, 0.30 mmol) and 
allene 88a (164 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 89ba (107 mg, 82%) as white solid.  
M.p. = 56–57 °C. 1H NMR (600 MHz, CDCl3): δ = 8.33 (dd, J = 8.1, 1.2 Hz, 1H), 
7.70 (s, 1H), 7.56 (ddd, J = 8.1, 7.0, 1.3 Hz, 1H), 7.42–7.35 (m, 2H), 6.33 (s, 
1H), 5.36 (s, 2H), 4.23(t, J = 7.8 Hz, 2H), 2.96 (t, J = 7.8 Hz, 2H), 1.90–1.78 (m, 
2H), 1.73–1.67 (m, 2H), 1.54–1.42 (m, 2H), 1.38–1.31 (m, 2H), 1.30–1.26 (m, 
4H), 1.25–1.18 (m, 10H), 0.87 (t, J = 7.0 Hz, 3H), 0.83 (t, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ = 163.2 (Cq), 144.0 (Cq), 143.6 (Cq), 136.9 (Cq), 
132.3 (CH), 127.6 (CH), 125.9 (CH), 125.4 (CH), 124.2 (Cq), 123.7 (CH), 105.1 
(CH), 50.5 (CH2), 39.2 (CH2), 33.1 (CH2), 31.9 (CH2), 31.8 (CH2), 30.3 (CH2), 
29.4 (CH2), 29.3 (CH2), 29.1 (CH2), 29.0 (CH2), 28.9 (CH2), 26.6 (CH2), 22.8 
(CH2), 22.7 (CH2), 14.2 (CH3), 14.2 (CH3). IR (ATR): 2954, 2918, 2852, 1648, 
1592, 1461, 1337, 1169, 1048, 723 cm−1. MS (EI) m/z (relative intensity): 436 
(75) [M]+, 365 (47), 352 (40), 242 (43), 159 (100). HR-MS (EI) m/z calcd for 












The general procedure GPA was followed using 51c (87.7 mg, 0.30 mmol) and 
allene 88a (164 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 89ca (99.5 mg, 80%) as white solid.  
M.p. = 96–97 °C. 1H NMR (300 MHz, CDCl3): δ = 8.32 (dd, J = 8.1, 1.3 Hz, 1H), 
7.68 (s, 1H), 7.58 (ddd, J = 8.1, 7.1, 1.3 Hz, 1H), 7.46–7.39 (m, 2H), 7.39–7.32 
(m, 3H), 7.30–7.25 (m, 2H), 6.34 (s, 1H), 5.43 (s, 2H), 5.36 (s, 2H), 2.98 (t, 
J = 7.8 Hz, 2H), 1.78–1.65 (m, 2H), 1.58–1.40 (m, 2H), 1.40–1.27 (m, 6H), 0.91 
(t, J = 6.9 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ = 163.4 (Cq), 144.6 (Cq), 143.6 
(Cq), 137.0 (Cq), 134.6 (Cq), 132.4 (CH), 129.2 (CH), 128.8 (CH), 128.2 (CH), 
127.7 (CH), 126.0 (CH), 125.5 (CH), 124.2 (Cq), 124.0 (CH), 105.2 (CH), 54.3 
(CH2), 39.1 (CH2), 33.1 (CH2), 31.9 (CH2), 29.4 (CH2), 29.3 (CH2), 28.8 (CH2), 
22.8 (CH2), 14.2 (CH3). IR (ATR): 2956, 2919, 2853, 1646, 1622, 1455, 1050, 
728, 710, 693 cm−1. MS (EI) m/z (relative intensity): 414 (26) [M]+, 295 (26), 242 













The general procedure GPA was followed using 51d (83.6 mg, 0.30 mmol) and 
allene 88a (164 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 89da (82.8 mg, 69%) as white solid.  
M.p. = 110–111 °C. 1H NMR (300 MHz, CDCl3): δ = 8.32 (d, J = 8.0 Hz, 1H), 
7.75 (s, 1H), 7.60–7.52 (m, 1H), 7.44–7.35 (m, 2H), 6.33 (s, 1H), 5.36 (s, 2H), 
4.43 (t, J = 6.7 Hz, 2H), 3.47 (t, J = 6.1 Hz, 2H), 2.96 (t, J = 7.8 Hz, 2H), 2.38–
2.18 (m, 2H), 1.78–1.64(m, 2H), 1.51–1.43(m, 2H), 1.39–1.32(m, 2H), 1.31–
1.26 (m, 4H), 0.87 (t, J = 6.8 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ = 163.4 
(Cq), 144.3 (Cq), 143.6 (Cq), 137.0 (Cq), 132.5 (CH), 127.8 (CH), 126.1 (CH), 
125.5 (CH), 124.6 (CH), 124.3 (Cq), 105.3 (CH), 47.3 (CH2), 41.3 (CH2), 39.1 
(CH2), 33.2 (CH2), 32.7 (CH2), 31.9 (CH2), 29.4 (CH2), 29.3 (CH2), 28.8 (CH2), 
22.8 (CH2), 14.2 (CH3). IR (ATR): 2954, 2926, 2856, 1715, 1648, 1464, 1285, 
1087, 799, 764 cm−1. MS (EI) m/z (relative intensity): 400 (57) [35Cl, M]+, 316 
(37), 295 (86), 242 (66), 172 (46), 159 (100). HR-MS (ESI) m/z calcd for 












The general procedure GPA was followed using 32a (85.9 mg, 0.30 mmol) and 
allene 88a (164 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 90aa (114 mg, 93%) as a colorless oil. 
1H NMR (600 MHz, C6D6): δ = 8.35 (dd, J = 7.6, 1.5 Hz, 1H), 7.49 (s, 1H), 7.05 
(ddd, J = 7.5, 7.5, 1.5 Hz, 1H), 7.00 (ddd, J = 7.5, 7.5, 1.3 Hz, 1H), 6.84 (d, 
J = 7.2, 1H), 5.54 (t, J = 7.8, 1H), 3.69 (t, J = 7.3 Hz, 2H), 3.42 (s, 2H), 2.13 (s, 
6H), 1.88 (dt, J = 7.3 Hz, 2H), 1.40–1.33 (m, 2H), 1.22–1.07 (m, 8H), 1.00–0.91 
(m, 2H), 0.83 (t, J = 7.2 Hz, 3H), 0.63 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, 
C6D6): δ = 164.7 (Cq), 153.7 (Cq), 139.0 (Cq), 135.6 (Cq), 131.6 (CH), 131.5 (Cq), 
129.1 (CH), 126.8 (CH), 126.4 (CH), 123.1 (CH), 121.9 (CH), 58.0 (Cq), 49.7 
(CH2), 32.9 (CH2), 32.5 (CH2), 32.1 (CH2), 30.2 (CH2), 30.0 (CH3), 29.5 (CH2), 
27.6 (CH2), 23.1 (CH2), 20.1 (CH2), 14.5 (CH3), 13.7 (CH3). IR (ATR): 2956, 
2927, 2856, 1649, 1457, 1375, 1323, 1169, 1046, 737 cm−1. MS (EI) m/z 
(relative intensity): 408 (6) [M]+, 323 (12), 243 (16), 172 (35), 166 (100), 172 












The general procedure GPA was followed using 32b (96.1 mg, 0.30 mmol) and 
allene 88a (164 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 90ba (100 mg, 76%) as colorless oil. 
1H NMR (600 MHz, C6D6): δ=  8.34 (dd, J = 7.7, 1.5 Hz, 1H), 7.45 (s, 1H), 7.03 
(ddd, J = 7.4, 7.4, 1.5 Hz, 1H), 7.01–6.96 (m, 4H), 6.90 (dd, J = 7.9, 1.6 Hz, 
2H), 6.82 (d, J = 7.7 Hz, 1H), 5.51 (t, J = 7.7 Hz, 1H), 4.86 (s, 2H), 3.40 (s, 2H), 
2.04 (s, 6H), 1.85 (dt, J = 7.2 Hz, 2H), 1.20–1.08 (m, 8H), 0.84 (t, J = 7.2 Hz, 
3H). 13C NMR (126 MHz, C6D6): δ = 164.7 (Cq), 154.4 (Cq), 139.0 (Cq), 136.1 
(Cq), 135.5 (Cq), 131.5 (CH), 131.5 (Cq), 129.1 (CH), 129.0 (CH), 128.4 (CH), 
128.0 (CH), 126.9 (CH), 126.3 (CH), 123.1 (CH), 121.9 (CH), 58.0 (Cq), 53.6 
(CH2), 32.8 (CH2), 32.1 (CH2), 30.1 (CH2), 29.8 (CH3), 29.5 (CH2), 27.5 (CH2), 
23.1 (CH2), 14.5 (CH3). IR (ATR): 2926, 2854, 1647, 1456, 1374, 1323, 1169, 
1046, 733, 499 cm−1. MS (ESI) m/z (relative intensity): 907 (100) [2M+Na]+,465 
(47) [M+Na]+, 443 (48) [M+H]+, 200 (50). HR-MS (ESI) m/z calcd for C28H35N4O 












The general procedure GPA was followed using 32c (101 mg, 0.30 mmol) and 
allene 88a (164 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 90ca (100 mg, 73%) as colorless oil. 
1H NMR (300 MHz, C6D6): δ = 8.39 (dd, J = 7.6, 1.7 Hz, 1H), 7.97 (s, 1H), 7.33 
(d, J = 9.0 Hz, 2H), 7.10–6.94 (m, 2H), 6.90–6.78 (m, 1H), 6.64–6.49 (m, 2H), 
5.55 (t, J = 8.1 Hz, 1H), 3.44 (s, 2H), 3.20 (s, 3H), 2.18 (s, 6H), 1.86 (t, J = 
7.2 Hz, 2H), 1.23–1.05 (m, 8H), 0.83 (t, J = 6.9 Hz, 3H). 13C NMR (75 MHz, 
C6D6): δ = 164.9 (Cq), 159.6 (Cq), 154.5 (Cq), 139.0 (Cq), 135.5 (Cq), 131.6 (CH), 
131.4 (Cq), 131.3 (Cq), 129.2 (CH), 126.9 (CH), 126.4 (CH), 123.2 (CH), 122.1 
(CH), 120.3 (CH), 114.7 (CH), 57.9 (Cq), 55.0 (CH3), 32.7 (CH2), 32.0 (CH2), 
30.0 (CH2), 29.7 (CH3), 29.4 (CH2), 27.5 (CH2), 23.0 (CH2), 14.3 (CH3). 
IR (ATR): 2928, 2855, 2167, 1648, 1516, 1252, 1172, 1038, 735, 499 cm−1. 
MS (EI) m/z (relative intensity): 458 (5) [M]+, 415 (13), 373 (12), 216 (41), 188 





                     5. Experimental Part 
97 
 




The general procedure GPA was followed using 51e (90.1 mg, 0.30 mmol) and 
allene 88a (164 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 89ea (101 mg, 80%) as white solid. 
M. p. = 71–72 °C. 1H NMR (600 MHz, CDCl3): δ = 8.21 (d, J = 8.1 Hz, 1H), 7.68 
(s, 1H), 7.20 (dd, J = 8.1, 1.7 Hz 1H), 7.18 (s, 1H), 6.26 (s, 1H), 5.35 (s, 2H), 
4.40–4.08 (m, 2H), 3.03–2.82 (m, 2H), 2.41 (s, 3H), 1.90–1.75 (m, 2H), 1.71–
1.65 (m, 2H), 1.48–1.42 (m, 2H), 1.38–1.32 (m, 2H), 1.31–1.26 (m, 4H), 1.26–
1.22 (m, 6H), 0.87 (t, J = 7.0 Hz, 3H), 0.82 (t, J = 6.9 Hz, 3H). 13C NMR 
(126 MHz, CDCl3): δ = 163.2 (Cq), 144.2 (Cq), 143.5 (Cq), 142.8 (Cq), 137.0 
(Cq), 127.6 (CH), 127.6 (CH), 125.0 (CH), 123.7 (CH), 122.0 (Cq), 105.0 (CH), 
50.4 (CH2), 39.1 (CH2), 33.1 (CH2), 31.9 (CH2), 31.2 (CH2), 30.2 (CH2), 29.4 
(CH2), 29.3 (CH2), 28.9 (CH2), 26.3 (CH2), 22.8 (CH2), 22.5 (CH2), 21.9 (CH3), 
14.2 (CH3), 14.0 (CH3). IR (ATR): 2927, 2856, 1649, 1625, 1601, 1264, 1046, 
788, 735, 702 cm−1. MS (ESI) m/z (relative intensity): 445 (100) [M+Na]+, 423 
(45) [M+H]+, 399 (5), 377 (15). HR-MS (ESI) m/z calcd for C26H39N4O [M+H]+ 










The general procedure GPA was followed using 51f (109 mg, 0.30 mmol) and 
allene 88a (164 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 89fa (102 mg, 70%) as white solid. 
M.p. = 95–96 °C. 1H NMR (300 MHz, CDCl3): δ = 8.41 (d, J = 8.2 Hz, 1H), 7.72 
(s, 1H), 7.69–7.60 (m, 4H), 7.52–7.37 (m, 3H), 6.41 (s, 1H), 5.40 (s, 2H), 4.26 
(t, J = 7.5 Hz, 2H), 3.00 (t, J = 7.8 Hz, 2H), 1.90–1.83 (m, 2H), 1.77–1.70 (m, 
2H), 1.55–1.46 (m, 2H), 1.41–1.35 (m, 2H), 1.34–1.24 (m, 10H), 0.90 (t, 
J = 7.2 Hz, 3H), 0.85 (t, J = 6.9 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ = 163.3 
(Cq), 145.2 (Cq), 144.2 (Cq), 144.1 (Cq), 140.4 (Cq), 137.4 (Cq), 129.0 (CH), 
128.4 (CH), 128.2 (CH), 127.5 (CH), 125.3 (CH), 123.9 (CH), 123.7 (CH), 123.2 
(Cq), 105.4 (CH), 50.5 (CH2), 39.1 (CH2), 33.2 (CH2), 31.9 (CH2), 31.2 (CH2), 
30.3 (CH2), 29.4 (CH2), 29.3 (CH2), 28.8 (CH2), 26.3 (CH2), 22.8 (CH2), 22.5 
(CH2), 14.2 (CH3), 14.0 (CH3). IR (ATR): 2925, 2855, 1647, 1622, 1598, 1422, 
1044, 757, 697 cm−1. MS (EI) m/z (relative intensity): 484 (86) [M]+, 413 (36), 
371 (57), 318 (50), 235 (61), 225 (44), 43 (100). HR-MS (ESI) m/z calcd 











The general procedure GPA was followed using 51g (94.9 mg, 0.30 mmol) and 
allene 88a (164 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 89ga (108 mg, 82%) as white solid. 
M.p. = 62–63 °C. 1H NMR (600 MHz, CDCl3): δ = 8.24 (d, J = 8.9 Hz, 1H), 7.69 
(s, 1H), 6.97 (dd, J = 8.9, 2.5 Hz, 1H), 6.76 (d, J = 2.5 Hz, 1H), 6.26 (s, 1H), 
5.34 (s, 2H), 4.23 (t, J = 7.5 Hz, 2H), 3.87 (s, 3H), 2.94 (t, J = 7.8 Hz, 2H), 1.86–
1.79 (m, 2H), 1.73–1.65 (m, 2H), 1.50–1.43 (m, 2H), 1.39–1.33 (m, 2H), 1.32–
1.27 (m, 4H), 1.27–1.22 (m, 6H), 0.88 (t, J = 6.9 Hz, 3H), 0.82 (t, J = 7.2 Hz, 
3H). 13C NMR (126 MHz, CDCl3): δ = 162.9 (Cq), 162.8 (Cq), 144.3 (Cq), 144.2 
(Cq), 139.0 (Cq), 129.7 (CH), 123.7 (CH), 118.2 (Cq), 115.8 (CH), 106.0 (CH), 
105.0 (CH), 55.6 (CH3), 50.5 (CH2), 39.0 (CH2), 33.2 (CH2), 31.9 (CH2), 31.3 
(CH2), 30.3 (CH2), 29.4 (CH2), 29.3 (CH2), 28.9 (CH2), 26.3 (CH2), 22.8 (CH2), 
22.5 (CH2), 14.3 (CH3), 14.1 (CH3). IR (ATR): 2953, 2925, 2855, 1648, 1619, 
1596, 1250, 1168, 1028, 788 cm−1. MS (EI) m/z (relative intensity): 438 (96) 
[M]+, 367 (61), 325 (100), 272 (72), 202 (49), 189 (75). HR-MS (EI) m/z calcd 











The general procedure GPA was followed using 51h (106 mg, 0.30 mmol) and 
allene 88a (164 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 89ha (92.9 mg, 65%) as white solid. 
M.p. = 114–116 °C. 1H NMR (300 MHz, CDCl3): δ = 8.44 (dd, J = 8.4, 1.0 Hz, 
1H), 7.74–7.68 (m, 2H), 7.58 (dd, J = 8.4, 1.7 Hz, 1H), 6.41 (s, 1H), 5.38 (s, 
2H), 4.26 (t, J = 7.5 Hz, 2H), 3.03 (t, J = 7.8 Hz, 2H), 1.91–1.79 (m, 2H), 1.76–
1.69 (m, 2H), 1.52–1.44 (m, 2H), 1.42–1.35 (m, 2H), 1.34–1.29 (m, 4H), 1.28–
1.22 (m, 6H), 0.88 (t, J = 7.0 Hz, 3H), 0.84 (t, J = 7.0 Hz, 3H). 13C NMR 
(75 MHz, CDCl3): δ = 162.6 (Cq), 145.5 (Cq), 143.6 (Cq), 136.9 (Cq), 134.0 (q, 
2JC–F = 32.4 Hz, Cq), 128.9 (CH), 126.2 (Cq), 123.9 (CH),123.9 (q, 1JC–F = 272.7 
Hz, Cq), 122.8 (q, 3JC–F = 4.2 Hz, CH), 121.8 (q, 3JC–F = 3.5 Hz, CH), 104.8 (CH), 
50.5 (CH2), 39.3 (CH2), 33.2 (CH2), 31.9 (CH2), 31.2 (CH2), 30.2 (CH2), 29.3 
(CH2), 29.3 (CH2), 28.7 (CH2), 26.2 (CH2), 22.8 (CH2), 22.5 (CH2), 14.2 (CH3), 
14.0 (CH3). 19F NMR (282 MHz, CDCl3): δ = −63.08 (s). IR (ATR): 2925, 2855, 
1653, 1607, 1322, 1157, 1121, 1065, 796, 693 cm−1. MS (EI) m/z (relative 
intensity): 476 (73) [M]+, 405 (44), 392 (44), 227 (54), 167 (35), 138 (42), 43 











The general procedure GPA was followed using 51i (91.3 mg, 0.30 mmol) and 
allene 88a (164 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 89ia (65.3 mg, 51%) as white solid. 
M.p. = 57–58 °C. 1H NMR (300 MHz, CDCl3): δ = 8.34 (dd, J = 8.9 Hz, 5.7 Hz, 
1H), 7.70 (s, 1H), 7.15–6.95 (m, 2H), 6.28 (s, 1H), 5.35 (s, 2H), 4.25 (t, 
J = 7.4 Hz, 2H), 2.97 (t, J = 7.7 Hz, 2H), 1.95–1.77 (m, 2H), 1.77–1.61 (m, 2H), 
1.53–1.42 (m, 2H), 1.40–1.34 (m, 2H), 1.32–1.23 (m, 10H), 0.83 (t, J = 7.5 Hz, 
3H), 0.83 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ = 165.2 (d,     
1JC–F = 251.8 Hz, Cq), 162.6 (Cq), 145.2 (Cq), 143.8 (Cq), 139.1 (d, 3JC–F = 
10.5 Hz, Cq), 130.9 (d, 3JC–F = 10.1 Hz, CH), 123.7 (CH), 120.9 (d, 4JC–F = 1.6 
Hz, Cq), 114.6 (d, 2JC–F = 23.6 Hz, CH), 110.0 (d, 2JC–F = 21.6 Hz, CH), 104.5 
(CH), 50.5 (CH2), 39.1 (CH2), 33.2 (CH2), 31.9 (CH2), 31.2 (CH2), 30.3 (CH2), 
29.4 (CH2), 29.3 (CH2), 28.8 (CH2), 26.3 (CH2), 22.8 (CH2), 22.5 (CH2), 14.3 
(CH3), 14.0 (CH3). 19F NMR (282 MHz, CDCl3): δ = −106.75 (ddd, J = 8.9, 8.9, 
5.9 Hz). IR (ATR): 2927, 2857, 1645, 1623, 1604, 1446, 1249, 1154, 793, 
474 cm−1. MS (ESI) m/z (relative intensity): 875 (100) [2M+Na]+, 449 (20) 
[M+Na]+, 427 (64) [M+H]+. HR-MS (ESI) m/z calcd for C25H36FN4O [M+H]+ 










The general procedure GPA was followed using 51j (96.2 mg, 0.30 mmol) and 
allene 88a (164 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 89ja (74.4 mg, 56%) as white solid. 
M.p. = 58–59 °C. 1H NMR (500 MHz, CDCl3): δ = 8.24 (d, J = 8.6 Hz, 1H), 7.69 
(s, 1H), 7.38 (d, J = 2.0 Hz, 1H), 7.31 (dd, J = 8.6, 2.0 Hz, 1H), 6.25 (s, 1H), 
5.34 (s, 2H), 4.24 (t, J = 7.4 Hz, 2H), 2.97 (t, J = 7.8 Hz, 2H), 1.87–1.79 (m, 
2H), 1.74–1.64 (m, 2H), 1.50–1.42 (m, 2H), 1.39–1.33 (m, 2H), 1.31–1.27 (m, 
4H), 1.27–1.22 (m, 6H), 0.87 (t, J = 7.0 Hz, 3H), 0.83 (t, J = 7.0 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ = 162.8 (Cq), 145.3 (Cq), 143.8 (Cq), 138.8 (Cq), 
138.2 (Cq), 129.6 (CH), 126.5 (CH), 124.6 (CH), 123.8 (CH), 122.5 (Cq), 104.2 
(CH), 50.5 (CH2), 39.1 (CH2), 33.1 (CH2), 31.8 (CH2), 31.2 (CH2), 30.2 (CH2), 
29.3 (CH2), 29.2 (CH2), 28.7 (CH2), 26.2 (CH2), 22.7 (CH2), 22.5 (CH2), 14.2 
(CH3), 13.0 (CH3). IR (ATR): 2954, 2927, 1717, 1650, 1593, 1464, 1286, 1049, 
786 cm−1. MS (EI) m/z (relative intensity): 442 (72) [35Cl, M]+, 371 (49), 358 (45), 
329 (41), 193 (57), 138 (60), 43 (100). HR-MS (EI) m/z calcd for C25H3535ClN4O 









oquinolin-6(7H)-one (89ka) and 7-n-Heptyl-6-[(1-n-hexyl-1H-1,2,3-triazol-4-
yl)methyl]-[1,3]dioxolo[4,5-g]isoquinolin-5(6H)-one (89ka’) 
 
The general procedure GPA was followed using 51k (99.1 mg, 0.30 mmol) and 
allene 88a (164 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 89ka (49.6 mg, 36%) and 89ka’ (41.3 mg, 31%) 
as white solids. 
8-n-Heptyl-7-[(1-n-hexyl-1H-1,2,3-triazol-4-yl)methyl]-[1,3]dioxolo[4,5-f]is-
oquinolin-6(7H)-one (89ka):  
M.p. = 62–63 °C. 1H NMR (600 MHz, CDCl3): δ = 7.96 (d, J = 8.5 Hz, 1H), 7.68 
(s, 1H), 6.95 (d, J = 8.5 Hz, 1H), 6.31 (s, 1H), 6.11 (s, 2H), 5.33 (s, 2H), 4.24 (t, 
J = 7.3 Hz, 2H), 2.95 (t, J = 7.8 Hz, 2H), 1.87–1.82 (m, 2H), 1.73–1.67 (m, 2H), 
1.51–1.44 (m, 2H), 1.39–1.34 (m, 2H), 1.31–1.25 (m, 10H), 0.88 (t, J = 6.9 Hz, 
3H), 0.84 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ = 162.7 (Cq), 149.5 
(Cq), 144.4 (Cq), 144.2 (Cq), 140.6 (Cq), 123.7 (CH), 123.1 (CH), 121.4 (Cq), 
119.6 (Cq), 108.2 (CH), 102.2 (CH2), 97.6 (CH), 50.5 (CH2), 39.1 (CH2), 33.4 
(CH2), 31.9 (CH2), 31.3 (CH2), 30.3 (CH2), 29.4 (CH2), 29.3 (CH2), 28.8 (CH2), 
26.3 (CH2), 22.8 (CH2), 22.6 (CH2), 14.3 (CH3), 14.1 (CH3). IR (ATR): 2954, 
2921, 1602, 1589, 1477, 1425, 1243, 1036, 936, 749 cm−1. MS (EI) m/z (relative 
intensity): 452 (100) [M]+, 381 (45), 368 (40), 339 (57), 286 (71), 203 (98). 
HR-MS (EI) m/z calcd for C26H36N4O3 [M]+ 452.2787, found 452.2779. 
 




soquinolin-5(6H)-one (89ka’):  
M.p. = 90–91 °C. 1H NMR (300 MHz, CDCl3): δ = 7.69 (s, 1H), 7.68 (s, 1H), 
6.77 (s, 1H), 6.23 (s, 1H), 6.04 (s, 2H), 5.36 (s, 2H), 4.25 (t, J = 7.4 Hz, 2H), 
2.94 (t, J = 7.8 Hz, 2H), 1.91–1.80 (m, 2H), 1.71–1.66 (m, 2H), 1.50–1.43 (m, 
2H), 1.40–1.34 (m, 2H), 1.31–1.23 (m,10H), 0.89 (t, J = 7.0 Hz, 3H), 0.84 (t, 
J = 7.2 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ = 162.4 (Cq), 152.0 (Cq), 147.2 
(Cq), 144.1 (Cq), 142.4 (Cq), 134.4 (Cq), 123.8 (CH), 119.6 (Cq), 105.5 (CH), 
105.1 (CH), 103.2 (CH), 101.6 (CH2), 50.5 (CH2), 39.3 (CH2), 33.1 (CH2), 32.0 
(CH2), 31.3 (CH2), 30.3 (CH2), 29.5 (CH2), 29.4 (CH2), 29.0 (CH2), 26.4 (CH2), 
22.8 (CH2), 22.6 (CH2), 14.3 (CH3), 14.1 (CH3). IR (ATR): 2954, 2924, 2857, 
1649, 1597, 1478, 1427, 1247, 1037, 934 cm−1. MS (EI) m/z (relative intensity): 
452 (100) [M]+, 339 (63), 286 (51), 203 (71). HR-MS (ESI) m/z calcd 




The general procedure GPA was followed using 89l (94.3 mg, 0.30 mmol) and 
allene 88a (164 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 4/1) yielded 89la (90.4 mg, 69%) as white solid. 
M.p. = 105–106 °C. 1H NMR (600 MHz, CDCl3): δ = 8.08 (s, 1H), 7.68 (s, 1H), 
7.17 (s, 1H), 6.24 (s, 1H), 5.35 (s, 2H), 4.22 (t, J = 7.8 Hz, 2H), 2.92 (t, 
J = 7.8 Hz, 2H), 2.35 (s, 3H), 2.33 (s, 3H), 1.87–1.77 (m, 2H), 1.71–1.64 (m, 
2H), 1.48–1.42 (m, 2H), 1.38–1.31 (m, 2H), 1.29–1.27 (m, 4H), 1.26–1.22 (m, 
6H), 0.87 (t, J = 7.0 Hz, 3H), 0.82 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, 
CDCl3): δ = 163.1 (Cq), 144.3 (Cq), 142.6 (Cq), 142.2 (Cq), 135.3 (Cq), 135.2 
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(Cq), 127.6 (CH), 125.7 (CH), 123.7 (CH), 122.4 (Cq), 104.8 (CH), 50.4 (CH2), 
39.1 (CH2), 33.1 (CH2), 31.9 (CH2), 31.2 (CH2), 30.3 (CH2), 29.4 (CH2), 29.3 
(CH2), 28.9 (CH2), 26.3 (CH2), 22.8 (CH2), 22.5 (CH2), 20.4 (CH3), 19.9 (CH3), 
14.2 (CH3), 14.0 (CH3). IR (ATR): 2954, 2921, 2857, 1647, 1594, 1455, 1378, 
1052, 897, 797 cm−1. MS (ESI) m/z (relative intensity): 896 (56) [2M+Na]+, 437 





The general procedure GPA was followed using 51m (87.7 mg, 0.30 mmol) and 
allene 88a (164 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 4/1) yielded 89ma (83.3 mg, 67%) as white solid.  
M.p. = 94–95 °C. 1H NMR (600 MHz, CDCl3): δ = 7.75 (s, 1H), 7.62 (d, J = 5.1 
Hz, 1H), 7.10 (d, J = 5.1 Hz, 1H), 6.50 (s, 1H), 5.39 (s, 2H), 4.24 (t, J = 7.8 Hz, 
2H), 3.00 (t, J = 3.0 Hz, 2H), 1.86–1.80 (m, 2H), 1.72–1.65 (m, 2H), 1.50–1.43 
(m, 2H), 1.39–1.33 (m, 2H), 1.30–1.22 (m, 10H), 0.88 (t, J = 7.0 Hz, 3H), 0.85–
0.81 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ = 159.4 (Cq), 145.3 (Cq), 
145.1 (Cq), 143.8 (Cq), 133.3 (CH), 127.5 (Cq), 124.0 (CH), 124.0 (CH), 102.5 
(CH), 50.5 (CH2), 39.1 (CH2), 33.3 (CH2), 31.9 (CH2), 31.3 (CH2), 30.3 (CH2), 
29.4 (CH2), 29.3 (CH2), 28.1 (CH2), 26.3 (CH2), 22.8 (CH2), 22.5 (CH2), 14.3 
(CH3), 14.1 (CH3). IR (ATR): 3061, 2923, 2853, 1635, 1576, 1444, 1053, 805, 
792, 657 cm−1. MS (ESI) m/z (relative intensity): 851 (100) [2M+Na]+, 437 (38) 
[M+Na]+, 415 (20) [M+H]+. HR-MS (ESI) m/z calcd for C23H35N4OS [M+H]+ 
415.2526, found 415.2525. 
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The general procedure GPA was followed using 32f (90.1 mg, 0.30 mmol) and 
allene 88a (164 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 90fa (86.2 mg, 68%) as a colorless oil. 
1H NMR (600 MHz, C6D6): δ = 8.32 (d, J = 7.9 Hz, 1H), 7.50 (s, 1H), 6.81 (dd, 
J = 7.9, 1.7, 1H), 6.63 (s, 1H), 5.58 (t, J = 7.7 Hz, 1H), 3.65 (t, J = 7.3 Hz, 2H), 
3.43 (s, 2H), 2.17 (s, 6H), 2.00 (s, 3H), 1.93 (dt, J = 7.4 Hz, 2H), 1.39–1.30 (m, 
2H), 1.21–1.10 (m, 8H), 0.98–0.91 (m, 2H), 0.84 (t, J = 7.1 Hz, 3H), 0.62 (t, 
J = 7.4 Hz, 3H). 13C NMR (126 MHz, C6D6): δ = 164.9 (Cq), 153.7 (Cq), 141.8 
(Cq), 139.0 (Cq), 135.8 (Cq), 129.2 (CH), 129.0 (Cq), 127.7 (CH), 127.0 (CH), 
122.8 (CH), 122.0 (CH), 57.9 (Cq), 49.6 (CH2), 32.9 (CH2), 32.5 (CH2), 32.1 
(CH2), 30.2 (CH2), 30.1 (CH3), 29.5 (CH2), 27.6 (CH2), 23.2 (CH2), 21.5 (CH3), 
20.1 (CH2), 14.5 (CH3), 13.6 (CH3). IR (ATR): 2957, 2930, 2871, 1648, 1457, 
1378, 1163, 1046, 835, 498 cm−1. MS (ESI) m/z (relative intensity): 868 (100) 
[2M+Na]+, 445 (94) [M+Na]+, 423 (93) [M+H]+, 407 (100) [M+H]+. HR-MS (ESI) 










The general procedure GPA was followed using 32g (106 mg, 0.30 mmol) and 
allene 88a (164 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 90ga (116 mg, 81%) as a colorless oil. 
1H NMR (600 MHz, C6D6): δ = 8.19 (d, J = 8.1 Hz, 1H), 7.35 (s, 1H), 7.15–7.11 
(m, 1H), 7.09 (d, J = 1.7 Hz, 1H), 5.57 (t, J = 7.8 Hz, 1H), 3.66 (t, J = 7.3 Hz, 
2H), 3.27 (s, 2H), 2.08 (s, 6H), 1.83 (dt, J = 7.4 Hz, 2H), 1.37–1.32 (m, 2H), 
1.19–1.05 (m, 8H), 0.98–0.92 (m, 2H), 0.84 (t, J = 7.2 Hz, 3H), 0.63 (t, 
J = 7.4 Hz, 3H). 13C NMR (126 MHz, C6D6): δ = 163.4 (Cq), 153.3 (Cq), 139.8 
(Cq), 134.5 (Cq), 134.4 (Cq) 133.0 (q, 2JC–F = 32.0 Hz, Cq), 129.6 (CH), 128.3 
(CH), 124.6 (q, 1JC–F = 272.3 Hz, Cq), 123.7 (q, 3JC–F = 3.6 Hz, CH), 123.4 (q, 
3JC–F = 3.7 Hz, CH), 121.6 (CH), 58.2 (Cq), 49.7 (CH2), 32.5 (CH2), 32.5 (CH2), 
32.1 (CH2), 30.0 (CH2), 29.8 (CH3), 29.4 (CH2), 27.6 (CH2), 23.1 (CH2), 20.0 
(CH2), 14.4 (CH3), 13.6 (CH3). 19F NMR (282 MHz, C6D6) : δ = −62.50 (s). 
IR (ATR): 2930, 2858, 1652, 1458, 1431, 1324, 1166, 1126, 730, 418 cm−1. 
MS (ESI) m/z (relative intensity): 975 (75) [2M+Na]+, 953 (13) [2M+H]+, 499 (42) 
[M+Na]+, 477 (100) [M+H]+. HR-MS (ESI) m/z calcd for C26H36F3N4O [M+H]+ 










The general procedure GPA was followed using 32h (99.7 mg, 0.30 mmol) and 
allene 88a (164 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 90ha (96.8 mg, 71%) as a colorless oil. 
1H NMR (300 MHz, C6D6): δ = 8.27 (d, J = 8.1, 1H), 7.46 (s, 1H), 6.83 (dd, 
J = 8.2, 2.0 Hz, 1H), 6.80 (s, 1H), 5.58 (t, J = 7.7 Hz, 1H), 3.65 (t, J = 7.3 Hz, 
2H), 3.37 (s, 2H), 2.16 (s, 6H),1.95–1.88 (m, 2H), 1.87 (s, 3H), 1.45–1.29 (m, 
2H), 1.23–1.07 (m, 8H), 1.02–0.90 (m, 2H), 0.85 (t, J = 6.9 Hz, 3H), 0.63 (t, 
J = 7.3 Hz, 3H). 13C NMR (126 MHz, C6D6): δ = 164.7 (Cq), 153.7 (Cq), 143.9 
(Cq), 139.4 (Cq), 135.4 (Cq), 129.6 (CH), 128.4 (Cq) 123.8 (CH), 123.4 (CH), 
123.2 (CH), 121.9 (CH), 57.9 (Cq), 49.7 (CH2), 32.9 (CH2), 32.4 (CH2), 32.1 
(CH2), 30.2 (CH2), 30.0 (CH3), 29.5 (CH2), 27.6 (CH2), 23.2 (CH2), 20.1 (CH2), 
14.7 (CH3), 14.5 (CH3), 13.6 (CH3). IR (ATR): 2956, 2927, 2856, 1645, 1593, 
1323, 1164, 1046, 831, 677 cm−1. MS (ESI) m/z (relative intensity): 932 (100) 
[2M+Na]+, 910 (18) [2M+H]+, 477 (39) [M+Na]+, 455 (46) [M+H]+. HR-MS (ESI) 












The general procedure GPA was followed using 32i (110 mg, 0.30 mmol) and 
allene 88a (164 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 90ia (131 mg, 90%) as a colorless oil. 
1H NMR (300 MHz, C6D6): δ = 8.03 (d, J = 8.3 Hz, 1H), 7.38 (s, 1H), 7.06 (dd, 
J = 8.3, 2.0 Hz, 1H), 6.96 (s, 1H), 5.56 (t, J = 7.8 Hz, 1H), 3.64 (t, J = 7.3 Hz, 
2H), 3.23 (s, 2H), 2.09 (s, 6H), 1.90–1.76 (m, 2H), 1.42–1.26 (m, 2H), 1.24–
1.08 (m, 8H), 1.01–0.83 (m, 5H), 0.62 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, 
C6D6): δ = 163.9 (Cq), 153.4 (Cq), 140.9 (Cq), 134.8 (Cq), 130.7 (CH), 130.3 (Cq), 
130.2 (CH), 129.4 (CH), 126.2 (Cq), 123.8 (CH), 121.7 (CH), 58.1 (Cq), 49.7 
(CH2), 32.5 (CH2), 32.5 (CH2), 32.1 (CH2), 30.1 (CH2), 29.8 (CH3), 29.5 (CH2), 
27.6 (CH2), 23.2 (CH2), 20.0 (CH2), 14.5 (CH3), 13.6 (CH3). IR (ATR): 2956, 
2927, 2855, 1649, 1590, 1321, 1167, 1045, 766, 498 cm−1. MS (ESI) m/z 
(relative intensity): 509 (16) [79Br, 2M+Na]+, 487 (34) [79Br, M+H]+, 166 (100). 












The general procedure GPA was followed using 32j (91.3 mg, 0.30 mmol) and 
allene 88a (164 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 90ja (97.3 mg, 76%) as a colorless oil. 
1H NMR (600 MHz, C6D6): δ = 8.06 (dd, J = 9.3, 2.8 Hz, 1H), 7.43 (s, 1H), 6.72 
(ddd, J = 8.3, 8.3, 2.8 Hz, 1H), 6.60 (dd, J = 8.3, 5.1 Hz, 1H), 5.55 (t, J = 7.8 Hz, 
1H), 3.69 (t, J = 7.3 Hz, 2H), 3.32 (s, 2H), 2.09 (s, 6H), 1.87 (dt, J = 7.3 Hz, 2H), 
1.41–1.33 (m, 2H), 1.21–1.06 (m, 8H), 1.00–0.90 (m, 2H), 0.84 (t, J = 7.2 Hz, 
3H), 0.64 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, C6D6): δ = 163.5 (d,   4JC–
F  = 2.5 Hz, Cq), 162.1 (d, 1JC–F = 244.0 Hz, Cq), 153.4 (Cq), 135.2 (Cq), 134.7 
(d, 4JC–F = 3.0 Hz, Cq), 133.4 (d, 3JC–F = 7.1 Hz, Cq), 128.4 (CH), 123.6 (CH), 
121.8 (CH), 118.5 (d, 2JC–F = 22.0 Hz, CH), 115.4 (d, 2JC–F = 23.0 Hz, CH), 58.2 
(Cq), 49.7 (CH2), 32.5 (CH2), 32.1 (CH2), 32.0 (CH2), 30.1 (CH2), 29.8 (CH3), 
29.5 (CH2), 27.6 (CH2), 23.1 (CH2), 20.0 (CH2), 14.4 (CH3),13.6 (CH3). 19F NMR 
(282 MHz, C6D6): δ = −115.37 (td, J = 8.6, 5.0 Hz). IR (ATR): 2955, 2928, 2858, 
1713, 1684, 1606, 1484, 1347, 1280, 1151, 783 cm−1. MS (ESI) m/z (relative 
intensity): 875 (56) [2M+Na]+, 853 (11) [2M+H]+, 427 (100) [M+H]+, 166 (96). 
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5.3.4 Analytical Data – Products of TAM Benzamide Annulation with 




The general procedure GPA was followed using 32a (85.9 mg, 0.30 mmol) and 
allene 88h (151 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 90ah (90.0 mg, 76%) as a colorless oil. 
1H NMR (600 MHz, C6D6): δ = 8.40 (dd, J = 7.6, 1.5 Hz, 1H), 7.47 (s, 1H), 7.03 
(ddd, J = 7.4, 7.4, 1.6 Hz, 1H), 6.99 (ddd, J = 7.4, 7.4, 1.4 Hz, 1H), 6.82 (dd, 
J = 7.4, 1.0 Hz, 1H), 5.57 (t, J = 7.7 Hz, 1H), 3.65 (t, J = 7.3 Hz, 2H), 3.40 (s, 
2H), 2.15 (s, 6H), 1.86 (dt, J = 7.5 Hz, 2H), 1.38–1.29 (m, 2H), 1.18–1.05 (m, 
6H), 0.98–0.91 (m, 2H), 0.79 (t, J = 7.2 Hz, 3H), 0.62 (t, J = 7.4 Hz, 3H). 
13C NMR (126 MHz, C6D6): δ = 164.7 (Cq), 153.6 (Cq), 139.0 (Cq), 135.5 (Cq), 
131.5 (CH), 131.5 (Cq), 129.1 (CH), 126.9 (CH), 126.3 (CH), 123.1 (CH), 121.9 
(CH), 58.0 (Cq), 49.6 (CH2), 32.9 (CH2), 32.4 (CH2), 32.0 (CH2), 30.0 (CH2), 
29.9 (CH3), 27.5 (CH2), 23.0 (CH2), 20.0 (CH2), 14.4 (CH3), 13.6 (CH3). 
IR (ATR): 2927, 2861, 1647, 1457, 1372, 1319, 1168, 1045, 736 cm−1. MS (ESI) 
m/z (relative intensity): 811 (4) [2M+Na]+, 395 (22) [M+H]+, 166 (100). HR-MS 










The general procedure GPA was followed using 32a (85.9 mg, 0.30 mmol) and 
allene 88i (182 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 90ai (112 mg, 87%) as a colorless oil. 
1H NMR (300 MHz, C6D6): δ = 8.49–8.27 (m, 1H), 7.44 (s, 1H), 7.13–7.05 (m, 
2H), 7.03–6.98 (m, 3H), 6.97–6.93 (m, 2H), 6.77–6.72 (m, 1H), 5.56 (t, 
J = 7.6 Hz, 1H), 3.66 (t, J = 7.3 Hz, 2H), 3.31 (s, 2H), 2.37 (t, J = 7.7 Hz, 2H), 
2.18–2.12 (m, 2H), 2.10 (s, 6H), 1.46–1.24 (m, 2H), 1.02–0.86 (m, 2H), 0.62 (t, 
J = 7.3 Hz, 3H). 13C NMR (75 MHz, C6D6): δ = 164.7 (Cq), 153.7 (Cq), 141.7 
(Cq), 138.8 (Cq), 136.0 (Cq), 131.6 (CH), 131.3 (Cq), 129.0 (CH), 128.7 (CH), 
128.6 (CH), 126.8 (CH), 126.4 (CH), 126.3 (CH), 122.0 (CH), 121.8 (CH), 57.9 
(Cq), 49.5 (CH2), 36.1 (CH2), 32.6 (CH2), 32.3 (CH2), 29.8 (CH3), 29.3 (CH2), 
19.9 (CH2), 13.5 (CH3). IR (ATR): 2931, 2866, 1648, 1456, 1373, 1321, 1167, 
738, 699 cm−1. MS (ESI) m/z (relative intensity): 451 (78) [M+Na]+, 429 













The general procedure GPA was followed using 32a (85.9 mg, 0.30 mmol) and 
allene 88j (222 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 90aj (111 mg, 78%) as a colorless oil. 
1H NMR (300 MHz, C6D6): δ = 8.41–8.36 (m, 1H), 7.44 (s, 1H), 7.30–7.25 (m, 
2H), 7.23–7.18 (m, 2H), 7.14–7.07 (m, 1H), 7.03–6.97 (m, 2H), 6.80–6.74 (m, 
1H), 5.53 (t, J = 7.9 Hz, 1H), 4.22 (s, 2H), 3.66 (t, J = 7.3 Hz, 2H), 3.41 (s, 2H), 
3.13 (t, J = 6.0 Hz, 2H), 2.12 (s, 6H), 2.04 (dt, J = 7.4 Hz, 2H), 1.48–1.29 (m, 
4H), 1.04–0.85 (m, 2H), 0.62 (t, J = 7.3 Hz, 3H). 13C NMR (75 MHz, C6D6): 
δ = 164.8 (Cq), 153.6 (Cq), 139.5 (Cq), 139.0 (Cq), 136.1 (Cq), 131.5 (CH), 131.4 
(Cq), 129.0 (CH), 128.6 (CH), 127.7 (CH),127.6 (CH), 126.8 (CH), 126.5 (CH), 
122.3 (CH), 121.9 (CH), 73.0 (CH2), 69.3 (CH2), 57.9 (Cq), 49.5 (CH2), 32.5 
(CH2), 32.3 (CH2), 30.0 (CH2), 29.8 (CH3), 23.9 (CH2), 19.9 (CH2), 13.5 (CH3). 
IR (ATR): 2930, 2863, 1648, 1456, 1371, 1320, 1102, 738, 697, 459 cm−1. 
MS (ESI) m/z (relative intensity): 495 (6) [M+Na]+, 473 (31) [M+H]+, 308 (10), 











The general procedure GPA was followed using 32a (85.9 mg, 0.30 mmol) and 
allene 88k (195 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 90ak (90.4 mg, 68%) as a colorless oil. 
1H NMR (300 MHz, C6D6): δ = 8.41–8.32 (m, 1H), 7.49 (s, 1H), 7.09–6.95 (m, 
2H), 6.88–6.76 (m, 1H), 5.56 (t, J = 7.8 Hz, 1H), 3.67 (t, J = 7.3 Hz, 2H), 3.40 
(s, 2H), 3.08 (t, J = 6.7 Hz, 2H), 2.13 (s, 6H), 1.83 (dt, J = 7.4 Hz, 2H), 1.42–
1.27 (m, 4H), 1.09–0.86 (m, 8H), 0.63 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, 
C6D6): δ = 164.7 (Cq), 153.5 (Cq), 139.0 (Cq), 135.6 (Cq), 131.6 (CH), 131.4 (Cq), 
129.1 (CH), 126.9 (CH), 126.3 (CH), 122.9 (CH), 122.0 (CH), 57.9 (Cq), 49.7 
(CH2), 45.1 (CH2), 32.9 (CH2), 32.9 (CH2), 32.5 (CH2), 29.9 (CH3), 29.8 (CH2), 
28.8 (CH2), 27.3 (CH2), 27.0 (CH2), 20.0 (CH2), 13.7 (CH3). IR (ATR): 2931, 
2857, 1601, 1457, 1374, 1323, 1306, 1046, 737 cm−1. MS (EI) m/z (relative 
intensity): 442 (6) [35Cl, M]+, 323 (15), 242 (13), 172 (39), 166 (100), 84 (38). 
HR-MS (ESI) m/z calcd for C25H35N4O35Cl [M+Na]+ 465.2392, found 465.2380. 
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5.3.5 Traceless Removal of TAM Group 
 
To a stirred solution of benzamide 32a (85.9 mg, 0.30 mmol), ZnBr2·TMEDA 
(206 mg, 0.60 mmol), dppe (17.9 mg, 15 mol %) in THF (0.20 mL), iPrMgBr 
(3.0 M in 2-MeTHF, 300 µL, 0.90 mmol) was added in one portion and the 
reaction mixture was stirred for 5 min at ambient temperature. Then, Fe(acac)3 
(15.9 mg, 15 mol %) was added in a single portion. After stirring the solution for 
an additional 5 min, allene 88a (164 mg, 0.90 mmol) was added as a solutionin 
THF (0.20 mL) in one portion. After completion, the mixture was placed in a 
pre-heated oil bath at 65 °C, and stirred for 16 h. The reaction mixture was then 
transfered into a sealed tube using THF (2.0 mL). Conc. HCl (5.0 mL) was 
added, and the reaction mixture was placed in a pre-heated oil bath at 130 °C 
and stirred for 5 h. The mixture was allowed to cool to ambient temperature. 
The reaction mixture was extracted with CH2Cl2 (3  15 mL), and the combined 
organic layers were washed with sat. aqueous NaHCO3 (15 mL), dried over 
Na2SO4, filtered and concentrated. Purification by column chromatography 
(nhexane/EtOAc = 5/1) yielded 102 (65.7 mg, 90%) as a white solid. 
M.p. = 86–87 °C. 1H NMR (600 MHz, CDCl3): δ = 10.82 (s, 1H), 8.39–8.36 (m, 
1H), 7.62 (ddd, J = 8.1, 7.1, 1.4 Hz, 1H), 7.47 (d, J = 7.9 Hz, 1H), 7.42 (ddd, 
J = 8.1, 7.1, 1.1 Hz, 1H), 6.31 (s, 1H), 2.63 (t,J = 7.0 Hz, 2H), 1.75 (dt, J = 15.3, 
7.6 Hz, 2H), 1.43–1.38 (m, 2H), 1.37–1.32 (m, 2H), 1.30–1.25 (m, 4H), 0.87 (t, 
J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ = 164.5 (Cq), 142.0 (Cq), 138.8 
(Cq), 132.6 (CH), 127.4 (CH), 125.8 (CH), 125.7 (CH), 124.5 (Cq), 103.9 (CH), 
33.7 (CH2), 31.9 (CH2), 29.3 (CH2), 29.2 (CH2), 28.6 (CH2), 22.9 (CH2), 14.3 
(CH3). IR (ATR): 2926, 2855, 1642, 1607, 1555, 1465, 1346, 1044, 755, 
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582 cm−1. MS (EI) m/z (relative intensity): 243 (42) [M]+, 172 (29), 159 (100), 
158 (18), 41 (33). HR-MS (EI) m/z calcd for C16H21NO [M]+ 243.1623, found 
243.1623. 
5.3.6 Mechanistic Studies 
Intermolecular Competition Experiment 
 
To a stirred solution of 51e (45.1 mg, 0.15 mmol), 51h (53.3 mg, 0.15 mmol), 
ZnBr2·TMEDA (206 mg, 0.60 mmol), dppe (17.9 mg, 15 mol %) in THF 
(0.20 mL), iPrMgBr (3.0 M in 2-MeTHF, 300 µL, 0.90 mmol) was added in one 
portion and the reaction mixture was stirred for 5 min at ambient temperature. 
Then, Fe(acac)3 (15.9 mg, 15 mol %) was added in a single portion. After 
stirring the solution for additional 5 min, a solution of allene 88a (164 mg, 
0.90 mmol) in THF (0.20 mL) was added in one portion. The mixture was placed 
in a pre-heated oil bath at 65 °C. After stirring for 2 min, sat. aqueous NH4Cl 
(2.0 mL) was added to the reaction mixture, which was extracted with CH2Cl2 
(3  15 mL). The combined organic extracts were dried over Na2SO4, filtered 
and concentrated. Purification by column chromatography 
(nhexane/EtOAc = 3/1) yielded 89ea (19.0 mg, 15%) and 89ha (35.7 mg, 25%). 
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Kinetic Isotope Effect (KIE) Measurement 
 
To a stirred solution of 51a (172 mg, 0.60 mmol) or [D]5-51a (175 mg, 
0.60 mmol), ZnBr2·TMEDA (412 mg, 1.20 mmol) and dppe (35.8 mg, 15 mol %) 
in THF (1.2 mL), iPrMgBr (3.0 M in THF, 600 μL, 1.80 mmol) was added in one 
portion and the reaction mixture was stirred for 5 min at ambient temperature. 
Fe(acac)3 (31.8 mg, 15 mol %) was added in a single portion. After stirring the 
solution for additional 5 min, allene 88a (328 mg, 1.80 mmol) was added as a 
solution in THF (1.2 mL) in one portion. An in stitu IR spectrum was acquired 
every 30 s for 2 h. 
The KIE was determined by measuring initial rates from the increase of the 
peak at 1643 cm−1, which corresponds to a C=O vibration of product 89aa. The 
absolute peak area was measured from 1659 to 1635 cm–1 with a one-point 
baseline at 1659 cm–1. A linear fit was employed to derive the initial rates.  
 





Figure 5.1. Plot of peak area at 1643 cm–1 vs reaction time for 89aa (top) and [D]5-
89aa (bottom). 
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Intermolecular KIE Measurement 
 
To a stirred solution of 51a (43.0 mg, 0.15 mmol), [D]5-51a (43.7 mg, 
0.15 mmol), ZnBr2·TMEDA (206 mg, 0.60 mmol) and dppe (17.9 mg, 15 mol 
%) in THF (0.6 mL), iPrMgBr (3.0 M in THF, 300 μL, 0.9 mmol) was added in 
one portion and the reaction mixture was stirred for 5 min at ambient 
temperature. Fe(acac)3 (15.9 mg, 15 mol %) was added in a single portion. 
After stirring the solution for additional 5 min, allene 88a (164 mg, 0.90 mmol) 
was added as a solution in THF (0.6 mL) in one portion. After stirring for 45 min, 
sat. aqueous NH4Cl (2.0 mL) was added to the reaction mixture, which was 
then extracted with CH2Cl2 (3  15 mL). The combined organic extracts were 
dried over Na2SO4, filtered and concentrated. The crude product was purified 
by column chromatography (nhexane/EtOAc = 3/1). The mixture was analyzed 
by 1H-NMR spectroscopy to determine the ratio of 89aa/[D]4-89aa. 
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Experiments with Isotopically-labelled Substrates 
 
To a stirred solution of [D]5-51a (87.4 mg, 0.30 mmol), ZnBr2·TMEDA (206 mg, 
0.60 mmol), dppe (17.9 mg, 15 mol %) in THF (0.20 mL), iPrMgBr (3.0 M in 2-
MeTHF, 300 µL, 0.90 mmol) was added in one portion and the reaction mixture 
was stirred for 5 min at ambient temperature. Then, Fe(acac)3 (15.9 mg, 
15 mol %) was added in a single portion. After stirring the solution for additional 
5 min, a solution of allene 88a (164 mg, 0.90 mmol) in THF (0.20 mL) was 
added in one portion. The mixture was placed in a pre-heated oil bath at 65 °C. 
After stirring for 16 h, sat. aqueous NH4Cl (2.0 mL) was added to the reaction 
mixture, which was extracted with CH2Cl2 (3  15 mL). The combined organic 
extracts were dried over Na2SO4, filtered and concentrated. Purification by 
column chromatography (nhexane/EtOAc = 3/1) yielded [D]4-89aa (79.2 mg, 
64%) as white solid. HR-MS (ESI) m/z calcd for C25H33N4OD4 [M+H]+ 413.3213, 
found 413.3201. 








To a stirred solution of 51a (85.9 mg, 0.30 mmol), ZnBr2·TMEDA (206 mg, 0.60 
mmol), dppe (17.9 mg, 15 mol %) in d8-THF (0.20 mL), iPrMgBr (3.0 M in 2-
MeTHF, 300 µL, 0.90 mmol) was added in a single portion and the reaction 
mixture was stirred for 5 min at ambient temperature. Then, Fe(acac)3 
(15.9 mg, 15 mol %) was added in a single portion. After stirring the solution for 
additional 5 min, a solution of allene 88a (166 mg, 0.90 mmol) in d8-THF 
(0.20 mL) was added in one portion. The mixture was placed in a pre-heated 
oil bath at 65 °C. After stirring for 16 h, sat. aqueous NH4Cl (2.0 mL) was added 
to the reaction mixture, which was extracted with CH2Cl2 (3  15 mL). The 
combined organic extracts were dried over Na2SO4, filtered and concentrated. 
The crude product was purified by column chromatography 
(nhexane/EtOAc = 3/1) yielded 89aa (76.4 mg, 64%).  
 
To a stirred solution of [D]-51a (86.1 mg, 0.30 mmol), ZnBr2·TMEDA (206 mg, 
0.60 mmol), dppe (17.9 mg, 15 mol %) in THF (0.20 mL), iPrMgBr (3.0 M in 2-
MeTHF, 300 µL, 0.90 mmol) was added in a single portion and the reaction 
mixture was stirred for 5 min at ambient temperature. Then, Fe(acac)3 
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(15.9 mg, 15 mol %) was added in a single portion. After stirring the solution for 
additional 5 min, a solution of allene 88a (166 mg, 0.90 mmol) in THF (0.20 mL) 
was added in one portion. The mixture was placed in a pre-heated oil bath at 
65 °C. After stirring for 16 h, sat. aqueous NH4Cl (2.0 mL) was added to the 
reaction mixture, which was extracted with CH2Cl2 (3  15 mL). The combined 
organic extracts were dried over Na2SO4, filtered and concentrated. The crude 
product was purified by column chromatography (nhexane/EtOAc = 3/1) 
yielded [D]-89aa (76.4 mg, 64%).  
 
To a stirred solution of 32a (85.9 mg, 0.30 mmol), ZnBr2·TMEDA (206 mg, 0.60 
mmol), dppe (17.9 mg, 15 mol %) in THF (0.20 mL), iPrMgBr (3.0 M in 2-
MeTHF, 300 µL, 0.90 mmol) was added in a single portion and the reaction 
mixture was stirred for 5 min at ambient temperature. Then, Fe(acac)3 
(15.9 mg, 15 mol %) was added in a single portion. After stirring the solution for 
additional 5 min, a solution of allene [D]2-88a (166 mg, 0.90 mmol) in THF 
(0.20 mL) was added in one portion. The mixture was placed in a pre-heated 
oil bath at 65 °C. After stirring for 16 h, sat. aqueous NH4Cl (2.0 mL) was added 
to the reaction mixture, which was extracted with CH2Cl2 (3  15 mL). The 
combined organic extracts were dried over Na2SO4, filtered and concentrated. 
The crude product was purified by column chromatography 
(nhexane/EtOAc = 3/1) yielded [D]2-90aa (87.5 mg, 71%). HR-MS (ESI) m/z 
calcd for C25H35N4OD2 [M+H]+ 411.3087, found 411.3094. 








Experiments with DCIB as Additive 
 
To a stirred solution of 51a (86.1 mg, 0.30 mmol), ZnBr2·TMEDA (206 mg, 
0.60 mmol), dppe (17.9 mg, 15 mol %) in THF (0.20 mL), iPrMgBr (3.0 M in 2-
MeTHF, 300 µL, 0.90 mmol) was added in a single portion and the reaction 
mixture was stirred for 5 min at ambient temperature. Then, Fe(acac)3 
(15.9 mg, 15 mol %) was added in a single portion. After stirring the solution for 
additional 5 min, a solution of allene 88a (166 mg, 0.90 mmol) and DCIB 
(76.2 mg, 0.60 mmol) in THF (0.20 mL) was added in one portion. The mixture 
was placed in a pre-heated oil bath at 65 °C. After stirring for 16 h, sat. aqueous 
NH4Cl (2.0 mL) was added to the reaction mixture, which was extracted with 
CH2Cl2 (3  15 mL). The combined organic extracts were dried over Na2SO4, 
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filtered and concentrated. The crude product was purified by column 
chromatography (nhexane/EtOAc = 3/1) yielded 89aa (101 mg, 85%).  
5.4 Iron-Catalyzed C–H/N–H Annulation with Propargyl 
Acetates 




The general procedure GPB was followed using 51a (85.9 mg, 0.30 mmol) and 
alkyne 88a (130 mg, 0.60 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/2) yielded 92aa (79.5 mg, 60%) as a white solid.  
M.p. = 97–98 °C. 1H NMR (600 MHz, CDCl3): δ = 8.49 (d, J = 8.0 Hz, 1H), 
7.74–7.68 (m, 3H), 7.48 (t, J = 7.3 Hz, 1H), 7.33 (t, J = 7.7 Hz, 2H), 7.28–7.24 
(m, 3H), 5.19 (br s, 2H), 4.61 (s, 2H), 4.26 (t, J = 7.3 Hz, 2H), 2.77–2.71 (m, 
2H), 1.89–1.82 (m, 2H), 1.61–1.53 (m, 2H), 1.32–1.23 (m, 6H), 0.99 (t, 
J = 7.3 Hz, 3H), 0.84 (t, J = 6.7 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ = 162.7 
(Cq), 144.2 (Cq), 137.4 (Cq), 137.1 (Cq), 136.7 (Cq), 132.4 (CH), 129.1 (CH), 
128.3 (CH), 128.0 (CH), 126.9 (CH), 126.2 (CH), 125.3 (Cq), 124.0 (CH), 123.1 
(CH), 116.4 (Cq), 50.5 (CH2), 40.0 (CH2), 35.0 (CH2), 31.3 (CH2), 30.4 (CH2), 
30.3 (CH2), 26.3 (CH2), 23.6 (CH2), 22.6 (CH2), 14.6 (CH3), 14.1 (CH3). 
IR (ATR): 3122, 2952, 2931, 1650, 1610, 1313, 1063, 776, 732, 715 cm−1. 
MS (EI) m/z (relative intensity): 442 (72) [M]+, 329 (32), 276 (86), 248 (100), 
                     5. Experimental Part 
128 
 
242 (47), 112 (64). HR-MS (EI) m/z calcd for C28H34N4O [M]+ 442.2733, found 
442.2722. 
5.4.2 Traceless Removal of TAH Group 
 
Figure 5.2 Traceless removal of TAH group. 
The general procedure GPD was followed using 92aa (97.0 mg, 0.22 mmol). 
Purification by column chromatography (nhexane/EtOAc = 3/2) yielded 93aa 
(54.0 mg, 73%) as a white solid. 
M.p. = 194–196 °C. 1H NMR (300 MHz, CDCl3): δ = 9.92 (s, 1H), 8.44 (d, 
J = 7.9 Hz, 1H), 7.72 (dd, J = 4.3, 2.0 Hz, 2H), 7.48 (ddd, J = 8.1, 5.4, 2.8 Hz, 
1H), 7.38–7.18 (m, 5H), 4.08 (s, 2H), 2.81 (t, J = 8.1, 2H), 1.65–1.54 (m, 2H), 
1.06 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ = 163.2 (Cq), 138.3 (Cq), 
137.1 (Cq), 135.5 (Cq), 132.6 (CH), 129.1 (CH), 128.9 (CH), 128.0 (CH), 127.3 
(CH), 125.9 (CH), 125.6 (Cq), 123.3 (CH), 114.2 (Cq), 36.8 (CH2), 29.0 (CH2), 
23.5 (CH2), 14.4 (CH3). IR (ATR): 3022, 2954, 2871, 2031, 1653, 1630, 1606, 
758, 709, 511 cm−1. MS (ESI) m/z (relative intensity): 168 (100), 278 (67) 
[M+H]+, 577 (25) [2M+Na]+. HR-MS (ESI) m/z calcd for C19H19NO [M+H]+ 
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5.4.3 Mechanistic Studys 
Reaction Using Deuterium-Labelled Solvent 
 
To a stirred solution of 51a (85.9 mg, 0.3 mmol), ZnBr2∙TMEDA (205 mg, 
0.60 mmol) and dppe (17.9 mg, 15 mol %) in d8-THF (0.4 mL), iPrMgBr (0.5 M 
in d8-THF, 1.8 mL, 0.90 mmol) was added in one portion and the reaction 
mixture was stirred for 5 min at ambient temperature. Then, FeCl2 (5.7 mg, 
15 mol %) was added in a single portion. After stirring for additional 5 min, a 
solution of alkyne 91a (130 mg, 0.60 mmol) in d8-THF (0.40 mL) was added in 
one portion. The reaction mixture was stirred at ambient temperature. After 
16 h, sat. aqueous NH4Cl (3.0 mL) was added and the reaction mixture was 
extracted with CH2Cl2 (3  15 mL). The combined organic extracts were dried 
over Na2SO4, filtered and concentrated. Purification by column chromatography 
(nhexane/EtOAc = 3/2) yielded the annulated isoquinolone 92aa (86.8 mg, 
50%) as a white solid.  
GC-Headspace Detection of H2 for Standard Reaction 
 
To a stirred solution of 51a (0.9 mmol), ZnBr2∙TMEDA (2.0 equiv) and dppe 
(15 mol %) in THF (1.2 mL), iPrMgBr (3.0 M in 2-MeTHF, 3.0 equiv) was added 
in one portion and the reaction mixture was stirred for 5 min at ambient 
temperature. Then, FeCl2 (15 mol %) was added in a single portion. After 
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stirring the solution for additional 5 min, alkyne 91a (2.70 mmol, 3.0 equiv) was 
added as a solution in THF (1.2 mL). Then, the mixture was stirred at ambient 
temperature. After stirring for 16 h, the gas of headspace was injected to GC-
Ms. 
 
Deprotonation of Substrate 51a by PhZnCl 
 
To a Schlenk tube charged with 51a (85.9 mg, 0.30 mmol), PhZnCl (0.55 M in 
THF, 1.1 mL, 2.0 equiv) was added in one portion and the reaction mixture was 
stirred at ambient temperature. After 2 h, D2O (2.0 mL) was added and the 
mixture was extracted with CH2Cl2 (3  15 mL). The combined organic extracts 
were dried over Na2SO4, filtered and concentrated under reduced pressure. 
Deuterium contents were determined by 1H NMR spectroscopic analysis. 




Reaction Using Propargyl Acetate 91b 
 
To a stirred solution of 51a (85.9 mg, 0.30 mmol), ZnBr2∙TMEDA (205 mg, 
0.60 mmol) and dppe (17.9 mg, 15 mol %) in THF (0.40 mL), iPrMgBr (3.0 M in 
THF, 300 μL, 0.90 mmol) was added in oneportion and the reaction mixture 
was stirred for 5 min at ambient temperature. Then, FeCl2 (5.7 mg, 15 mol %) 
was added in a single portion. After stirring the solution for additional 5 min, 
alkyne 91b (175 mg, 0.60 mmol) was added as a solution in THF (0.40 mL). 
Then, the mixture was stirred at ambient temperature. After stirring for 16 h, 
sat. aqueous NH4Cl (3.0 mL) was added and the reaction mixture was extracted 
with CH2Cl2 (3  15 mL). The combined organic extracts were dried over 
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Na2SO4, filtered and concentrated. Product 110 was not observed by 1H NMR 
spectroscopic analysis. 
5.5 Iron-Catalyzed C–H/C–C Activations 





The general procedure GPC was followed using 51a (85.9 mg, 0.30 mmol) and 
BCP 94g (137 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/2) yielded 95ag (90.8 mg, 80%) as colourless oil.  
1H NMR (300 MHz, CDCl3): δ = 8.44 (d, J = 7.8 Hz, 1H), 7.74 (s, 1H), 7.70–
7.56 (m, 2H), 7.49–7.37 (m, 1H), 6.18–6.05 (m, 1H), 5.32 (s, 2H), 5.20 (dd, 
J = 10.3, 1.5 Hz, 1H), 5.02 (dd, J = 17.3, 1.5 Hz, 1H), 4.24 (t, J = 7.5 Hz, 2H), 
3.89 (s, 2H), 2.71 (q, J = 7.5 Hz, 2H), 1.87–1.78 (m, 2H), 1.30–1.21 (m, 6H), 
1.15 (t, J = 7.5 Hz, 3H), 0.81 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3): 
δ = 162.6 (Cq), 144.4 (Cq), 136.4 (Cq), 136.4 (Cq), 134.2 (CH), 132.3 (CH), 128.2 
(CH), 126.0 (CH), 125.1 (Cq), 124.0 (CH), 122.8 (CH), 117.1 (CH2), 117.1 (Cq), 
50.5 (CH2), 40.0 (CH2), 33.1 (CH2), 31.3 (CH2), 30.3 (CH2), 26.3 (CH2), 22.5 
(CH2), 21.1 (CH2), 14.7 (CH3), 14.1 (CH3). IR (ATR): 2925, 2855, 1642, 1592, 
1337, 1183, 1047, 968, 773, 678 cm−1. MS (ESI) m/z (relative intensity): 379 
(100) [M+H]+, 401 (21) [M+Na]+, 757 (36) [2M+H]+, 779 (50) [2M+Na]+. HR-MS  
(ESI) m/z calcd for C23H31N4O [M+H]+ 379.2492, found 379.2492.  








The general procedure GPC was followed using 51b (98.6 mg, 0.30 mmol) and 
BCP 94g (137 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/2) yielded 95bg (82.9 mg, 68%) as colourless oil. 
1H NMR (400 MHz, CDCl3): δ = 8.44 (d, J = 7.8 Hz, 1H), 7.74 (s, 1H), 7.68–7.60 
(m, 2H), 7.43 (d, J = 8.1 Hz, 1H), 6.11 (ddt, J = 17.3, 10.3, 4.7 Hz, 1H), 5.32 (s, 
2H), 5.20 (dd, J = 10.3, 1.5 Hz, 1H), 5.02 (dd, J = 17.3, 1.5 Hz, 1H), 4.22 (t, 
J = 7.4 Hz, 2H), 3.90 (s, 2H), 2.71 (q, J = 7.5 Hz, 2H), 1.82 (t, J = 7.4 Hz, 2H), 
1.28–1.18 (m, 10H), 1.15 (t, J = 7.5 Hz, 3H), 0.81 (d, J = 7.1 Hz, 3H). 13C NMR 
(101 MHz, CDCl3): δ = 162.8 (Cq), 144.5 (Cq), 136.6 (Cq), 136.5 (Cq), 134.3 
(CH), 132.5 (CH), 128.3 (CH), 126.1 (CH), 125.2 (Cq), 124.2 (CH), 122.9 (CH), 
117.2 (CH2), 117.2 (Cq), 50.5 (CH2), 39.9 (CH2), 33.0 (CH2), 31.8 (CH2), 30.3 
(CH2), 29.1 (CH2), 29.0 (CH2), 26.6 (CH2), 22.7 (CH2), 21.0 (CH2), 14.6 (CH3), 
14.2 (CH3). IR (ATR): 2926, 2855, 1643, 1592, 1428, 1336, 1047, 916, 773, 
700 cm−1. MS (ESI) m/z (relative intensity): 407 (100) [M+H]+, 429 (21) [M+Na]+, 
769 (50) [2M+H]+, 835 (54) [2M+Na]+. HR-MS (ESI) m/z calcd for C25H35N4O 










The general procedure GPC was followed using 51c (87.7 mg, 0.30 mmol) and 
BCP 94g (137 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/2) yielded 95cg (70.4 mg, 61%) as colourless oil.  
1H NMR (400 MHz, CDCl3): δ = 8.41 (dd, J = 8.0, 0.7 Hz, 1H), 7.72 (s, 1H), 
7.68–7.61 (m, 2H), 7.41 (ddd, J = 8.1, 6.4, 1.8 Hz, 1H), 7.32–7.27 (m, 3H), 
7.24–7.21 (m, 2H), 6.16–6.06 (m, 1H), 5.41 (s, 2H), 5.30 (s, 2H), 5.19 (dd, 
J = 10.3, 1.3 Hz, 1H), 5.01 (dd, J = 17.3, 1.3 Hz, 1H), 3.89 (s, 2H), 2.70 (q, 
J = 7.5 Hz, 2H), 1.15 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ = 162.7 
(Cq), 144.9 (Cq), 136.5 (Cq), 136.3 (Cq), 134.6 (Cq), 134.2 (CH), 132.4 (CH), 
129.1 (CH), 128.8 (CH), 128.3 (CH), 128.2 (CH), 126.0 (CH), 125.1 (Cq), 124.2 
(CH), 122.9 (CH), 117.1 (CH2), 117.1 (Cq), 54.2 (CH2), 39.8 (CH2), 33.0 (CH2), 
20.9 (CH2), 14.6 (CH3). IR (ATR): 2958, 2928, 1642, 1602, 1472, 1433, 1302, 
1033, 812, 778 cm−1. MS (ESI) m/z (relative intensity): 385 (100) [M+H]+, 407 
(23) [M+Na]+, 769 (35) [2M+H]+, 791 (48) [2M+Na]+. HR-MS (ESI) m/z calcd for 











The general procedure GPC was followed using 51r (88.9 mg, 0.30 mmol) and 
BCP 94g (137 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/2) yielded 95rg (69.9 mg, 60%) as a white solid.  
M.p. = 138–139 °C. 1H NMR (400 MHz, CDCl3): δ = 8.46 (ddd, J = 8.1, 1.4, 
0.7 Hz, 1H), 8.21 (s, 1H), 7.73–7.65 (m, 4H), 7.46 (ddd, J = 8.1, 6.4, 1.8 Hz, 
1H), 7.19–7.12 (m, 2H), 6.17 (ddt, J = 17.3, 10.3, 4.7 Hz, 1H), 5.42 (s, 2H), 5.26 
(dd, J = 10.3, 1.3 Hz, 1H), 5.08 (dd, J = 17.3, 1.3 Hz, 1H), 3.95 (s, 2H), 2.74 (q, 
J = 7.5 Hz, 2H), 1.18 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ = 162.9 
(Cq), 162.5 (d, 1JC–F = 249.1 Hz, Cq), 145.4 (Cq), 136.6 (Cq), 136.3 (Cq), 134.2 
(CH), 133.4 (d, 4JC–F = 3.3 Hz, Cq), 132.6 (CH), 128.3 (CH), 126.2 (CH), 125.2 
(Cq), 123.0 (CH), 122.8 (CH), 122.6 (d, 3JC–F = 8.6 Hz, CH), 117.4 (Cq), 117.4 
(CH2), 116.8 (d, 2JC–F = 23.3 Hz, CH), 39.9 (CH2), 33.1 (CH2), 21.0 (CH2), 14.6 
(CH3). 19F NMR (377 MHz, CDCl3): δ = –112.25 (tt, J = 8.4, 4.6 Hz). IR (ATR): 
3081, 2969, 2930, 1639, 1598, 1431, 1313, 1232, 1042, 837 cm−1. MS (ESI) 
m/z (relative intensity): 389 (100) [M+H]+, 777 (24) [2M+H]+, 799 (35) [2M+Na]+. 











The general procedure GPC was followed using 51d (86.3 mg, 0.30 mmol) and 
BCP 94g (137 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/2) yielded 95dg (55.7 mg, 50%) as colourless oil.  
1H NMR (400 MHz, CDCl3): δ = 8.45 (d, J = 8.1 Hz, 1H), 7.81 (s, 1H), 7.71–7.63 
(m, 2H), 7.45 (d, J = 8.1 Hz, 1H), 6.13 (ddt, J = 17.3, 10.3, 4.7 Hz, 1H), 5.33 (s, 
2H), 5.23 (dd, J = 10.3, 1.9 Hz, 1H), 5.04 (dd, J = 17.3, 1.9 Hz, 1H), 4.45 (t, 
J = 6.7 Hz, 2H), 3.90 (s, 2H), 3.50 (t, J = 6.1 Hz, 2H), 2.73 (q, J = 7.5 Hz, 2H), 
2.33 (q, J = 6.7 Hz, 2H), 1.17 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3): 
δ = 162.7 (Cq), 144.6 (Cq), 136.5 (Cq), 136.3 (Cq), 134.2 (CH), 132.5 (CH), 128.3 
(CH), 126.1 (CH), 125.1 (Cq), 124.8 (CH), 122.9 (CH), 117.2 (Cq), 117.2 (CH2), 
47.2 (CH2), 41.3 (CH2), 39.8 (CH2), 33.0 (CH2), 32.6 (CH2), 21.0 (CH2), 14.6 
(CH3). IR (ATR): 2965, 1710, 1611, 1590, 1428, 1338, 1221, 1047, 774, 700 
cm−1. MS (ESI) m/z (relative intensity): 371 (100) [35Cl, M+H]+, 763 (67) [35Cl, 
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3-Allyl-4-ethylisoquinolin-1(2H)-one (97ae) and 1-Butyl-4-(prop-1-en-2-yl)-
1H-1,2,3-triazole (119): 
 
The general procedure GPC was followed using 32a (85.9 mg, 0.30 mmol) and 
BCP 94e (177 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc/DCM = 3/1/1) yielded 97ae (33.2 mg, 52%) as a white solid 
and 119 (25.7 mg, 52%) as colourless oil. 
3-Allyl-4-ethylisoquinolin-1(2H)-one (97ae):  
M.p. = 109–110 °C. 1H NMR (400 MHz, CDCl3): δ = 9.55 (s, 1H), 8.43 (dd, 
J = 8.0, 1.0 Hz, 1H), 7.72–7.67 (m, 2H), 7.45 (ddd, J = 8.1, 5.6, 2.6 Hz, 1H), 
5.91 (ddt, J = 16.7, 10.0, 6.5 Hz, 1H), 5.34–5.12 (m, 2H), 3.42 (d, J = 6.5 Hz, 
2H), 2.76 (q, J = 7.5 Hz, 2H), 1.19 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, 
CDCl3): δ = 163.1 (Cq), 138.1 (Cq), 133.9 (Cq), 133.4 (CH), 132.8 (CH), 128.1 
(CH), 126.0 (CH), 125.4 (Cq), 123.1 (CH), 119.2 (CH2), 115.5 (Cq), 35.3 (CH2), 
19.8 (CH2), 14.8 (CH3). IR (ATR): 2965, 2932, 1726, 1654, 1607, 1552, 1469, 
1355, 914, 773 cm−1. MS (ESI) m/z (relative intensity): 214 (100) [M+H]+, 256 
(64), 321 (77), 449 (54) [2M+Na]+. HR-MS (ESI) m/z calcd for C14H16NO [M+H]+ 
214.1226, found 214.1227. 
1-Butyl-4-(prop-1-en-2-yl)-1H-1,2,3-triazole (119):  
1H NMR (400 MHz, CDCl3): δ = 7.47 (s, 1H), 5.69 (s, 1H), 5.09 (s, 1H), 4.34 (t, 
J = 7.2 Hz, 2H), 2.14 (d, J = 1.2 Hz, 3H), 1.89 (p, J = 7.4 Hz, 2H), 1.37 (h, 
J = 7.4 Hz, 2H), 0.96 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ = 148.9 
(Cq), 133.9 (Cq), 119.5 (CH), 112.4 (CH2), 50.1 (CH2), 32.5 (CH2), 20.8 (CH3), 
19.9 (CH2), 13.6 (CH3). IR (ATR): 3124, 2959, 2933, 2873, 1640, 1456, 1228, 
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1127, 1046, 892, cm−1. MS (ESI) m/z (relative intensity): 166 (100) [M+H]+, 188 
(54) [M+Na]+. HR-MS (ESI) m/z calcd for C9H16N3 [M+H]+ 166.1339, found 
166.1341. 




The general procedure GPC was followed using 51e (90.1 mg, 0.30 mmol) and 
BCP 94g (137 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/2) yielded 95eg (70.7 mg, 60%) as colourless oil.  
1H NMR (300 MHz, CDCl3): δ = 8.36 (d, J = 8.2 Hz, 1H), 7.77 (s, 1H), 7.47 (s, 
1H), 7.37–7.26 (m, 1H), 6.15 (ddt, J = 17.3, 10.3, 4.6 Hz, 1H), 5.34 (s, 2H), 5.23 
(dd, J = 10.3, 1.6 Hz, 1H), 5.05 (dd, J = 17.3, 1.6 Hz, 1H), 4.27 (t, J = 7.4 Hz, 
2H), 3.91 (d, J = 4.6 Hz, 2H), 2.73 (q, J = 7.5 Hz, 2H), 2.51 (s, 3H), 2.03–1.72 
(m, 2H), 1.33–1.22 (m, 6H), 1.18 (t, J = 7.5 Hz, 3H), 0.85 (t, J = 7.0 Hz, 3H). 
13C NMR (75 MHz, CDCl3): δ = 162.7 (Cq), 144.6 (Cq), 142.8 (Cq), 136.6 (Cq), 
136.4 (Cq), 134.3 (CH), 128.3 (CH), 127.7 (CH), 124.1 (CH), 123.0 (Cq), 122.7 
(CH), 117.1 (CH2), 116.9 (Cq), 50.4 (CH2), 39.8 (CH2), 33.0 (CH2), 31.2 (CH2), 
30.2 (CH2), 26.2 (CH2), 22.5 (CH2), 22.3 (CH3), 20.9 (CH2), 14.6 (CH3), 14.0 
(CH3). IR (ATR): 2958, 2928, 1642, 1602, 1472, 1433, 1302, 1033, 812, 778 
cm−1. MS (ESI) m/z (relative intensity): 393 (71) [M+H]+, 415 (100) [M+Na]+, 
807 (48) [2M+Na]+. HR-MS (ESI) m/z calcd for C24H33N4O [M+H]+ 393.2649, 
found 393.2650. 
 






The general procedure GPC was followed using 51g (94.9 mg, 0.30 mmol) and 
BCP 94g (137 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/2) yielded 95gg (95.6 mg, 78%) as colourless oil.  
1H NMR (400 MHz, CDCl3): δ = 8.39–8.35 (m, 1H), 7.74 (s, 1H), 7.04–7.00 (m, 
2H), 6.11 (ddt, J = 17.3, 10.4, 4.6 Hz, 1H), 5.30 (s, 2H), 5.21 (d, J = 10.4 Hz, 
1H), 5.02 (d, J = 17.3 Hz, 1H), 4.24 (t, J = 7.3 Hz, 2H), 3.90 (s, 3H), 3.88 (s, 
2H), 2.67 (q, J = 7.5 Hz, 2H), 1.84 (q, J = 7.2 Hz, 2H), 1.28–1.22 (m, 6H), 1.16 
(t, J = 7.5 Hz, 3H), 0.81 (t, J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3): 
δ = 163.0 (Cq), 162.4 (Cq), 144.6 (Cq), 138.5 (Cq), 137.2 (Cq), 134.2 (CH), 130.4 
(CH), 124.1 (CH), 119.2 (Cq), 117.1 (CH2), 116.7 (Cq), 114.8 (CH), 104.8 (CH), 
55.5 (CH3), 50.5 (CH2), 39.7 (CH2), 33.1 (CH2), 31.2 (CH2), 30.2 (CH2), 26.2 
(CH2), 22.5 (CH2), 21.1 (CH2), 14.4 (CH3), 14.0 (CH3). IR (ATR): 2956, 2929, 
1642, 1612, 1491, 1464, 1235, 1215, 1035, 790 cm−1. MS (ESI) m/z (relative 
intensity): 409 (67) [M+H]+, 431 (100) [M+Na]+, 839 (48) [2M+Na]+. HR-MS 





The general procedure GPC was followed using 51s (99.8 mg, 0.30 mmol) and 
BCP 94g (137 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/2) yielded 95sg (89.2 mg, 70%) as colourless oil. 
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1H NMR (400 MHz, CDCl3): δ = 8.33 (d, J = 8.5 Hz, 1H), 7.74 (s, 1H), 7.42 (d, 
J = 1.8 Hz, 1H), 7.29 (dd, J = 8.5, 1.8 Hz, 1H), 6.12 (ddt, J = 17.3, 10.3, 4.6 Hz, 
1H), 5.30 (s, 2H), 5.22 (dd, J = 10.3, 1.4 Hz, 1H), 5.03 (dd, J = 17.3, 1.4 Hz, 
1H), 4.25 (t, J = 7.4 Hz, 2H), 3.89 (s, 2H), 2.69 (q, J = 7.5 Hz, 2H), 2.55 (s, 3H), 
1.89–1.78 (m, 2H), 1.30–1.24 (m, 6H), 1.16 (t, J = 7.5 Hz, 3H), 0.83 (J = 6.9 Hz, 
3H). 13C NMR (101 MHz, CDCl3): δ = 162.5 (Cq), 144.7 (Cq), 144.4 (Cq), 137.4 
(Cq), 136.8 (Cq), 134.1 (CH), 128.6 (CH), 124.1 (CH), 123.8 (CH), 122.1 (Cq), 
118.5 (CH), 117.2 (CH2), 116.4 (Cq), 50.4 (CH2), 39.8 (CH2), 33.0 (CH2), 31.2 
(CH2), 30.2 (CH2), 26.2 (CH2), 22.4 (CH2), 20.9 (CH2), 15.2 (CH3), 14.5 (CH3), 
14.0 (CH3). IR (ATR): 2957, 2927, 2870, 1638, 1583, 1428, 1324, 1182, 1047, 
790 cm−1. MS (ESI) m/z (relative intensity): 425 (100) [M+H]+, 447 (50) [M+Na]+. 





The general procedure GPC was followed using 51f (109 mg, 0.30 mmol) and 
BCP 94g (137 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/2) yielded 95fg (83.2 mg, 61%) as colourless oil.  
1H NMR (400 MHz, CDCl3): δ = 8.53 (d, J = 8.3 Hz, 1H), 7.86 (s, 1H), 7.78 (s, 
1H), 7.72–7.64 (m, 3H), 7.52–7.46 (m, 2H), 7.41 (dd, J = 7.3, 7.3 Hz, 1H), 6.15 
(ddd, J = 17.8, 10.1, 4.9 Hz, 1H), 5.37 (s, 2H), 5.25 (d, J = 10.4 Hz, 1H), 5.07 
(d, J = 17.3 Hz, 1H), 4.27 (t, J = 7.4 Hz, 2H), 3.94 (s, 2H), 2.80 (q, J = 7.5 Hz, 
2H), 1.85 (q, J = 7.2 Hz, 2H), 1.42–1.25 (m, 6H), 1.22 (t, J = 7.5 Hz, 3H), 0.85 
(t, J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ = 162.7 (Cq), 145.3 (Cq), 
144.5 (Cq), 140.9 (Cq), 136.9 (Cq), 136.9 (Cq), 134.2 (CH), 129.1 (CH), 129.0 
(CH), 128.2 (CH), 127.7 (CH), 125.5 (CH), 124.1 (CH), 124.1 (Cq), 121.3 (CH), 
117.2 (CH2), 117.2 (Cq), 50.5 (CH2), 39.9 (CH2), 33.1 (CH2), 31.2 (CH2), 30.2 
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(CH2), 26.3 (CH2), 22.5 (CH2), 21.0 (CH2), 14.7 (CH3), 14.0 (CH3). IR (ATR): 
2929, 2870, 1642, 1615, 1591, 1451, 1429, 1328, 1047, 790 cm−1. MS (ESI) 
m/z (relative intensity): 455 (100) [M+H]+, 477 (29) [M+Na]+, 909 (33) [2M+H]+, 






The general procedure GPC was followed using 51j (96.2 mg, 0.30 mmol) and 
BCP 94g (137 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/2) yielded 95jg (64.4 mg, 52%) as colourless oil.  
1H NMR (400 MHz, CDCl3): δ = 8.38 (d, J = 8.6 Hz, 1H), 7.75 (s, 1H), 7.64 (s, 
1H), 7.39 (d, J = 8.6 Hz, 1H), 6.12 (ddt, J = 17.4, 10.3, 4.9 Hz, 1H), 5.31 (s, 2H), 
5.24 (d, J = 10.3 Hz, 1H), 5.03 (d, J = 17.4 Hz, 1H), 4.26 (t, J = 7.3 Hz, 2H), 
3.92 (s, 2H), 2.68 (q, J = 7.4 Hz, 2H), 1.85 (t, J = 7.2 Hz, 2H), 1.29–1.22(m, 
6H), 1.17 (t, J = 7.4 Hz, 3H), 0.84 (t, J = 6.4 Hz, 3H). 13C NMR (101 MHz, 
CDCl3): δ = 162.2 (Cq), 144.2 (Cq), 139.2 (Cq), 138.1 (Cq), 137.9 (Cq), 133.9 
(CH), 130.2 (CH), 126.6 (CH), 124.2 (CH), 123.5 (Cq), 122.5 (CH), 117.4 (CH2), 
116.3 (Cq), 50.5 (CH2), 40.0 (CH2), 33.1 (CH2), 31.2 (CH2), 30.2 (CH2), 26.3 
(CH2), 22.5 (CH2), 21.0 (CH2), 14.5 (CH3), 14.0 (CH3). IR (ATR): 2957, 2929, 
1644, 1474, 1429, 1378, 1326, 1173, 1047, 790 cm−1. MS (ESI) m/z (relative 
intensity): 413 (100) [35Cl, M+H]+, 435 (35) [35Cl, M+Na]+, 847 (53) [35Cl, 
2M+Na]+. HR-MS (ESI) m/z calcd for C23H30N4O35Cl [M+H]+ 413.2103, found 
413.2101. 
 






The general procedure GPC was followed using 51t (90.1 mg, 0.30 mmol) and 
BCP 94g (137 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/2) yielded 95tg (75.0 mg, 64%) as colourless oil.  
1H NMR (400 MHz, CDCl3): δ = 8.25 (d, J = 2.5 Hz, 1H), 7.75 (s, 1H), 7.58 (d, 
J = 8.4 Hz, 1H), 7.47 (d, J = 8.4 Hz, 1H), 6.12 (ddt, J = 17.3, 10.3, 4.6 Hz, 1H), 
5.33 (s, 2H), 5.20 (dd, J = 10.3, 1.7 Hz, 1H), 5.02 (dd, J = 17.3, 1.7 Hz, 1H), 
4.23 (t, J = 7.4 Hz, 2H), 3.87 (s, 2H), 2.70 (q, J = 7.5 Hz, 2H), 2.46 (s, 3H), 1.83 
(p, J = 7.3 Hz, 2H), 1.31–1.20 (m, 6H), 1.14 (t, J = 7.5 Hz, 3H), 0.83 (t, 
J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ = 162.7 (Cq), 144.5 (Cq), 136.0 
(Cq), 135.3 (Cq), 134.4 (CH), 134.2 (Cq), 133.9 (CH), 127.8 (CH), 125.1 (Cq), 
124.1 (CH), 122.9 (CH), 117.1 (CH2), 117.0 (Cq), 50.4 (CH2), 39.9 (CH2), 32.8 
(CH2), 31.1 (CH2), 30.2 (CH2), 26.2 (CH2), 22.4 (CH2), 21.3 (CH3), 21.0 (CH2), 
14.6 (CH3), 14.0 (CH3). IR (ATR): 2960, 2929, 1644, 1596, 1504, 1458, 1429, 
1340, 1300, 823 cm−1. MS (ESI) m/z (relative intensity): 393 (64) [M+H]+, 415 















The general procedure GPC was followed using 51u (91.3 mg, 0.30 mmol) and 
BCP 94g (137 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/2) yielded 95ug (94.0 mg, 79%) as light yellow oil.  
1H NMR (600 MHz, CDCl3): δ = 8.09 (dd, J = 9.3, 2.9 Hz, 1H), 7.76 (s, 1H), 7.69 
(dd, J = 9.0, 5.0 Hz, 1H), 7.40 (ddd, J = 9.0, 8.0, 2.9 Hz, 1H), 6.14 (ddt, J = 17.3, 
10.3, 4.7 Hz, 1H), 5.33 (s, 2H), 5.24 (dd, J = 10.3, 1.8 Hz, 1H), 5.04 (dd, 
J = 17.3, 1.8 Hz, 1H), 4.26 (t, J = 7.4 Hz, 2H), 3.92 (s, 2H), 2.72 (q, J = 7.6 Hz, 
2H), 1.86 (p, J = 7.2 Hz, 2H), 1.30–1.24 (m, 6H), 1.17 (t, J = 7.6 Hz, 3H), 0.84 
(t, J = 7.0 Hz, 3H). 13C NMR (151 MHz, CDCl3): δ = 162.0 (d, 4JC–F = 3.5 Hz, 
Cq), 161.1 (d, 1JC–F = 246.9 Hz, Cq), 144.2 (Cq), 135.7 (d, 4JC–F = 2.5 Hz, Cq), 
134.2 (CH), 133.2 (d, 4JC–F = 2.1 Hz, Cq), 126.8 (d, 3JC–F = 7.7 Hz, Cq), 125.5 
(d, 3JC–F = 7.7 Hz, CH), 124.2 (CH), 121.2 (d, 2JC–F = 23.3 Hz, CH), 117.3 (CH2), 
116.8 (Cq), 113.2 (d, 2JC–F = 22.4 Hz, CH), 50.5 (CH2), 40.1 (CH2), 32.9 (CH2), 
31.2 (CH2), 30.3 (CH2), 26.3 (CH2), 22.5 (CH2), 21.2 (CH2), 14.6 (CH3), 14.0 
(CH3). 19F NMR (377 MHz, CDCl3): δ = –114.75 (td, J = 8.6, 5.0 Hz). IR (ATR): 
2957, 2929, 1644, 1597, 1499, 1431, 1351, 1048, 827, 724 cm−1. MS (ESI) m/z 
(relative intensity): 397 (53) [M+H]+, 419 (100) [M+Na]+, 815 (47) [2M+Na]+. 













The general procedure GPC was followed using 51v (96.2 mg, 0.30 mmol) and 
BCP 94g (137 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/2) yielded 95vg (73.1 mg, 59%) as light yellow oil.  
1H NMR (300 MHz, CDCl3): δ = 8.44 (dd, J = 2.1, 0.7 Hz, 1H), 7.78 (s, 1H), 
7.70–7.52 (m, 2H), 6.15 (ddt, J = 17.3, 10.2, 4.6 Hz, 1H), 5.34 (s, 2H), 5.26 (dd, 
J = 10.2, 1.7 Hz, 1H), 5.05 (dd, J = 17.3, 1.7 Hz, 1H), 4.28 (t, J = 7.4 Hz, 2H), 
3.94 (s, 2H), 2.72 (q, J = 7.5 Hz, 2H), 1.87 (p, J = 7.3 Hz, 2H), 1.37–1.24 (m, 
6H), 1.17 (t, J = 7.5 Hz, 3H), 0.86 (t, J = 6.7 Hz, 3H). 13C NMR (126 MHz, 
CDCl3): δ = 161.7 (Cq), 144.1 (Cq), 136.9 (Cq), 134.9 (Cq), 134.0 (CH), 132.8 
(CH), 132.1 (Cq), 127.7 (CH), 126.3 (Cq), 124.7 (CH), 124.2 (CH), 117.3 (CH2), 
116.7 (Cq), 50.5 (CH2), 40.1 (CH2), 33.0 (CH2), 31.2 (CH2), 30.2 (CH2), 26.2 
(CH2), 22.5 (CH2), 21.0 (CH2), 14.6 (CH3), 14.0 (CH3). IR (ATR): 2956, 2928, 
1642, 1591, 1461, 1337, 1293, 1047, 910, 824 cm−1. MS (ESI) m/z (relative 
intensity): 413 (57) [35Cl, M+H]+, 435 (100) [35Cl, M+Na]+. HR-MS (ESI) m/z 





The general procedure GPC was followed using 51w (110 mg, 0.30 mmol) and 
BCP 94g (137 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/2) yielded 95wg (65.8 mg, 48%) as colourless oil.  
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1H NMR (600 MHz, CDCl3): δ = 8.59 (d, J = 2.2 Hz, 1H), 7.76 (s, 1H), 7.73 (dd, 
J = 8.7, 2.2 Hz, 1H), 7.55 (d, J = 8.7 Hz, 1H), 6.13 (ddt, J = 17.3, 10.4, 4.7 Hz, 
1H), 5.32 (s, 2H), 5.24 (dd, J = 10.4, 1.2 Hz, 1H), 5.03 (dd, J = 17.3, 1.2 Hz, 
1H), 4.26 (t, J = 7.4 Hz, 2H), 3.92 (s, 2H), 2.70 (q, J = 7.5 Hz, 2H), 1.85 (qd, 
J = 7.9, 7.2, 4.0 Hz, 2H), 1.30–1.25 (m, 6H), 1.15 (t, J = 7.5 Hz, 3H), 0.85 (t, 
J = 7.0 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ = 161.6 (Cq), 144.1 (Cq), 137.1 
(Cq), 135.6 (CH), 135.3 (Cq), 134.0 (CH), 130.9 (CH), 126.6 (Cq), 124.9 (CH), 
124.2 (CH), 120.0 (Cq), 117.3 (CH2), 116.8 (Cq), 50.5 (CH2), 40.1 (CH2), 33.0 
(CH2), 31.2 (CH2), 30.3 (CH2), 26.3 (CH2), 22.5 (CH2), 21.0 (CH2), 14.6 (CH3), 
14.0 (CH3). IR (ATR): 2956, 2928, 1644, 1588, 1478, 1336, 1293, 1048, 930, 
824 cm−1. MS (ESI) m/z (relative intensity): 457 (67) [79Br, M+H]+, 481 (100), 
937 (50). HR-MS (ESI) m/z calcd for C23H3079BrN4O [M+H]+ 457.1598, found 
457.1598. 
5.5.3 Analytical Data – Impact of CF3-Substitution of Benzamide 
3-Allyl-4-ethyl-2-[(1-hexyl-1H-1,2,3-triazol-4-yl)methyl]-6-(trifluoromethyl)-




The general procedure GPC was followed using 51h (106 mg, 0.30 mmol) and 
BCP 94g (137 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/2 to 1/1) yielded 95hg (9.4 mg, 7%) as a white solid. and 
95hg’ (49.8 mg, 39%) as yellow oil. 




isoquinolin-1(2H)-one (95hg):  
M.p. = 96–97 °C. 1H NMR (400 MHz, CDCl3): δ = 8.55 (dd, J = 8.3, 1.0 Hz, 1H), 
7.92 (s, 1H), 7.74 (s, 1H), 7.63 (dd, J = 8.3, 1.6 Hz, 1H), 6.13 (ddt, J = 17.3, 
10.3, 4.7 Hz, 1H), 5.33 (s, 2H), 5.24 (dd, J = 10.3, 1.4 Hz, 1H), 5.02 (dd, 
J = 17.3, 1.4 Hz, 1H), 4.25 (t, J = 7.4 Hz, 2H), 3.95 (s, 2H), 2.74 (q, J = 7.5 Hz, 
2H), 1.83 (q, J = 7.3 Hz, 2H), 1.27–1.22 (m, 6H), 1.17 (t, J = 7.5 Hz, 3H), 0.83 
(t, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ = 162.0 (Cq), 144.0 (Cq), 
138.3 (Cq), 136.6 (Cq), 134.1 (d, 2JC–F = 32.3 Hz, Cq), 133.9 (CH), 129.5 (CH), 
127.3 (Cq), 124.2 (CH), 124.1 (d, 1JC–F = 273.0 Hz, Cq), 122.1 (d, 3JC–F = 3.4 Hz, 
CH), 120.3 (d, 3JC–F = 4.2 Hz, CH), 117.5 (CH2), 117.0 (Cq), 50.5 (CH2), 40.1 
(CH2), 33.1 (CH2), 31.2 (CH2), 30.3 (CH2), 26.3 (CH2), 22.5 (CH2), 21.0 (CH2), 
14.6 (CH3), 14.0 (CH3). 19F NMR (376 MHz, CDCl3): δ = –62.89 (s). IR (ATR): 
2959, 2931, 2860, 1650, 1597, 1433, 1313, 1130, 1074, 797 cm−1. MS (ESI) 
m/z (relative intensity): 447 (86) [M+H]+, 469 (100) [M+Na]+. HR-MS (ESI) m/z 
calcd for C24H30F3N4O [M+H]+ 447.2366, found 447.2367. 
 
3-Allyl-6-(difluoromethyl)-2-[(1-hexyl-1H-1,2,3-triazol-4-yl)methyl]-4,5-dih-
ydrocyclopenta[de]isoquinolin-1(2H)-one (95hg’):  
1H NMR (400 MHz, CDCl3): δ = 8.05 (d, J = 8.2 Hz, 1H), 7.72 (s, 1H), 7.45 (d, 
J = 8.2 Hz, 1H), 6.75 (t, J = 55.6 Hz, 1H), 6.05 (ddt, J = 17.3, 10.3, 5.1 Hz, 1H), 
5.34 (s, 2H), 5.20 (dq, J = 10.3, 1.6 Hz, 1H), 5.08 (dq, J = 17.3, 1.6 Hz, 1H), 
4.25 (t, J = 7.3 Hz, 2H), 3.80 (s, 2H), 3.40–3.34 (m, 2H), 3.15–3.05 (m, 2H), 
1.84 (p, J = 7.4 Hz, 2H), 1.29–1.24 (m, 6H), 0.83 (t, J = 6.9 Hz, 3H). 13C NMR 
(101 MHz, CDCl3): δ = 162.3 (Cq), 144.3 (Cq), 144.0 (Cq), 142.0 (t, 3JC–F = 
4.5 Hz, Cq), 134.7 (Cq), 133.3 (CH), 132.3 (t, 2JC–F = 22.5 Hz, Cq), 124.4 (CH), 
124.2 (t, 3JC–F = 6.5 Hz, CH), 123.9 (CH), 123.2 (Cq), 121.8 (Cq), 117.2 (CH2), 
114.2 (t, 1JC–F = 239.0 Hz, CH), 50.5 (CH2), 39.5 (CH2), 34.5 (CH2), 31.2 (CH2), 
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30.2 (CH2), 29.7 (CH2), 27.5 (CH2), 26.2 (CH2), 22.5 (CH2), 14.0 (CH3). 19F NMR 
(377 MHz, CDCl3): δ = –112.87 (d, J = 55.5 Hz). IR (ATR): 2955, 2928, 2857, 
1664, 1619, 1428, 1371, 1103, 1027, 784 cm−1. MS (ESI) m/z (relative 
intensity): 427 (100) [M+H]+, 449 (67) [M+Na]+. HR-MS (ESI) m/z calcd for 
C24H28F2N4ONa [M+Na]+ 449.2123, found 449.2117. 
 
3-Allyl-4-ethyl-2-[(1-hexyl-1H-1,2,3-triazol-4-yl)methyl]-7-(trifluoromethyl)-




The general procedure GPC was followed using 51x (106 mg, 0.30 mmol) and 
BCP 94g (137 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/2) yielded 95xg (49.6 mg, 37%) as colourless oil and 
95xg’ (33.5 mg, 25%) as yellow oil. 
 
3-Allyl-4-ethyl-2-[(1-hexyl-1H-1,2,3-triazol-4-yl)methyl]-7-(trifluoromethyl)-
isoquinolin-1(2H)-one (95xg):  
1H NMR (400 MHz, CDCl3): δ = 8.75 (s, 1H), 7.89–7.75 (m, 3H), 6.15 (ddt, 
J = 17.3, 10.2, 2.9 Hz, 1H), 5.35 (s, 2H), 5.26 (dd, J = 10.2, 1.5 Hz, 1H), 5.05 
(dd, J = 17.3, 1.5 Hz, 1H), 4.27 (t, J = 6.9 Hz, 2H), 3.98 (s, 2H), 2.81–2.70 (m, 
2H), 1.93–1.81 (m, 2H), 1.31–1.25 (m, 6H), 1.18 (t, J = 7.6 Hz, 3H), 0.85 (t, 
J = 6.7 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ = 162.2 (Cq), 143.9 (Cq), 139.2 
(Cq), 139.0 (Cq), 133.8 (CH), 128.3 (q, 3JC–F = 3.4 Hz, CH), 127.9 (q, 2JC–F = 33.5 
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Hz, Cq), 126.6 (q, 1JC–F = 249.3 Hz, Cq), 126.0 (q, 3JC–F = 4.1 Hz, CH), 124.9 
(Cq), 124.3 (CH), 123.9 (CH), 117.5 (CH2), 116.7 (Cq), 50.5 (CH2), 40.1 (CH2), 
33.2 (CH2), 31.2 (CH2), 30.3 (CH2), 26.3 (CH2), 22.5 (CH2), 21.1 (CH2), 14.5 
(CH3), 14.0 (CH3). 19F NMR (282 MHz, CDCl3): δ = –62.35 (s). IR (ATR): 2958, 
2930, 1652, 1598, 1554, 1323, 1292, 1163, 1126, 840 cm−1. MS (ESI) m/z 
(relative intensity): 447 (57) [M+H]+, 469 (100) [M+Na]+. HR-MS (ESI) m/z calcd 
for C24H30F3N4O [M+H]+ 447.2366, found 447.2368. 
3'-Allyl-2'-[(1-hexyl-1H-1,2,3-triazol-4-yl)methyl]-7'-(trifluoromethyl)-2',3'-
dihydro-1'H-spiro(cyclopropane-1,4'-isoquinolin)-1'-one (95xg’):  
1H NMR (600 MHz, CDCl3): δ =8.31 (d, J = 2.1 Hz, 1H), 7.65–7.60 (m, 2H), 6.93 
(d, J = 8.1 Hz, 1H), 5.71 (ddt, J = 16.8, 10.2, 7.4 Hz, 1H), 5.36 (d, J = 14.9 Hz, 
1H), 4.98–4.94 (m, 2H), 4.29 (td, J = 7.2, 2.7 Hz, 2H), 4.19 (d, J = 14.9 Hz, 1H), 
3.19 (t, J = 6.7 Hz, 1H), 2.38–2.33 (m, 2H), 1.85 (t, J = 7.2 Hz, 2H), 1.55 (ddd, 
J = 9.6, 6.3, 6.0 Hz, 1H), 1.27–1.22 (m, 6H), 1.00 (ddd, J = 9.8, 6.8, 6.0 Hz, 
1H), 0.83 (t, J = 7.0 Hz, 3H), 0.68 (ddd, J = 9.6, 6.3, 4.4 Hz, 1H), 0.35 (ddd, 
J = 9.8, 6.8, 4.4 Hz, 1H). 13C NMR (101 MHz, CDCl3): δ = 162.6 (Cq), 145.1 
(Cq), 144.3 (Cq), 133.8 (CH), 130.9 (Cq), 129.2 (Cq), 129.0 (q, 3JC–F = 3.0 Hz, 
CH), 125.4 (q, 3JC–F = 3.9 Hz, CH), 124.0 (q, 1JC–F = 271.7 Hz, Cq), 123.1 (CH), 
122.5 (CH), 118.6 (CH2), 64.6 (CH), 50.5 (CH2), 42.0 (CH2), 38.4 (CH2), 31.2 
(CH2), 30.3 (CH2), 26.2 (CH2), 23.4 (Cq), 22.5 (CH2), 19.8 (CH2), 14.0 (CH3), 
10.1 (CH2). 19F NMR (565 MHz, CDCl3): δ = –62.58 (s). IR (ATR): 2929, 2860, 
1649, 1617, 1469, 1331, 1252, 1160, 1129, 922 cm−1. MS (ESI) m/z (relative 
intensity): 447 (45) [M+H]+, 469 (100) [M+Na]+. HR-MS (ESI) m/z calcd for 
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3-Allyl-4-ethyl-6-(trifluoromethyl)isoquinolin-1(2H)-one (97gg) and 1-
Butyl-4-(prop-1-en-2-yl)-1H-1,2,3-triazole (119): 
 
The procedure was followed using 32g (106 mg, 0.30 mmol) and BCP 94g 
(137 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc/DCM = 3/1/1) yielded 97gg (27.2 mg, 32%) as a white solid 
and 119 (16.4 mg, 33%) as colourless oil. 
3-Allyl-4-ethyl-6-(trifluoromethyl)isoquinolin-1(2H)-one (97gg):  
M.p. = 97–98 °C. 1H NMR (400 MHz, CDCl3): δ = 9.76 (s, 1H), 8.62–8.43 (m, 
1H), 7.98 (s, 1H), 7.75–7.58 (m, 1H), 5.96 (ddt, J = 16.7, 10.1, 6.5 Hz, 1H), 
5.37–5.28 (m, 2H), 3.49 (dt, J = 6.5, 1.8 Hz, 2H), 2.82 (q, J = 7.6 Hz, 2H), 1.25 
(t, J = 7.6 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ = 162.1 (Cq), 138.1 (Cq), 
135.5 (Cq), 134.4 (d, 2JC–F = 32.0 Hz, Cq), 132.8 (CH), 129.2 (CH), 127.8 (Cq), 
124.1 (d, 1JC–F = 272.8 Hz, Cq), 122.1 (d, 3JC–F = 3.9 Hz, CH), 120.5 (d, 3JC–F = 
4.5 Hz, CH), 119.9 (CH2), 115.0 (Cq), 35.3 (CH2), 19.8 (CH2), 14.8 (CH3). 19F 
NMR (377 MHz, CDCl3): δ = –62.90 (s). IR (ATR): 2963, 2923, 2851, 1651, 
1626, 1459, 1300, 1179, 1119, 842 cm-1. MS (ESI) m/z (relative intensity): 282 
(86) [M+H]+, 304 (100). HR-MS (ESI) m/z calcd for C15H15F3N4O [M+H]+ 
282.1100, found 282.1101. 
1-Butyl-4-(prop-1-en-2-yl)-1H-1,2,3-triazole (119):  
1H NMR (400 MHz, CDCl3): δ = 7.47 (s, 1H), 5.69 (s, 1H), 5.09 (s, 1H), 4.34 (t, 
J = 7.2 Hz, 2H), 2.14 (d, J = 1.2 Hz, 3H), 1.89 (p, J = 7.4 Hz, 2H), 1.37 (h, 
J = 7.4 Hz, 2H), 0.96 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ = 148.9 
(Cq), 133.9 (Cq), 119.5 (CH), 112.4 (CH2), 50.1 (CH2), 32.5 (CH2), 20.8 (CH3), 
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19.9 (CH2), 13.6 (CH3). IR (ATR): 3124, 2959, 2933, 2873, 1640, 1456, 1228, 
1127, 1046, 892, cm−1. MS (ESI) m/z (relative intensity): 166 (100) [M+H]+, 188 
(54) [M+Na]+. HR-MS (ESI) m/z calcd for C9H16N3 [M+H]+ 166.1339, found 
166.1341. 




The general procedure GPC was followed using 51a (85.9 mg, 0.30 mmol) and 
BCP 94h (213 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/2) yielded 95ah (84.8 mg, 61%) as colourless oil.  
1H NMR (400 MHz, CDCl3): δ = 8.46 (d, J = 7.5 Hz, 1H), 7.75 (s, 1H), 7.70–
7.63 (m, 2H), 7.44 (ddd, J = 8.1, 6.5, 1.7 Hz, 1H), 5.74–5.63 (m, 1H), 5.50–5.40 
(m, 1H), 5.37 (s, 2H), 4.25 (t, J = 7.4 Hz, 2H), 3.83 (s, 2H), 2.74 (q, J = 7.5 Hz, 
2H), 2.03 (q, J = 6.7 Hz, 2H), 1.84 (p, J = 7.2 Hz, 2H), 1.29–1.22 (m, 14H), 1.17 
(t, J = 7.5 Hz, 3H), 0.87–0.81 (m, 6H). 13C NMR (101 MHz, CDCl3): δ = 162.8 
(Cq), 144.6 (Cq), 137.5 (Cq), 136.6 (Cq), 133.5 (CH), 132.4 (CH), 128.3 (CH), 
125.9 (CH), 125.5 (CH), 125.1 (Cq), 124.1 (CH), 122.9 (CH), 116.7 (Cq), 50.4 
(CH2), 39.9 (CH2), 32.7 (CH2), 32.0 (CH2), 31.8 (CH2), 31.2 (CH2), 30.2 (CH2), 
29.3 (CH2), 28.9 (CH2), 26.2 (CH2), 22.7 (CH2), 22.5 (CH2), 20.9 (CH2), 14.6 
(CH3), 14.2 (CH3), 14.0 (CH3). IR (ATR): 2955, 2926, 2856, 1643, 1592, 1460, 
1337, 1047, 968, 773 cm−1. MS (ESI) m/z (relative intensity): 469 (100), 495 
(17) [M+Na]+. HR-MS (ESI) m/z calcd for C29H43N4O [M+H]+ 463.3431, found 
463.3426. 
 






The general procedure GPC was followed using 51a (85.9 mg, 0.30 mmol) and 
BCP 94i (205 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 3/2) yielded 95ai (72.3 mg, 53%) as colourless oil.  
1H NMR (400 MHz, CDCl3): δ = 8.50 (d, J = 6.6 Hz, 1H), 7.78 (s, 1H), 7.74–7.68 
(m, 2H), 7.49 (ddd, J = 8.1, 6.6, 1.6 Hz, 1H), 7.39–7.27 (m, 4H), 7.24–7.18 (m, 
1H), 6.50 (dt, J = 16.1, 4.9 Hz, 1H), 6.37 (d, J = 16.1 Hz, 1H), 5.40 (s, 2H), 4.25 
(t, J = 7.4 Hz, 2H), 4.10 (s, 2H), 2.80 (q, J = 7.5 Hz, 2H), 1.91–1.80 (m, 2H), 
1.34–1.24 (m, 6H), 1.21 (t, J = 7.5 Hz, 3H), 0.85 (t, J = 7.6 Hz, 3H). 13C NMR 
(101 MHz, CDCl3): δ = 162.8 (Cq), 144.4 (Cq), 136.9 (Cq), 136.7 (Cq), 136.5 
(Cq), 132.5 (CH), 131.9 (CH), 128.7 (CH), 128.3 (CH), 127.6 (CH), 126.3 (CH), 
126.2 (CH), 125.8 (CH), 125.3 (Cq), 124.1 (CH), 123.0 (CH), 117.2 (Cq), 50.5 
(CH2), 40.0 (CH2), 32.3 (CH2), 31.2 (CH2), 30.2 (CH2), 26.2 (CH2), 22.5 (CH2), 
21.1 (CH2), 14.6 (CH3), 14.0 (CH3). IR (ATR): 2929, 2869, 1641, 1591, 1459, 
1336, 1219, 1048, 773 cm−1. MS (ESI) m/z (relative intensity): 455 (100) 
[M+H]+, 477 (77) [M+Na]+, 931 (62) [2M+Na]+. HR-MS (ESI) m/z calcd for 
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The general procedure GPC was followed using 51a (85.9 mg, 0.30 mmol) and 
BCP 94a (112 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 1/2) yielded 96aa (51 mg, 45%) as colourless oil.  
1H NMR (600 MHz, CDCl3): δ = 8.02 (dd, J = 7.7, 1.5 Hz, 1H), 7.60 (s, 1H), 7.38 
(td, J = 7.7, 7.5 Hz, 1H), 7.27 (dd, J = 7.8, 7.6 Hz, 1H), 6.98 (dd, J = 7.8, 1.1 
Hz, 1H), 5.02 (s, 2H), 4.27 (t, J = 7.2 Hz, 2H), 2.49 (d, J = 11.1 Hz, 2H), 1.86–
1.82 (m, 4H), 1.77 (dt, J = 11.5, 9.1 Hz, 1H), 1.56 (dt, J = 11.5, 9.1 Hz, 1H), 
1.26–1.23 (m, 6H), 1.05–1.01 (m, 2H), 0.99–0.93 (m, 2H), 0.82 (t, J = 6.8 Hz, 
3H). 13C NMR (126 MHz, CDCl3): δ = 164.6 (Cq), 146.0 (Cq), 141.4 (Cq), 132.2 
(CH), 130.3 (Cq), 128.3 (CH), 126.4 (CH), 123.1 (CH), 122.2 (CH), 63.3 (Cq), 
50.5 (CH2), 38.2 (CH2), 31.3 (CH2), 30.3 (CH2), 30.1 (CH2), 26.3 (CH2), 25.8 
(Cq), 22.6 (CH2), 14.6 (CH2), 14.1 (CH3), 10.3 (CH2). IR (ATR): 2954, 2931, 
2858, 1640, 1603, 1461, 1394, 1276, 1045, 757 cm−1. MS (ESI) m/z (relative 
intensity): 379 (100) [M+H]+, 757 (36) [2M+H]+, 779 (29) [2M+Na]+. HR-MS 










The general procedure GPC was followed using 51b (98.6 mg, 0.30 mmol) and 
BCP 94a (112 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 1/2) yielded 96ba (42.6 mg, 35%) as colourless oil.  
1H NMR (600 MHz, CDCl3): δ = 8.03 (dd, J = 7.7, 1.5 Hz, 1 H), 7.61 (s, 1H), 
7.40 (dd, J = 7.7, 7.6 Hz, 1H), 7.28 (dd, J = 7.8, 7.5 Hz, 1H), 7.00 (dd, J = 7.8, 
1.2 Hz, 1H), 5.03 (s, 2H), 4.28 (t, J = 7.2 Hz, 2H), 2.56–2.45 (m, 2H), 1.88–1.83 
(m, 4H), 1.80–1.75 (m, 1H), 1.58 (dt, J = 11.6, 9.1 Hz, 1H), 1.26–1.20 (m, 10H), 
1.06–1.03 (m, 2H), 1.00–0.94 (m, 2H), 0.83 (t, J = 7.0 Hz, 3H). 
13C NMR (151 MHz, CDCl3): δ = 164.8 (Cq), 146.1 (Cq), 141.5 (Cq), 132.3 (CH), 
130.4 (Cq), 128.4 (CH), 126.5 (CH), 123.2 (CH), 122.3 (CH), 63.3 (Cq), 50.5 
(CH2), 38.2 (CH2), 31.8 (CH2), 30.3 (CH2), 29.9 (CH2), 29.2 (CH2), 29.1 (CH2), 
26.6 (CH2), 25.8 (Cq), 22.7 (CH2), 14.6 (CH2), 14.2 (CH3), 10.2 (CH2). IR (ATR): 
2925, 2854, 1642, 1604, 1462, 1395, 1329, 1276, 1047, 769 cm−1. MS (ESI) 
m/z (relative intensity): 407 (59) [M+H]+, 429 (100) [M+Na]+, 835 (24) [2M+Na]+. 












The general procedure GPC was followed using 51y (83.5 mg, 0.30 mmol) and 
BCP 94a (112 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 1/2) yielded 96ya (33.3 mg, 30%) as colourless oil.  
1H NMR (400 MHz, CDCl3): δ = 8.13 (s, 1H), 8.06 (ddd, J = 7.7, 1.5, 0.5 Hz, 
1H), 7.77–7.73 (m, 2H), 7.52–7.48 (m, 2H), 7.45–7.39 (m, 2H), 7.31 (dd, 
J = 7.6, 7.3 Hz, 1H), 7.03 (dd, J = 8.1, 1.1 Hz, 1H), 5.13 (s, 2H), 2.58 (d, 
J = 11.3 Hz, 2H), 1.96–1.91 (m, 2H), 1.89–1.83 (m, 1H), 1.65–1.60 (m, 1H), 
1.15–1.07 (m, 2H), 1.06–0.98 (m, 2H). 13C NMR (101 MHz, CDCl3): δ = 164.9 
(Cq), 146.8 (Cq), 141.5 (Cq), 137.2 (Cq), 132.4 (CH), 130.4 (Cq), 129.8 (CH), 
128.8 (CH), 128.4 (CH), 126.6 (CH), 122.4 (CH), 121.6 (CH), 120.5 (CH), 63.4 
(Cq), 38.2 (CH2), 30.1 (CH2), 25.8 (Cq), 14.6 (CH2), 10.3 (CH2). IR (ATR): 2923, 
2853, 1639, 1601, 1502, 1434, 1395, 1280, 1041, 758 cm−1. MS (ESI) m/z 
(relative intensity): 371 (48) [M+H]+, 393 (100) [M+Na]+, 763 (29) [2M+Na]+.  












The general procedure GPC was followed using 51d (86.3 mg, 0.30 mmol) and 
BCP 94a (112 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 1/2) yielded 96da (40.0 mg, 36%) as colourless oil.  
1H NMR (500 MHz, CDCl3): δ = 8.05 (ddd, J = 7.7, 1.5, 0.5 Hz, 1H), 7.69 (s, 
1H), 7.42 (dd, J = 7.7, 7.6 Hz, 1H), 7.31 (dd, J = 7.8, 7.6 Hz, 1H), 7.02 (ddd, J 
= 7.8, 1.2, 0.5 Hz, 1H), 5.05 (s, 2H), 4.51 (t, J = 6.7 Hz, 2H), 3.52–3.48 (m, 2H), 
2.51 (d, J = 11.2 Hz, 2H), 2.40–2.34 (m, 2H), 1.94–1.87 (m, 2H), 1.84–1.77 (m, 
1H), 1.66–1.60 (m, 1H), 1.11–1.05 (m, 2H), 1.05–0.96 (m, 2H). 13C NMR 
(126 MHz, CDCl3): δ = 164.8 (Cq), 146.3 (Cq), 141.5 (Cq), 132.4 (CH), 130.3 
(Cq), 128.4 (CH), 126.6 (CH), 123.9 (CH), 122.3 (CH), 63.3 (Cq), 47.2 (CH2), 
41.2 (CH2), 38.2 (CH2), 32.7 (CH2), 30.0 (CH2), 25.7 (Cq), 14.6 (CH2), 10.2 
(CH2). IR (ATR): 2948, 1639, 1604, 1461, 1406, 1298, 1152, 1044, 758, 557 
cm−1. MS (ESI) m/z (relative intensity): 371 (40) [35Cl, M+H]+, 393 (100) [35Cl, 
M+Na]+, 763 (13) [35Cl, 2M+Na]+. HR-MS (ESI) m/z calcd for C20H2435ClN4O 












The general procedure GPC was followed using 51e (90.1 mg, 0.30 mmol) and 
BCP 94a (112 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 1/2) yielded 96ea (37.6 mg, 32%) as colourless oil.  
1H NMR (600 MHz, CDCl3): δ = 7.60 (s, 1H), 7.22 (d, J = 7.6 Hz, 1H), 7.08 (d, 
J = 7.6 Hz, 1H), 6.86 (s, 1H), 4.99 (s, 2H), 4.28 (t, J = 7.2 Hz, 2H), 2.67 (s, 3H), 
2.61–2.33 (m, 2H), 1.87–1.78 (m, 4H), 1.75 (ddd, J = 11.5, 7.3, 2.4 Hz, 1H), 
1.56 (dt, J = 11.5, 9.0 Hz, 1H), 1.29–1.22 (m, 6H), 0.99–0.80 (m, 7H). 13C NMR 
(101Mz, CDCl3): δ = 165.3 (Cq), 146.4 (Cq), 142.0 (Cq), 140.4 (Cq), 131.0 (CH), 
130.6 (CH), 129.2 (Cq), 123.1 (CH), 120.6 (CH), 62.7 (Cq), 50.5 (CH2), 37.9 
(CH2), 31.3 (CH2), 30.3 (CH2), 29.9 (CH2), 26.7 (CH2), 26.3 (Cq), 22.6 (CH2), 
22.3 (CH3), 14.7 (CH2), 14.1 (CH3), 10.0 (CH2). IR (ATR): 2954, 2929, 2857, 
1636, 1469, 1389, 1277, 1045, 778, 705 cm−1. MS (ESI) m/z (relative intensity): 
393 (100) [M+H]+, 4415 (95) [M+Na]+. HR-MS (ESI) m/z calcd for C24H33N4O 












The general procedure GPC was followed using 51s (99.8 mg, 0.30 mmol) and 
BCP 94a (112 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 1/2) yielded 96sa (50.8 mg, 40%) as colourless oil.  
1H NMR (400 MHz, CDCl3): δ = 7.93 (d, J = 8.2 Hz, 1H), 7.60 (s, 1H), 7.10 (dd, 
J = 8.2, 1.8 Hz, 1H), 6.82 (s, 1H), 5.00 (s, 2H), 4.27 (t, J = 7.2  Hz, 2H), 2.50–
2.44 (m, 5H), 1.88–1.82 (m, 4H), 1.79–1.73 (m, 1H), 1.56 (dt, J = 11.5, 9.0 Hz, 
1H), 1.28–1.22 (m, 6H), 1.06–1.02 (m, 2H), 0.99–0.92 (m, 2H), 0.83 (t, 
J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ = 164.5 (Cq), 146.1 (Cq), 144.2 
(Cq), 142.0 (Cq), 128.9 (CH), 127.0 (CH), 123.1(Cq), 123.0 (CH), 119.4 (CH), 
63.2 (Cq), 50.5 (CH2), 38.1 (CH2), 31.2 (CH2), 30.3 (CH2), 30.0 (CH2), 26.2 
(CH2), 25.9 (Cq), 22.5 (CH2), 15.1 (CH3), 14.5 (CH2), 14.0 (CH3), 10.2 (CH2). 
IR (ATR): 2854, 2928, 2857, 1638, 1594, 1435, 1422, 1384, 1046, 784 cm−1. 
MS (ESI) m/z (relative intensity): 425 (100) [M+H]+, 447 (60) [M+Na]+. HR-MS 












The general procedure GPC was followed using 51h (106 mg, 0.30 mmol) and 
BCP 94a (112 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 1/2) yielded 96ha (37.5 mg, 28%) as colourless oil.  
1H NMR (600 MHz, CDCl3): δ = 8.14 (dd, J = 8.0, 0.7 Hz, 1H), 7.61 (s, 1H), 7.54 
(ddd, J = 8.0, 1.7, 0.8 Hz, 1H), 7.23 (d, J = 1.6 Hz, 1H), 5.03 (s, 2H), 4.29 (t, 
J = 7.2 Hz, 2H), 2.54 (d, J = 11.9 Hz, 2H), 1.88–1.83 (m, 4H), 1.83–1.7 (m, 1H), 
1.60 (dt, J = 11.6, 9.1 Hz, 1H), 1.32–1.23 (m, 6H), 1.15–1.10 (m, 2H), 1.08–
0.99 (m, 2H), 0.83 (t, J = 7.0 Hz, 3H). 13C NMR (151 MHz, CDCl3): δ = 163.6 
(Cq), 145.6 (Cq), 142.6 (Cq), 133.9 (q, 2JC–F = 32.3 Hz, Cq), 133.5 (Cq), 129.0 
(CH), 123.9 (q, 1JC–F = 272.8 Hz, Cq), 123.4 (q, 3JC–F = 3.9 Hz, CH), 123.0 (CH), 
119.5 (q, 3JC–F = 3.9 Hz, CH), 63.3 (Cq), 50.5 (CH2), 38.3 (CH2), 31.2 (CH2), 
30.3 (CH2), 30.0 (CH2), 26.3 (CH2), 25.9 (Cq), 22.5 (CH2), 14.5 (CH2), 14.0 
(CH3), 10.6 (CH2). 19F NMR (565 MHz, CDCl3): δ = –62.89 (s). IR (ATR): 2954, 
2933, 1646, 1443, 1295, 1443, 1295, 1167, 1128, 1048 cm−1. MS (ESI) m/z 
(relative intensity): 447 (45) [M+H]+, 469 (100) [M+Na]+. HR-MS (ESI) m/z calcd 












The general procedure GPC was followed using 51w (110 mg, 0.30 mmol) and 
BCP 94a (112 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 1/2) yielded 96wa (42.3 mg, 31%) as colourless oil.  
1H NMR (500 MHz, CDCl3): δ = 8.15 (d, J = 2.2 Hz, 1H), 7.60 (s, 1H), 7.50 (d, 
J = 8.3 Hz, 1H), 6.87 (d, J = 8.3 Hz, 1H), 5.00 (s, 2H), 4.28 (t, J = 7.2 Hz, 2H), 
2.50 (d, J = 11.8 Hz, 2H), 1.88–1.83 (m, 4H), 1.80–1.74 (m, 1H), 1.57 (dt, 
J = 11.5, 9.1 Hz, 1H), 1.28–1.23 (m, 6H), 1.09–1.04 (m, 2H), 0.97–0.91 (m, 2H), 
0.83 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ = 163.5 (Cq), 145.7 (Cq), 
140.6 (Cq), 135.1 (CH), 132.2 (Cq), 131.3 (CH), 124.3 (CH), 123.18 (CH), 120.3 
(Cq), 63.2 (Cq), 50.5 (CH2), 38.3 (CH2), 31.2 (CH2), 30.3 (CH2), 30.0 (CH2), 26.2 
(CH2), 25.6 (Cq), 22.5 (CH2), 14.5 (CH2), 14.0 (CH3), 10.4 (CH2). IR (ATR): 
2954, 2930, 1642, 1425, 1374, 1320, 1249, 1132, 1047, 789 cm−1. MS (ESI) 
m/z (relative intensity): 457 (47) [79Br, M+H]+, 479 (100) [79Br, M+Na]+. HR-MS 















The general procedure GPC was followed using 51u (91.3 mg, 0.30 mmol) and 
BCP 94a (112 mg, 0.90 mmol). Purification by column chromatography 
(nhexane/EtOAc = 1/2) yielded 96ua (34.5 mg, 29%) as colourless oil.  
1H NMR (400 MHz, CDCl3): δ = 7.75 (dd, J = 9.1, 2.8 Hz, 1H), 7.65 (s, 1H), 7.12 
(dd, J = 8.4, 2.8 Hz, 1H), 7.00 (dd, J = 8.5, 4.9 Hz, 1H), 5.05 (s, 2H), 4.32 (t, 
J = 7.2 Hz, 2H), 2.61–2.48 (m, 2H), 1.92–1.86 (m, 4H), 1.82–1.76 (m, 1H), 1.61 
(dt, J = 11.4, 9.1 Hz, 1H), 1.34–1.24 (m, 6H), 1.12–1.06 (m, 2H), 1.01–0.94 (m, 
2H), 0.87 (t, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ = 163.7 (d, 4JC–F = 
2.6 Hz, Cq), 161.6 (d, 1JC–F = 245.1 Hz, Cq), 145.7 (Cq), 137.2 (d, 4JC–F = 3.0 Hz, 
Cq), 132.3 (d, 3JC–F = 7.4 Hz, CH), 124.3 (d, 3JC–F = 7.6 Hz, Cq), 123.1 (CH), 
119.1 (d, 2JC–F = 21.9 Hz, CH), 115.1 (d, 2JC–F = 23.2 Hz, CH), 63.4 (Cq), 50.5 
(CH2), 38.3 (CH2), 31.2 (CH2), 30.3 (CH2), 29.9 (CH2), 26.2 (CH2), 25.3 (Cq), 
22.5 (CH2), 14.5 (CH2), 14.0 (CH3), 10.2 (CH2). 19F NMR (377 MHz, CDCl3): 
δ = –115.76  (td, J = 8.8, 5.0 Hz). IR (ATR): 2955, 2931, 2858, 1642, 1588, 
1443, 1382, 1265, 1047, 825 cm−1. MS (ESI) m/z (relative intensity): 397 (44) 
[M+H]+, 419 (100) [M+Na]+, 815 (20) [2M+Na]+. HR-MS (ESI) m/z calcd for 
C23H30FN4O [M+H]+ 397.2398, found 397.2402.  
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The general procedure GPD was followed using 96aa (114 mg, 0.30 mmol). 
Purification by column chromatography (nhexane/EtOAc = 1/2) yielded 120 
(42.2 mg, 66%) as a white solid.  
M.p. = 188–189 °C. 1H NMR (400 MHz, CDCl3): δ = 8.09 (dd, J = 7.7, 1.6 Hz, 
1H), 7.47 (dd, J = 7.7, 7.6 Hz, 1H), 7.33 (dd, J = 7.8, 7.5 Hz, 1H), 7.02 (dd, 
J = 7.8, 1.3 Hz, 1H), 6.41 (s, 1H), 2.18–2.10 (m, 2H), 2.03–1.94 (m, 3H), 1.76–
1.66 (m, 1H), 1.19–1.13 (m, 2H), 1.07–1.00 (m, 2H). 13C NMR (101 MHz, 
CDCl3): δ = 165.6 (Cq), 141.8 (Cq), 132.8 (CH), 129.7 (Cq), 128.2 (CH), 126.4 
(CH), 122.4 (CH), 59.2 (Cq), 32.5 (CH2), 25.5 (Cq), 13.9 (CH2), 10.6 (CH2). 
IR (ATR): 2954, 2930, 2857, 1665, 1605, 1465, 1439, 1382, 1052, 759 cm−1. 
MS (ESI) m/z (relative intensity): 214 (100) [M+H]+, 256 (78) [M+Na]+, 449 (48) 
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5.5.7 Mechanistic Studies 
Competition Experiments 
 
To a stirred solution of 51e (45.1 mg, 0.15 mmol), 51h (53.2 mg, 0.15 mmol), 
ZnBr2∙TMEDA (205 mg, 0.60 mmol) and dppe (17.9 mg, 15 mol %) in THF 
(0.20 mL), iPrMgBr (3.0 M in 2-MeTHF, 300 μL, 0.90 mmol) was added in one 
portion and the reaction mixture was stirred for 5 min at ambient temperature. 
Then, Fe(acac)3 (15.9 mg, 15 mol %) was added. After stirring for additional 
5 min, a solution of BCP 94g (137 mg, 0.90 mmol) in THF (0.20 mL) was added 
in one portion. The reaction mixture was stirred at 65 °C. After 10 min, sat. 
aqueous NH4Cl (3.0 mL) was added and the aqueous phase was extracted with 
CH2Cl2 (3  15 mL). The combined organic phases were dried over Na2SO4, 
filtered and concentrated. Purification by column chromatography 
(nhexane/EtOAc = 3/1 to 3/2) yielded 95eg (19.9 mg, 34%), 95hg (10.2 mg, 
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Intermolecular Kinetic Isotope Effect (KIE) Study 
 
To a stirred solution of 51r (29.6 mg, 0.10 mmol) or [D5]-51r (30.1 mg, 
0.10 mmol), ZnBr2∙TMEDA (68.3 mg, 0.20 mmol) and dppe (5.98 mg, 
15 mol %) in THF (0.1 mL), iPrMgBr (3.0 M in 2-MeTHF, 0.30 mmol) was added 
in one portion and the reaction mixture was stirred for 5 min at ambient 
temperature. Then, Fe(acac)3 (5.29 mg, 15 mol %) in THF (0.1 mL) was added 
in a single portion. After stirring for additional 5 min, BCP 94g (30.8 mg, 
0.2 mmol) was added in one portion. The reaction mixture was stirred at 65 °C. 
After the times indicated below, sat. aqueous NH4Cl (3.0 mL) was added and 
the aqueous phase was extracted with CH2Cl2 (3  15 mL). The combined 
organic phases were dried over Na2SO4, filtered and concentrated. 1,3,5-
Triisopropylbenzene (10.2 mg, 0.05 mmol) was added into the reaction mixture 
then diluted with CDCl3 (0.7 mL). The yields of product were determined via 
1H NMR using 1,3,5-Triisopropylbenzene (10.2 mg, 0.05 mmol) as the 
standard. 
Time [min] 1 3 5 7 9 11 13 
95rg [%] 0.0 4.0 6.0 8.0 11.0 13.0 15.0 
[D4]-95rg [%] 1.0 3.0 5.0 7.0 10.0 11.0 13.0 
 




Figure 5.3 Initial rates for the reaction of 51r or [D5]-51r with 94g.  
 
 
To a stirred solution of 51a (43.0 mg, 0.15 mmol), [D5]-51a (43.7 mg, 
0.15 mmol) ZnBr2∙TMEDA (205 mg, 0.60 mmol) and dppe (17.9 mg, 15 mol %) 
in THF (0.20 mL), iPrMgBr (3.0 M in 2-MeTHF, 300 μL, 0.90 mmol) was added 
in one portion and the reaction mixture was stirred for 5 min at ambient 
temperature. Then, Fe(acac)3 (15.9 mg, 15 mol %) was added. After stirring for 
additional 5 min, a solution of BCP 94g (137 mg, 0.90 mmol) in THF (0.2 mL) 
was added in one portion. After stirring 10 min at 65 °C, sat. aqueous NH4Cl 
(3.0 mL) was added and aqueous phase was extracted with CH2Cl2 
(3  15 mL). The combined organic phases were dried over Na2SO4, filtered 
and concentrated under reduced pressure. Purification by column 
y = 1,2002x - 0,226
R² = 0,992
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chromatography (nhexane/EtOAc = 3/2) afforded a mixture of both products. 





To a stirred solution of [D5]-51a (87.4 mg, 0.30 mmol), ZnBr2∙TMEDA (205 mg, 
0.60 mmol), dppe (17.9 mg, 15 mol %) in THF (0.20 mL), iPrMgBr (3.0 M in 2-
MeTHF, 300 µL, 0.90 mmol) was added in one portion and the reaction mixture 
was stirred for 5 min at ambient temperature. Then, Fe(acac)3 (15.9 mg, 
15 mol %) was added. After stirring the solution for additional 5 min, a solution 
of BCP 94g (137 mg, 0.90 mmol) in THF (0.20 mL) was added in one portion. 
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The mixture was placed in a pre-heated oil bath at 65 °C. After stirring for 16 h, 
sat. aqueous NH4Cl (2.0 mL) was added to the reaction mixture and the 
aqueous phase was extracted with CH2Cl2 (3  15 mL). The combined organic 
phases were dried over Na2SO4, filtered and concentrated. Purification by 
column chromatography (nhexane/EtOAc = 3/2) yielded [Dn]-95ag (66.6 mg, 












To a stirred solution of [D5]-51a (87.4 mg, 0.30 mmol), ZnBr2∙TMEDA (205 mg, 
0.60 mmol), dppe (17.9 mg, 15 mol %) in THF (0.20 mL), iPrMgBr (3.0 M in 2-
MeTHF, 300 µL, 0.90 mmol) was added in one portion and the reaction mixture 
was stirred for 5 min at ambient temperature. Then, Fe(acac)3 (15.9 mg, 
15 mol %) was added. After stirring the solution for additional 5 min, a solution 
of BCP 94a (137 mg, 0.90 mmol) in THF (0.20 mL) was added in one portion. 
The mixture was placed in a pre-heated oil bath at 65 °C. After stirring for 16 h, 
sat. aqueous NH4Cl (2.0 mL) was added to the reaction mixture and the 
aqueous phase was extracted with CH2Cl2 (3  15 mL). The combined organic 
phases were dried over Na2SO4, filtered and concentrated. Purification by 
column chromatography (nhexane/EtOAc = 1/2) yielded [Dn]-96aa (19.5 mg, 
17%) as colourless oil. 
 




To a stirred solution of 51a (85.9 mg, 0.3 mmol), ZnBr2∙TMEDA (205 mg, 
0.60 mmol) and dppe (17.9 mg, 15 mol %) in THF (0.2 mL), iPrMgBr (3.0 M in 
2-MeTHF, 300 μL, 0.90 mmol) was added in one portion and the reaction 
mixture was stirred for 5 min at ambient temperature. Then, Fe(acac)3 
(15.9 mg, 15 mol %) was added. After stirring for additional 5 min, a solution of 
BCP 94g (137 mg, 0.90 mmol) in THF (0.20 mL) was added in one portion. The 
reaction mixture was stirred at 65 °C. After 5 min, D2O (2.0 mL) was added and 
the aqueous phase was extracted with CH2Cl2 (3  15 mL). The combined 
organic phases were dried over Na2SO4, filtered and concentrated. Purification 
by column chromatography (nhexane/EtOAc = 3/2) yielded [D]-95ag (27 mg, 
24%) The amount of deuterium incorporation was determined by 1H NMR.  
 




To a stirred solution of 51a (85.9 mg, 0.3 mmol), ZnBr2∙TMEDA (205 mg, 
0.60 mmol) and dppe (17.9 mg, 15 mol %) in THF (0.2 mL), iPrMgBr (3.0 M in 
2-MeTHF, 300 μL, 0.90 mmol) was added in one portion and the reaction 
mixture was stirred for 5 min at ambient temperature. Then, Fe(acac)3 
(15.9 mg, 15 mol %) was added. After stirring for additional 5 min, a solution of 
BCP 94a (112 mg, 0.90 mmol) in THF (0.20 mL) was added in one portion. The 
reaction mixture was stirred at 65 °C. After 3 h, D2O (2.0 mL) was added and 
the aqueous phase was extracted with CH2Cl2 (3  15 mL). The combined 
organic phases were dried over Na2SO4, filtered and concentrated. Purification 
by column chromatography (nhexane/EtOAc = 1/2) yielded [D]-96aa (10.2 mg, 
9%) The position of deuterium incorporation was determined by 1H NMR. 
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5.6 Mössbauer Measurement 
After sample preparation, the spectra were recorded and interpreted by Dr. S. 
Demeshko.  
Table 5.1 Mössbauer parameters of reaction mixtures. 








1 57FeCl2 + THF +2HS 1.26 3.05 100 
2 Entry 1 + MeMgBr +1.4[91] 0.29 0.88   100 





























































































































[a] used MeMgBr (3 equiv), ZnBr2·TMEDA (2 equiv). n.a. = not assign. 
Sample Preparation for Mössbauer Measurements 
Entry 1. 57FeCl2 + THF 
Inside a nitrogen-filled glovebox, a suspension of 57FeCl2 (3.2 mg, 25 µmol) in 
THF (0.80 mL) was stirred at ambient temperature for 5 min. Then, the solution 
was filtered and added into a sample holder. The sample holder was taken out 
of the glovebox and frozen in liquid nitrogen immediately.  
Entry 2. 57FeCl2 + MeMgBr + THF 
Inside a nitrogen-filled glovebox, a suspension of MeMgBr (3.0 M in Et2O, 
75 µL, 9.0 equiv) in THF (17 µL) was stirred at ambient temperature for 5 min. 
Then, 57FeCl2 (3.2 mg, 25 µmol) was added. After stirring for additional 5 min, 
the solution was diluted to 5.0 mL by adding THF, 0.80 mL of the solution was 
filtered and added into a sample holder. The sample holder was taken out of 
the glovebox and frozen in liquid nitrogen immediately. 
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Entry 3. 57FeCl2 + MeMgBr + ZnBr2·TMEDA + THF 
Inside a nitrogen-filled glovebox, to a stirred solution of ZnBr2·TMEDA 
(51.6 mg, 6.0 equiv) in THF (17 µL), MeMgBr (3.0 M in Et2O, 75 µL, 9.0 equiv) 
was added in one portion and the reaction mixture was stirred for 5 min at 
ambient temperature. Then, 57FeCl2 (3.2 mg, 25 µmol) was added. After stirring 
for additional 5 min, the solution was diluted to 5.0 mL by adding THF, 0.80 mL 
of the solution was filtered and added into a sample holder. The sample holder 
was taken out of the glovebox and frozen in liquid nitrogen immediately. 
Entry 4. 57FeCl2 + MeMgBr + ZnBr2·TMEDA + dppe + THF 
Inside a nitrogen-filled glovebox, to a stirred solution of ZnBr2·TMEDA 
(51.6 mg, 6.0 equiv) and dppe (10.0 mg, 1.0 equiv) in THF (17 µL), MeMgBr 
(3.0 M in Et2O, 75 µL, 9.0 equiv) was added in one portion and the reaction 
mixture was stirred for 5 min at ambient temperature. Then, 57FeCl2 (3.2 mg, 
25 µmol) was added. After stirring for additional 5 min, the solution was diluted 
to 5.0 mL by adding THF, 0.80 mL of the solution was filtered and added into a 
sample holder. The sample holder was taken out of the glovebox and frozen in 
liquid nitrogen immediately. 
Entry 5. 57FeCl2 + MeMgBr (9 equiv) + ZnBr2·TMEDA (3 equiv) + dppe + 
TAH-substrate (51a) + THF 
Inside a nitrogen-filled glovebox, to a stirred solution of 51a (7.2 mg, 1.0 equiv), 
ZnBr2·TMEDA (51.6 mg, 6.0 equiv) and dppe (10.0 mg, 1.0 equiv) in THF 
(17 µL), MeMgBr (3.0 M in Et2O, 75 µL, 9.0 equiv) was added in one portion 
and the reaction mixture was stirred for 5 min at ambient temperature. Then, 
57FeCl2 (3.2 mg, 25 µmol) was added. After stirring for additional 5 min, the 
solution was diluted to 5.0 mL by adding THF, 0.80 mL of the solution was 
filtered and added into a sample holder. The sample holder was taken out of 
the glovebox and frozen in liquid nitrogen immediately. 
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Entry 6. 57FeCl2 + MeMgBr + ZnBr2·TMEDA + dppe + TAH-substrate (51a) 
+ THF 
Inside a nitrogen-filled glovebox, to a stirred solution of 51a (7.2 mg, 1.0 equiv), 
ZnBr2·TMEDA (17.2 mg, 2.0 equiv) and dppe (10.0 mg, 1.0 equiv) in THF 
(17 µL), MeMgBr (3.0 M in Et2O, 25 µL, 3.0 equiv) was added in one portion 
and the reaction mixture was stirred for 5 min at ambient temperature. Then, 
57FeCl2 (3.2 mg, 25 µmol) was added. After stirring for additional 5 min, the 
solution was diluted to 5.0 mL by adding THF, 0.80 mL of the solution was 
filtered and added into a sample holder. The sample holder was taken out of 
the glovebox and frozen in liquid nitrogen immediately. 
Entry 7. 57FeCl2 + MeMgBr + ZnBr2·TMEDA + dppe + TAH-substrate (51a) 
+ allene (88a) + THF 
Inside a nitrogen-filled glovebox, to a stirred solution of 51a (7.2 mg, 1.0 equiv), 
ZnBr2·TMEDA (51.6 mg, 6.0 equiv) and dppe (10.0 mg, 1.0 equiv) in THF 
(17 µL), MeMgBr (3.0 M in Et2O, 75 µL, 9.0 equiv) was added in one portion 
and the reaction mixture was stirred for 5 min at ambient temperature. Then, 
57FeCl2 (3.2 mg, 25 µmol) was added. After stirring for additional 5 min, allene 
88a (13.6 mg, 3.0 equiv) was added as a solution in THF (17 µL). After stirring 
for additional 5 min, the solution was diluted to 5.0 mL by adding THF, 0.80 mL 
of the solution was filtered and added into a sample holder. The sample holder 
was taken out of the glovebox and frozen in liquid nitrogen immediately. 
Entry 8. 57FeCl2 + MeMgBr + ZnBr2·TMEDA + dppe + TAH-substrate (51a) 
+ alkyne (91a) + THF 
Inside a nitrogen-filled glovebox, to a stirred solution of 51a (7.2 mg, 1.0 equiv), 
ZnBr2·TMEDA (51.6 mg, 6.0 equiv) and dppe (10.0 mg, 1.0 equiv) in THF 
(17 µL), MeMgBr (3.0 M in Et2O, 75 µL, 9.0 equiv) was added in one portion 
and the reaction mixture was stirred for 5 min at ambient temperature. Then, 
                     5. Experimental Part 
174 
 
57FeCl2 (3.2 mg, 25 µmol) was added. After stirring for additional 5 min, alkyne 
91a (16.2 mg, 3.0 equiv) was added as a solution in THF (17 µL). After stirring 
for additional 5 min, the solution was diluted to 5.0 mL by adding THF, 0.80 mL 
of the solution was filtered and added into a sample holder. The sample holder 
was taken out of the glovebox and frozen in liquid nitrogen immediately. 
Entry 9. 57FeCl2 + MeMgBr + ZnBr2·TMEDA + dppe + TAH-substrate (51a) 
+ BCP (94g)+ THF 
Inside a nitrogen-filled glovebox, to a stirred solution of 51a (7.2 mg, 1.0 equiv), 
ZnBr2·TMEDA (17.2 mg, 2.0 equiv) and dppe (10.0 mg, 1.0 equiv) in THF 
(17 µL), MeMgBr (3.0 M in Et2O, 25 µL, 3.0 equiv) was added in one portion 
and the reaction mixture was stirred for 5 min at ambient temperature. Then, 
57FeCl2 (3.2 mg, 25 µmol) was added. After stirring for additional 5 min, BCP 
94g (11.4 mg, 3.0 equiv) was added as a solution in THF (17 µL). After stirring 
for additional 5 min, the solution was diluted to 5.0 mL by adding THF, 0.80 mL 
of the solution was filtered and added into a sample holder. The sample holder 
was taken out of the glovebox and frozen in liquid nitrogen immediately. 
Entry 10. 57FeCl2 + MeMgBr + ZnBr2·TMEDA + dppe + TAM-substrate (32a) 
+ BCP (94g)+ THF 
Inside a nitrogen-filled glovebox, to a stirred solution of 32a (7.2 mg, 1.0 equiv), 
ZnBr2·TMEDA (17.2 mg, 2.0 equiv) and dppe (10.0 mg, 1.0 equiv) in THF 
(17 µL), MeMgBr (3.0 M in Et2O, 25 µL, 3.0 equiv) was added in one portion 
and the reaction mixture was stirred for 5 min at ambient temperature. Then, 
57FeCl2 (3.2 mg, 25 µmol) was added. After stirring for additional 5 min, BCP 
94g (11.4 mg, 3.0 equiv) was added as a solution in THF (17 µL). After stirring 
for additional 5 min, the solution was diluted to 5.0 mL by adding THF, 0.80 mL 
of the solution was filtered and added into a sample holder. The sample holder 
was taken out of the glovebox and frozen in liquid nitrogen immediately. 
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Entry 11. 57FeCl2 + MeMgBr + ZnBr2·TMEDA + dppe + TAH-substrate (51a) 
+ BCP (94a)+ THF 
Inside a nitrogen-filled glovebox, to a stirred solution of 51a (7.2 mg, 1.0 equiv), 
ZnBr2·TMEDA (17.2 mg, 2.0 equiv) and dppe (10.0 mg, 1.0 equiv) in THF 
(17 µL), MeMgBr (3.0 M in Et2O, 25 µL, 3.0 equiv) was added in one portion 
and the reaction mixture was stirred for 5 min at ambient temperature. Then, 
57FeCl2 (3.2 mg, 25 µmol) was added. After stirring for additional 5 min, BCP 
94a (9.3 mg, 3.0 equiv) was added as a solution in THF (17 µL). After stirring 
for additional 20 min, the solution was diluted to 5.0 mL by adding THF, 0.80 mL 
of the solution was filtered and added into a sample holder. The sample holder 
was taken out of the glovebox and frozen in liquid nitrogen immediately. 
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5.7 X-Ray Crystallographic Analysis 
The crystal structures of 89la and 120 were measured and solved by Dr. 
Christopher Golz (Prof. Dr. Manuel Alcarazo research group). 
5.7.1 Data Analysis for Crystal Structure of 89la 
The crystal was kept at 99.98 K during data collection. Using Olex2,[104] the 
structure was solved with the XT[105] structure solution program using Intrinsic 
Phasing and refined with the XL[106] refinement package using Least Squares 
minimisation. 
 
Figure 5.4 Molecular structure of 89la with thermal ellipoids at 50% probability 
level. 
Crystal Data for C27H40N4O (M =436.63 g/mol) triclinic, space group P-1 (no. 
2), a = 5.6131(13) Å, b = 8.0980(19) Å, c = 27.986(7) Å, α = 87.340(7)°, 
β = 87.040(7)°, γ = 84.035(7)°, V = 1262.5(5) Å3, Z = 2, T = 99.98 K, 
μ(MoKα) = 0.071 mm-1, Dcalc = 1.149 g/cm3, 15862 reflections measured 
(4.376° ≤ 2Θ ≤ 63.042°), 8285 unique (Rint = 0.0437, Rsigma = 0.0624) which 
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were used in all calculations. The final R1 was 0.0547 (I > 2σ(I)) and wR2 was 
0.1521 (all data). 
Table 5.2 Crystal data and structure refinement for 89la.  
Compound 89la 
Identification code  mo_0230_CG_0m 
Empirical formula  C27H40N4O  
Formula weight  436.63  
Temperature/K  99.98  
Crystal system  triclinic  
Space group  P-1  
a/Å  5.6131(13)  
b/Å  8.0980(19)  
c/Å  27.986(7)  
α/°  87.340(7)  
β/°  87.040(7)  
γ/°  84.035(7)  
Volume/Å3 1262.5(5)  
Z  2  
ρcalcg/cm3 1.149  
μ/mm-1 0.071  
F(000)  476.0  
Crystal size/mm3 0.714 × 0.391 × 0.052  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.376 to 63.042  
Index ranges  -8 ≤ h ≤ 8, -11 ≤ k ≤ 9, -41 ≤ l ≤ 41  
Reflections collected  15862  
Independent reflections  8285 [Rint = 0.0437, Rsigma = 0.0624]  
Data/restraints/parameters  8285/0/293  
Goodness-of-fit on F2 1.031  
Final R indexes [I>=2σ (I)]  R1 = 0.0547, wR2 = 0.1421  
Final R indexes [all data]  R1 = 0.0688, wR2 = 0.1521  
Largest diff. peak/hole / e Å-3 0.52/-0.26  
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Table 5.3 Bond Lengths [Å] for 89la.  
Atom Atom Length/Å   Atom Atom Length/Å 
O1 C1 1.2339(13)   C6 C7 1.4127(15) 
N1 C1 1.3951(14)   C7 C8 1.4337(15) 
N1 C9 1.4023(14)   C8 C9 1.3534(15) 
N1 C19 1.4703(14)   C9 C12 1.5123(15) 
N2 N3 1.3207(14)   C12 C13 1.5332(16) 
N2 C20 1.3605(14)   C13 C14 1.5216(16) 
N3 N4 1.3428(12)   C14 C15 1.5224(16) 
N4 C21 1.3522(13)   C15 C16 1.5187(17) 
N4 C22 1.4588(14)   C16 C17 1.5173(18) 
C1 C2 1.4588(15)   C17 C18 1.522(2) 
C2 C3 1.4095(15)   C19 C20 1.4957(15) 
C2 C7 1.4036(15)   C20 C21 1.3724(15) 
C3 C4 1.3820(16)   C22 C23 1.5185(17) 
C4 C5 1.4213(16)   C23 C24 1.5230(17) 
C4 C10 1.5062(15)   C24 C25 1.5201(19) 
C5 C6 1.3861(15)   C25 C26 1.518(2) 
C5 C11 1.5071(16)   C26 C27 1.523(2) 
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Table 5.4 Bond Angles [˚] for 89la.  
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C1 N1 C9 123.33(9)   C2 C7 C8 118.76(10) 
C1 N1 C19 114.38(9)   C6 C7 C8 122.78(10) 
C9 N1 C19 122.19(9)   C9 C8 C7 121.64(10) 
N3 N2 C20 108.88(9)   N1 C9 C12 120.19(10) 
N2 N3 N4 107.19(9)   C8 C9 N1 119.25(10) 
N3 N4 C21 110.88(9)   C8 C9 C12 120.53(10) 
N3 N4 C22 119.81(9)   C9 C12 C13 117.73(9) 
C21 N4 C22 129.30(9)   C14 C13 C12 114.42(9) 
O1 C1 N1 119.83(10)   C13 C14 C15 112.60(9) 
O1 C1 C2 123.75(10)   C16 C15 C14 113.68(10) 
N1 C1 C2 116.42(9)   C17 C16 C15 113.71(11) 
C3 C2 C1 119.47(10)   C16 C17 C18 112.98(12) 
C7 C2 C1 120.36(10)   N1 C19 C20 113.87(9) 
C7 C2 C3 120.17(10)   N2 C20 C19 119.61(9) 
C4 C3 C2 121.04(10)   N2 C20 C21 108.30(10) 
C3 C4 C5 119.16(10)   C21 C20 C19 132.09(10) 
C3 C4 C10 120.39(10)   N4 C21 C20 104.74(9) 
C5 C4 C10 120.45(10)   N4 C22 C23 113.18(9) 
C4 C5 C11 120.17(10)   C22 C23 C24 110.42(10) 
C6 C5 C4 119.88(10)   C25 C24 C23 114.16(11) 
C6 C5 C11 119.95(10)   C26 C25 C24 112.80(13) 
C5 C6 C7 121.27(10)   C25 C26 C27 113.65(16) 
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5.7.2 Data Analysis for Crystal Structure of 120 
The crystal was kept at 100.0 K during data collection. Using Olex2,[104] the 
structure was solved with the XT[105] structure solution program using Intrinsic 




Figure 5.5 Molecular structure of 120 with thermal ellipoids at 50% probability 
level. 
Crystal Data for C14H15NO (M =213.27 g/mol): monoclinic, space group P21/n 
(no. 14), a = 13.9071(8) Å, b = 9.5864(5) Å, c = 16.9660(10) Å, 
β = 100.194(2)°, V = 2226.2(2) Å3, Z = 8, T = 100.0 K, μ(MoKα) = 0.080 mm-1, 
Dcalc = 1.273 g/cm3, 67587 reflections measured (4.168° ≤ 2Θ ≤ 54.268°), 
4911 unique (Rint = 0.0438, Rsigma = 0.0190) which were used in all calculations. 
The final R1 was 0.0774 (I > 2σ(I)) and wR2 was 0.2170 (all data). 
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Table 5.5 Crystal data and structure refinement for 120.  
CCDC code  2018011  
Empirical formula  C14H15NO  
Formula weight  213.27  
Temperature/K  100.0  
Crystal system  monoclinic  
Space group  P21/n  
a/Å  13.9071(8)  
b/Å  9.5864(5)  
c/Å  16.9660(10)  
α/°  90  
β/°  100.194(2)  
γ/°  90  
Volume/Å3  2226.2(2)  
Z  8  
ρcalcg/cm3  1.273  
μ/mm-1  0.080  
F(000)  912.0  
Crystal size/mm3  0.247 × 0.182 × 0.168  
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Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.168 to 54.268  
Index ranges  -17 ≤ h ≤ 17, -12 ≤ k ≤ 12, -21 ≤ l ≤ 21  
Reflections collected  67587  
Independent reflections  4911 [Rint = 0.0438, Rsigma = 0.0190]  
Data/restraints/parameters  4911/0/289  
Goodness-of-fit on F2  1.087  
Final R indexes [I>=2σ (I)]  R1 = 0.0774, wR2 = 0.2080  
Final R indexes [all data]  R1 = 0.0866, wR2 = 0.2170  
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Table 5.6 Bond Lengths [Å] for 120. 
Atom Atom Length/Å   Atom Atom Length/Å 
O1 C1 1.244(2)   O2 C15 1.245(2) 
N1 C1 1.339(2)   N2 C15 1.336(3) 
N1 C5 1.456(2)   N2 C19 1.456(2) 
C1 C2 1.486(3)   C15 C16 1.489(3) 
C2 C3 1.407(3)   C16 C17 1.405(3) 
C2 C14 1.402(3)   C16 C28 1.394(3) 
C3 C4 1.500(3)   C17 C18 1.498(3) 
C3 C11 1.395(3)   C17 C25 1.393(3) 
C4 C5 1.515(3)   C18 C19 1.510(3) 
C4 C9 1.513(3)   C18 C23 1.519(3) 
C4 C10 1.504(3)   C18 C24 1.500(3) 
C5 C6 1.564(3)   C19 C20 1.566(3) 
C5 C8 1.550(3)   C19 C22 1.551(3) 
C6 C7 1.533(3)   C20 C21 1.510(4) 
C7 C8 1.538(4)   C21 C22 1.543(4) 
C9 C10 1.500(3)   C23 C24 1.503(4) 
C11 C12 1.392(3)   C25 C26 1.389(3) 
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C12 C13 1.394(3)   C26 C27 1.399(3) 
C13 C14 1.383(3)   C27 C28 1.386(3) 
 
Table 5.7 Bond Angles [˚] for 120. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C1 N1 C5 124.01(17)   C15 N2 C19 124.42(18) 
O1 C1 N1 122.03(18)   O2 C15 N2 122.13(19) 
O1 C1 C2 121.65(17)   O2 C15 C16 121.22(18) 
N1 C1 C2 116.32(16)   N2 C15 C16 116.64(17) 
C3 C2 C1 120.44(17)   C17 C16 C15 120.48(18) 
C14 C2 C1 119.28(17)   C28 C16 C15 118.78(17) 
C14 C2 C3 120.20(18)   C28 C16 C17 120.67(19) 
C2 C3 C4 117.86(17)   C16 C17 C18 118.04(18) 
C11 C3 C2 118.41(18)   C25 C17 C16 118.01(19) 
C11 C3 C4 123.65(17)   C25 C17 C18 123.78(18) 
C3 C4 C5 111.78(16)   C17 C18 C19 112.54(17) 
C3 C4 C9 116.87(18)   C17 C18 C23 116.04(19) 
C3 C4 C10 120.92(17)   C17 C18 C24 121.00(18) 
C9 C4 C5 119.69(18)   C19 C18 C23 119.80(19) 
C10 C4 C5 118.90(17)   C24 C18 C19 118.23(19) 
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C10 C4 C9 59.62(14)   C24 C18 C23 59.73(16) 
N1 C5 C4 108.55(16)   N2 C19 C18 109.74(18) 
N1 C5 C6 114.59(17)   N2 C19 C20 111.50(18) 
N1 C5 C8 112.46(17)   N2 C19 C22 114.33(19) 
C4 C5 C6 113.59(17)   C18 C19 C20 116.56(18) 
C4 C5 C8 118.06(17)   C18 C19 C22 114.25(19) 
C8 C5 C6 88.71(17)   C22 C19 C20 89.32(19) 
C7 C6 C5 89.68(18)   C21 C20 C19 89.4(2) 
C6 C7 C8 90.31(17)   C20 C21 C22 91.7(2) 
C7 C8 C5 89.99(18)   C21 C22 C19 88.7(2) 
C10 C9 C4 59.90(13)   C24 C23 C18 59.54(15) 
C9 C10 C4 60.48(14)   C18 C24 C23 60.74(15) 
C12 C11 C3 120.95(19)   C26 C25 C17 121.29(19) 
C11 C12 C13      120.5(2)   C25 C26 C27 120.4(2) 
C14 C13 C12 119.26(19)   C28 C27 C26 118.9(2) 
C13 C14 C2 120.72(18)   C27 C28 C16 120.77(18) 
  




[1] a) J.-R. Pouliot, F. Grenier, J. T. Blaskovits, S. Beaupre, M. Leclerc, Chem. 
Rev. 2016, 116, 14225–14274; b) A. Paun, N. D. Hadade, C. C. 
Paraschivescua, M. Matache, Mater. Chem. C 2016, 4, 8596–8610; c) D. J. 
Schipper, K. Fagnou, Chem. Mater. 2011, 23, 1594–1600; d) V. Maman, Mini-
Reviews in Organic Chemistry 2008, 5, 303–312.  
[2] a) S. J. Kalita, F. Cheng, Y.‐Y. Huang, Adv. Synth. Catal. 2020, 362, 2778–
2800; b) E. R. Welin, A. Ngamnithiporn, M. Klatte, G. Lapointe, G. M. 
Pototschnig, M. S. J. McDermott, D. Conklin, C. D. Gilmore, P. M. Tadross, C. 
K. Haley, K. Negoro, E. Glibstrup, C. U. Grünanger, K. M. Allan, S. C. Virgil, D. 
J. Slamon, B. M. Stoltz, Science 2019, 363, 270–275; c) R. Rossi, F. Bellina, 
M. Lessi, C. Manzini, G. Marianetti, L. A. Perego, Curr. Org. Chem. 2015, 19, 
1302–1409; d) J. Yamaguchi, A. D. Yamaguchi, K. Itami, Angew. Chem. Int. 
Ed. 2012, 51, 8960–9009: e) K. C. Nicolaou, C. R. H. Hale, C. Nilewski, H. A. 
Ioannidou, Chem. Soc. Rev. 2012, 41, 5185–5238. 
[3] a) S. D. Friis, M. J. Johansson, L. Ackermann, Nat. Chem. 2020, 12, 511–519; 
b) T. Cernak, K. D. Dykstra, S. Tyagarajan, P. Vachal, S. W. Krska, Chem. Soc. 
Rev. 2016, 45, 546–576; c) M. Seki, Org. Process Res. Dev. 2016, 20, 867–
877; d) L. Ackermann, Org. Process Res. Dev. 2015, 19, 260–269. 
[4] a) P. Ruiz-Castillo, S. L. Buchwald, Chem. Rev. 2016, 116, 12564–12649; b) 
A. V. Bhatia, H. J. Federsel, Q. Chen, Org. Process Res. Dev. 2014, 18, 179–
179; c) N. Miyaura, A. Suzuki, Chem. Rev. 1995, 95, 2457–2483; d) J.-P. 
Corbet, G. Mignani, Chem. Rev. 2006, 106, 2651–2710. 
[5] a) A. Biffis, P. Centomo, A. D. Zotto, M. Zecca, Chem. Rev. 2018, 118, 2249–
229; b) C. C. C. J. Seechurn, M. O. Kitching, T. J. Colacot, V. Snieckus, Angew. 
Chem. Int. Ed. 2012, 51, 5062–5085. 
                     6. References 
187 
 
[6] a) P. T. Anastas, M. M. Kirchhoff, Acc. Chem. Res. 2002, 35, 686–694; b) P. 
T. Anastas, J. C. Warner, Green chemistry: theory and practice, Oxford 
University Press, Oxford, 1998. 
[7] a) X. Zhang, M. Fevre, G. O. Jones, R. M. Waymouth, Chem. Rev. 2018, 118, 
839–885; b) F. E. Celik, B. Peters, M.-O. Coppens, A. McCormick, R. F. Hicks, 
J. Ekerdt, ACS Catal. 2017, 7, 8628–8640. 
[8]  a) L. Ackermann, R. Vicente, A. R. Kapdi, Angew. Chem. Int. Ed. 2009, 48, 
9792–9826; b) R. G. Bergman, Nature 2007, 446, 391–393. 
[9] a) S. Rej, Y. Ano, N. Chatani, Chem. Rev. 2020, 120, 1788–1887; b) S. Rej, N. 
Chatani, Angew. Chem. Int. Ed. 2019, 58, 8304–8329; c) J. Kalepu, P. 
Gandeepan, L. Ackermann, L. Pilarski, Chem. Sci. 2018, 9, 4203–4216; d) J. 
He, M. Wasa, K. S. L. Chan, Q. Shao, J.-Q. Yu, Chem. Rev. 2017, 117, 8754–
8786; e) P. H. Dixneuf, H. Doucet, C–H Bond Activation and Catalytic 
Functionalization I, Springer, Cham, 2016; f) J. F. Hartwig, M. A. Larsen, ACS 
Cent. Sci. 2016, 2, 281–292; g) O. Daugulis, J. Roane, L. D. Tran, Acc. Chem. 
Res. 2015, 48, 1053–1064; h) A. D. Giuseppe, R. Castarlenas, L. A. Oroac, C. 
R. Chimie 2015, 18, 713–741; i) G. Rouquet, N. Chatani, Angew. Chem. Int. 
Ed. 2013, 52, 11726–11743; j) S. R. Neufeldt, M. S. Sanford, Acc. Chem. Res. 
2012, 45, 936–946; k) L. McMurray, F. O'Hara, M. J. Gaunt, Chem. Soc. Rev. 
2011, 40, 1885–1898; l) T. W. Lyons, M. S. Sanford, Chem. Rev. 2010, 110, 
1147–1169; m) O. Daugulis, H.-Q. Do, D. Shabashov, Acc. Chem. Res. 2009, 
42, 1074–1086.  
[10] a) R. A. Periana, G. Bhalla, W. J. Tenn III, K. J. H. Young, X. Y. Liu, O. Mironov, 
C. Jones, V. R. Ziatdinov, J. Mol. Catal. A: Chem. 2004, 220, 7–25; b) A. S. 
Goldman, K. I. Goldberg, ACS Symposium Series 885, Activation and 
Functionalization of C–H Bonds, 2004, 1–43; c) B. A. Arndtsen, R. G. Bergman, 
T. A. Mobley, T. H. Peterson, Acc. Chem. Res. 1995, 28, 154–162. 
                     6. References 
188 
 
[11] a) The Nobel prize in Chemistry 2010 – Press Release 
https://www.nobelprize.org/nobel_prizes/chemistry/laureates/2010/press.html 
(accessed on 18.08.2020); b) A. Suzuki, Angew. Chem. Int. Ed. 2011, 50, 
6722–6737; c) E.-i. Negishi, Angew. Chem. Int. Ed. 2011, 50, 6738–6764. 
[12] S. J. Blanksby, G. B. Ellison, Acc. Chem. Res. 2003, 36, 255–263. 
[13] a) L. N. Lewis, J. F. Smith, J. Am. Chem. Soc. 1986, 108, 2728–2735; b) P. 
Hong, B.-R. Cho, H. Yamazaki, Chem. Lett. 1979, 50, 339–342. 
[14] a) H. M. L. Davies, D. Morton, ACS Cent. Sci. 2017, 3, 936–943; b) J. R. 
Hummel, J. A. Boerth, J. A. Ellman, Chem. Rev. 2017, 117, 9163–9227; c) T. 
Gensch, M. N. Hopkinson, F. Glorius, Chem. Soc. Rev. 2016, 45, 2900–2936; 
d) P. Gandeepan, C.-H. Cheng, Chem. Asian J. 2015, 10, 824–838. 
[15] I. V. Seregin, V. Gevorgyan, Chem. Soc. Rev. 2007, 36, 1173–1193. 
[16] N. Kuhl, M. N. Hopkinson, J. Wencel-Delord, F. Glorius, Angew. Chem. Int. Ed. 
2012, 51, 10236–10254. 
[17] a) C. Sambiagio, D. Schönbauer, R. Blieck, T. Dao-Huy, G. Pototschnig, P. 
Schaaf, T. Wiesinger, M. F. Zia, J. Wencel-Delord, T. Besset, B. U. W. Maes, 
M. Schnürch, Chem. Soc. Rev. 2018, 47, 6603–6743; b) Y. Kuninobu, H. Ida, 
M. Nishi, M. Kanai, Nat. Chem. 2015, 7, 712–717; c) F. Zhang, D. R. Spring, 
Chem. Soc. Rev. 2014, 43, 6906–6919; d) L. Ackermann, Top. Organomet. 
Chem. 2007, 24, 35–60. 
[18] S. D. Sarkar, W. Liu, S. I. Kozhushkov, L. Ackermann, Adv. Synth. Catal. 2014, 
356, 1461–1479. 
[19] W. Ma, P. Gandeepan, J. Li, L. Ackermann, Org. Chem. Front. 2017, 4, 1435–
1467. 
[20] P. Gandeepan, L. Ackermann, Chem 2018, 4, 199–222. 
[21] a) L. Ackermann, Chem. Rev. 2011, 111, 1315–1345; b) D. Balcells, E. Clot, 
O. Eisenstein, Chem. Rev. 2010, 110, 749–823. 
                     6. References 
189 
 
[22] D. Lapointe, K. Fagnou, Chem. Lett. 2010, 39, 1118–1126. 
[23] a) Y. Boutadla, D. L. Davies, S. A. Macgregor, A. I. Poblador-Bahamonde, 
Dalton Trans. 2009, 5887–5893; b) Y. Boutadla, D. L. Davies, S. A. Macgregor, 
A. I. Poblador-Bahamonde, Dalton Trans. 2009, 5820–5831. 
[24] a) K. Naksomboon, J. Poater, F. M. Bickelhaupt, M. A. Fernandez-Ibanez, J. 
Am. Chem. Soc. 2019, 141, 6719–6725; b) E. Tan, O. Quinonero, M. E. de 
Orbe, A. M. Echavarren, ACS Catal. 2018, 8, 2166–2172; c) Y.-F. Liang, V. 
Müller, W. Liu, A. Münch, D. Stalke, L. Ackermann, Angew. Chem. Int. Ed. 
2017, 56, 9415–9419; d) D. Zell, M. Bursch, V. Müller, S. Grimme, L. 
Ackermann, Angew. Chem. Int. Ed. 2017, 56, 10378–10382; e) H. Wang, M. 
Moselage, M. J. González, L. Ackermann, ACS Catal. 2016, 6, 2705–2709; f) 
D. Santrač, S. Cella, W. Wang, L. Ackermann, Eur. J. Org. Chem. 2016, 5429–
5436; g) R. Mei, J. Loup, L. Ackermann, ACS Catal. 2016, 6, 793–797; h) W. 
Ma, R. Mei, G. Tenti, L. Ackermann, Chem. Eur. J. 2014, 20, 15248–15251. 
[25] J. Oxgaard, W. J. Tenn, R. J. Nielsen, R. A. Periana, W. A. Goddard, 
Organometallics 2007, 26, 1565–1567. 
[26] L. Wang, B. P. Carrow, ACS Catal. 2019, 9, 6821–6836. 
[27] a) http://www.infomine.com/investment/metal-prices/; b) 
https://mineralprices.com/. 
[28] J. W. Morgan, E. Anders, Proc. Natl. Acad. Sci. USA 1980, 77, 6973–6977. 
[29] a) P. B. Tchounwou, C. G. Yedjou, A. K. Patlolla, D. J. Sutton, in Molecular, 
clinical, and environmental toxicology (Ed.: A. Luch), Springer, Basel, 2009, 
133–164; b) S. H. Gilani, Y. Alibhai, J. Toxicol. Environ. Health 1990, 30, 23–
31. 
[30] a) P. Gandeepan, T. Müller, D. Zell, G. Cera, S. Warratz, L. Ackermann, Chem. 
Rev. 2019, 119, 2192–2452; b) L. Ackermann, T. B. Gunnoe, L. G. Habgood, 
Catalytic Hydroarylation of Carbon-Carbon Multiple Bonds, Wiley‐VCH: 
                     6. References 
190 
 
Weinheim, 2018; c) Y. Hu, B. Zhou, C. Wang, Acc. Chem. Res. 2018, 51, 816–
827; d) Y. Kommagalla, N. Chatani, Coord. Chem. Rev. 2017, 350, 117–135; 
e) M. Moselage, J. Li, L. Ackermann, ACS Catal. 2016, 6, 498–525; f) J. 
Yamaguchi, K. Muto, K. Itami, Top. Curr. Chem. 2016, 374, 157–189; g) L. C. 
M. Castro, N. Chatani, Chem. Lett. 2015, 44, 410–421; h) E. P. Jackson, H. A. 
Malik, G. J. Sormunen, R. D. Baxter, P. Liu, H. Wang, A.-R. Shareef, J. 
Montgomery, Acc. Chem. Res. 2015, 48, 1736–1745; i) K. Gao, N. Yoshikai, 
Acc. Chem. Res. 2014, 47, 1208–1219; j) A. A. Kulkarni, O. Daugulis, 
Synthesis 2009, (24), 4087–4109. 
[31] a) R. Shang, L. Ilies, E. Nakamura, Chem. Rev. 2017, 117, 9086–9139; b) G. 
Cera, L. Ackermann, Top. Curr. Chem. 2016, 374, 191–224. 
[32] K. S. Egorova, V. P. Ananikov, Angew. Chem. Int. Ed. 2016, 55, 12150–12162. 
[33] a) E. Bisz, M. Szostak, ChemSusChem 2017, 10, 3964–3981; b) A. Fürstner, 
ACS Cent. Sci. 2016, 2, 778–789; c) I. Bauer, H.-J. Knölker, Chem. Rev. 2015, 
115, 3170–3387; d) K. Schröder, K. Junge, B. Bitterlich, M. Beller, Top. 
Organomet. Chem. 2011, 33, 83–109; e) C.-L. Sun, B.-J. Li, Z.-J. Shi, Chem. 
Rev. 2011, 111, 1293–1314; f) A. A. O. Sarhan, C. Bolm, Chem. Soc. Rev. 
2009, 38, 2730–2744; g) S. Enthaler, K. Junge, M. Beller, Angew. Chem. Int. 
Ed. 2008, 47, 3317–3321; h) A. Correa, O. G. Mancheno, C. Bolm, Chem. Soc. 
Rev. 2008, 37, 1108–1117; i) C. Bolm, J. Legros, J. L. Paih, L. Zani, Chem. 
Rev. 2004, 104, 6217–6254. 
[34] a) E. McNeill, T. Ritter, Acc. Chem. Res. 2015, 48, 2330–2343; b) A. Fürstner, 
R. Martin, K. Majima, J. Am. Chem. Soc. 2005, 127, 12236–12237. 
[35] A. Guðmundsson, J.-E. Bäckvall, Molecules 2020, 25, 1349. 
[36] E. Nakamura, N. Yoshikai, J. Org. Chem. 2010, 75, 6061–6067. 
[37] G. Hata, H. Kondo, A. Miyake, J. Am. Chem. Soc. 1968, 90, 2278–2281. 
                     6. References 
191 
 
[38] a) M. V. Baker, L. D. Field, J. Am. Chem. Soc. 1987, 109, 2825–2826; b) J. W. 
Rathke, E. L. Muetterties, J. Am. Chem. Soc. 1975, 97, 3272–3273; c) H. H. 
Karsch, H.-F. Klein, H. Schmidbaur, Angew. Chem. Int. Ed. 1975, 14, 637–638. 
[39] a) S. Camadanli, R. Beck, U. Flörke, H.-F. Klein, Organometallics 2009, 28, 
2300–2310; b) H.-F. Klein, S. Camadanli, R. Beck, D. Leukel, U. Flörke, 
Angew. Chem. Int. Ed. 2005, 44, 975–977. 
[40] W. D. Jones, G. P. Foster, J. M. Putinas, J. Am. Chem. Soc. 1987, 109, 5047–
5048. 
[41]  E. Nakamura, Two stories of iron - 
https://chemistrycommunity.nature.com/posts/46018-two-stories-of-iron 
(consulted on 17.09.2020). 
[42] J. Norinder, A. Matsumoto, N. Yoshikai, E. Nakamura, J. Am. Chem. Soc. 2008, 
130, 5858–5859.  
[43] a) W. Xu, N. Yoshikai, ChemSusChem 2019, 12, 3049–3053; b) R. Shang, L. 
Ilies, E. Nakamura, J. Am. Chem. Soc. 2016, 138, 10132–10135; c) J. J. Sirois, 
R. Davis, B. DeBoef, Org. Lett. 2014, 16, 868–871; d) S. Asako, J. Norinder, L. 
Ilies, N. Yoshikai, E. Nakamura, Adv. Synth. Catal. 2014, 356, 1481–1485; e) 
L. Ilies, M. Kobayashi, A. Matsumoto, N. Yoshikai, E. Nakamura, Adv. Synth. 
Catal. 2012, 354, 593–596; f) L. Ilies, E. Konno, Q. Chen, E. Nakamura, Asian 
J. Org. Chem. 2012, 1, 142–145; g) L. Ilies, S. Asako, E. Nakamura, J. Am. 
Chem. Soc. 2011, 133, 7672–7675; h) N. Yoshikai, S. Asako, T. Yamakawa, 
L. Ilies, E. Nakamura, Chem. Asian J. 2011, 6, 3059–3065; i) N. Yoshikai, A. 
Matsumoto, J. Norinder, E. Nakamura, Synlett 2010, (2), 313–316; j) N. 
Yoshikai, A. Matsumoto, J. Norinder, E. Nakamura, Angew. Chem. Int. Ed. 
2009, 48, 2925–2928.  
[44] R. Shang, L. Ilies, A. Matsumoto, E. Nakamura, J. Am. Chem. Soc. 2013, 135, 
6030–6032. 
                     6. References 
192 
 
[45] Q. Gu, H. H. A. Mamari, K. Graczyk, E. Diers, L. Ackermann, Angew. Chem. 
Int. Ed. 2014, 53, 3868–3871. 
[46] C. Zhu, M. Stangier, J. C. A. Oliveira, L. Massignan, L. Ackermann, Chem. Eur. 
J. 2019, 25, 16382–16389. 
[47] R. Shang, L. Ilies, S. Asako, E. Nakamura, J. Am. Chem. Soc. 2014, 136, 
14349–14352. 
[48] L. lies, S. Ichikawa, S. Asako, T. Matsubara, E. Nakamura, Adv. Synth. Catal. 
2015, 357, 2175–2179. 
[49] R. Shang, L. Ilies, E. Nakamura, J. Am. Chem. Soc. 2015, 137, 7660–7663. 
[50] a) Z. Shen, G. Cera, T. Haven, L. Ackermann, Org. Lett. 2017, 19, 3795–3798; 
b) K. Graczyk, T. Haven, L. Ackermann, Chem. Eur. J. 2015, 21, 8812–8815. 
[51] a) G. Cera, T. Haven, L. Ackermann, Angew. Chem. Int. Ed. 2016, 55, 1484–
1488; b) E. R. Fruchey, B. M. Monks, S. P. Cook, J. Am. Chem. Soc. 2014, 
136, 13130–13133; c) L. Ilies, T. Matsubara, S. Ichikawa, S. Asako, E. 
Nakamura, J. Am. Chem. Soc. 2014, 136, 13126–13129; d) B. M. Monks, E. 
R. Fruchey, S. P. Cook, Angew. Chem. Int. Ed. 2014, 53, 11065–11069. 
[52] S. Asako, L. Ilies, E. Nakamura, J. Am. Chem. Soc. 2013, 135, 17755–17757. 
[53] G. Cera, T. Haven, L. Ackermann, Chem. Eur. J. 2017, 23, 3577–3582. 
[54] a) B. Plietker, A. Dieskau, K. Möws, A. Jatsch, Angew. Chem. Int. Ed. 2007, 
47, 198–201; b) B. Plietker, Angew. Chem. Int. Ed. 2006, 45, 1469–1473. 
[55] S. Ito, Y. Fujiwara, E. Nakamura, M. Nakamura, Org. Lett. 2009, 11, 4306–
4309. 
[56] a) M. D. Greenhalgh, A. S. Jones, S. P. Thomas, ChemCatChem 2015, 7, 190–
222; b) B. D. Sherry, A. Fürstner, Acc. Chem. Res. 2008, 41, 1500–1511. 
[57] A. Matsumoto, L. Ilies, E. Nakamura, J. Am. Chem. Soc. 2011, 133, 6557–
6559. 
                     6. References 
193 
 
[58] L. Ilies, A. Matsumoto, M. Kobayashi, N. Yoshikai, E. Nakamura, Synlett 2012, 
23, 2381–2384. 
[59] L. Adak, N. Yoshikai, Tetrahedron 2012, 68, 5167–5171. 
[60] T. Matsubara, L. Ilies, E. Nakamura, Chem. Asian J. 2016, 11, 380–384. 
[61] G. Cera, T. Haven, L. Ackermann, Chem. Commun. 2017, 53, 6460–6463. 
[62] M. M. Bagga, P. L. Pauson, F. J. Preston, R. I. Reed, Chem. Commun. 1965, 
543–544. 
[63] T. Jia, C. Zhao, R. He, H. Chen, C. Wang, Angew. Chem. Int. Ed. 2016, 55, 
5268–5271. 
[64]  a) S. Yu, S. Ma, Angew. Chem. Int. Ed. 2012, 51, 3074–3112; b) P. Rivera-
Fuentes, F. Diederich, Angew. Chem. Int. Ed. 2012, 51, 2818–2828. 
[65] J. Ye, S. Ma, Acc. Chem. Res. 2014, 47, 989–1000. 
[66] a) A. Ahlers, T. de Haro, B. Gabor, A. Fürstner, Angew. Chem. Int. Ed. 2016, 
55, 1406–1411; b) P. Rivera-Fuentes, F. Diederich, Angew. Chem. Int. Ed. 
2012, 51, 2818–2828. 
[67] a) Z. Dong, Z. Ren, S. J. Thompson, Y. Xu, G. Dong, Chem. Rev. 2017, 117, 
9333–9403; b) G. E. M. Crisenza, J. F. Bower, Chem. Lett. 2016, 45, 2–9; c) 
S. Pan, T. Shibata, ACS Catal. 2013, 3, 704–712; d) D. A. Colby, R. G. 
Bergman, J. A. Ellman, Chem. Rev. 2010, 110, 624–655. 
[68] a) Z.-J. Jia, C. Merten, R. Gontla, C. G. Daniliuc, A. P. Antonchick, H. 
Waldmann, Angew. Chem. Int. Ed. 2017, 56, 2429–2434; b) S. Nakanowatari, 
L. Ackermann, Chem. Eur. J. 2015, 21, 16246–16251; c) X.-F. Xia, Y.-Q. Wang, 
L.-L. Zhang, X.-R. Song, X.-Y. Liu, Y.-M. Liang, Chem. Eur. J. 2014, 20, 5087–
5091; d) B. Ye, N. Cramer, J. Am. Chem. Soc. 2013, 135, 636–639; e) R. Zeng, 
J. Ye, C. Fu, S. Ma, Adv. Synth. Catal. 2013, 355, 1963–1970; f) R. Zeng, C. 
Fu, S. Ma, J. Am. Chem. Soc. 2012, 134, 9597–9600; g) Y. J. Zhang, E. 
Skucas, M. J. Krische, Org. Lett. 2009, 11, 4248–4250. 
                     6. References 
194 
 
[69] a) A. Brandi, S. Cicchi, F. M. Cordero, A. Goti, Chem. Rev. 2014, 114, 7317–
7420; b) H. Pellissier, Tetrahedron 2010, 66, 8341–8375; c) A. Goti, M. F. 
Cordero, A. Brandi, Top. Curr. Chem. 2005, 178, 1–97; d) A. Brandi, S. Cicchi, 
F. M. Cordero, A. Goti, Chem. Rev. 2003, 103, 1213–1270; e) A. de Meijere, 
S. I. Kozhushkov, Eur. J. Org. Chem. 2000, 3809–3822; f) A. de Meijere, S. I. 
Kozhushkov, A. F. Khlebnikov, Top. Curr. Chem. 2000, 207, 89–147; g) A. de 
Meijere, S. I. Kozhushkov, A. F. Khlebnikov, Russ. J. Org. Chem. 1996, 32, 
1555–1575. 
[70] a) M. Schinkel, J. Wallbaum, S. I. Kozhushkov, I. Marek, L. Ackermann, Org. 
Lett. 2013, 15, 4482–4484; b) L. Ackermann, S. I. Kozhushkov, D. S. Yufit, Eur. 
J. Org. Chem. 2012, 12068–12077; c) S. I. Kozhushkov, D. S. Yufit, L. 
Ackermann, Org. Lett. 2008, 10, 3409–3412. 
[71] a) Y. Cohen, A. Cohen, I. Marek, Chem. Rev. 2020, doi: 
10.1021/acs.chemrev.0c00167; b) P. H. Chen, B. A. Billett, T. Tsukamoto, G. 
Dong, ACS Catal. 2017, 7, 1340–1360; c) D. S. Kim, W. J. Park, C. H. Jun, 
Chem. Rev. 2017, 117, 8977–9015; d) L. Souillart, N. Cramer, Chem. Rev. 
2015, 115, 9410–9464; e) T. Xu, A. Dermenci, G. Dong, Top. Curr. Chem. 
2014, 346, 233–257; f) K. Ruhland, Eur. J. Org. Chem. 2012, 2683–2706; g) 
M. Murakami, T. Matsuda, Chem. Commun. 2011, 47, 1100–1105. 
[72] M. Murakami, Y. Ito, Top. Organomet. Chem. 1999, 3, 97–127. 
[73] Z. Nairoukh, M. Cormier, I. Marek, Nat. Rev. Chem. 2017, 1, 0035. 
[74] a) K. Korvorapun, M. Moselage, J. Struwe, T. Rogge, A. M. Messinis, L. 
Ackermann, Angew. Chem. Int. Ed. 2020, doi: 10.1002/anie.202007144; b) N. 
Y. P. Kumar, T. Rogge, S. R. Yetra, A. Bechtoldt, E. Clot, L. Ackermann, Chem. 
Eur. J. 2017, 23, 17449–17453; c) N. Y. P. Kumar; A. Bechtoldt, K. 
Raghuvanshi, L. Ackermann, Angew. Chem. Int. Ed. 2016, 55, 6929–6932; d) 
M. P. Drapeau, L. J. Gooßen, Chem. Eur. J. 2016, 22, 18654–18677; e) X.-Y. 
Shi, X.-F. Dong, J. Fan, K.-Y. Liu, L.-F. Wei, C.-J. Li, Sci. China Chem. 2015, 
                     6. References 
195 
 
58, 1286–1292; f) X.-Y. Shi, K.-Y. Liu, J. Fan, X.-F. Dong, J.-F. Wei, C.-J. Li, 
Chem. Eur. J. 2014, 20, 1–5; g) W. I. Dzik, P. P. Lange, L. J. Gooßen, Chem. 
Sci. 2012, 3, 2671–2678; h) J. Cornella, M. Righi, I. Larrosa, Angew. Chem. 
Int. Ed. 2011, 50, 9429–9432; i) L. J. Gooßen, N. Rodriguez, K. Gooßen, 
Angew. Chem. Int. Ed. 2008, 47, 3100–3120. 
[75] a) A. Dermenci, G. Dong, Sci. China Chem. 2013, 56, 685–701; b) Q. Shuai, 
L. Yang, X. Guo, O. Baslé, C.-J. Li, J. Am. Chem. Soc. 2010, 132, 12212–
12213; c) X. Guo, J. Wang, C.-J. Li, J. Am. Chem. Soc. 2009, 131, 15092–
15093; d) P. Fristrup, M. Kreis, A. Palmelund, P.-O. Norrby, R. Madsen, J. Am. 
Chem. Soc. 2008, 130, 5206–5215; e) J. Tsuji, K. Ohno, Tetrahedron Lett. 
1965, 44, 3969–3971; f) H. E. Eschinazi, H. Pines, J. Org. Chem. 1959, 24, 
1369–1369. 
[76] a) C. L. Ladd, D. S. Roman, A. B. Charette,Tetrahedron 2013, 69, 4479–4487; 
b) D. A. Colby, A. S. Tsai, R. G. Bergman, A. J. Ellman, Acc. Chem. Res. 2012, 
45, 814–825; c) S. Rousseaux, B. Liégault, K. Fagnou, Chem. Sci. 2012, 3, 
244–248. 
[77] R. D. Bach, O. Dmitrenko, J. Am. Chem. Soc. 2004, 126, 4444–4452. 
[78] a) G. Fumagalli, S. Stanton, J. F. Bower, Chem. Rev. 2017, 117, 9404–9432; 
b) I. Marek, A. Masarwa, P. O. Delaye, M. Leibeling, Angew. Chem. Int. Ed. 
2015, 54, 414–429. 
[79] a) R. A. Periana, R. G. Bergman, J. Am. Chem. Soc. 1986, 108, 7346–7355; 
b) R. A. Periana, R. G. Bergman, J. Am. Chem. Soc. 1984, 106, 7272–7273. 
[80]  a) X. Zhou, S. Yu, L. Kong, X. Li, ACS Catal. 2016, 6, 647–651; b) X. Zhou, S. 
Yu, Z. Qi, L. Kong, X. Li, J. Org. Chem. 2016, 81, 4869–4875; c) A. Masarwa, 
M. Weber, R. Sarpong, J. Am. Chem. Soc. 2015, 137, 6327–6334; d) T. 
Matsuda, I. Yuihara, Chem. Commun. 2015, 51, 7393–7396; e) A. Vasseur, P. 
Perrin, O. Eisenstein, I. Marek, Chem. Sci. 2015, 6, 2770–2776; f) A. Masarwa, 
D. Didier, T. Zabrodski, M. Schinkel, L. Ackermann, I. Marek, Nature 2014, 505, 
                     6. References 
196 
 
199–203; g) D. Rosa, A. Orellana, Chem. Commun. 2012, 48, 1922–1924; h) 
Z. Chai, T. J. Rainey, J. Am. Chem. Soc. 2012, 134, 3615–3618; i) D. Crépin, 
J. Dawick, C. Aïssa, Angew. Chem. Int. Ed. 2010, 49, 620–623; j) T. Seiser, O. 
A. Roth, N. Cramer, Angew. Chem. Int. Ed. 2009, 48, 6320–6323; k) M. 
Shigeno, T. Yamamoto, M. Murakami, Chem. Eur. J. 2009, 15, 12929–12931; 
l) C. Aïssa, A. Fürstner, J. Am. Chem. Soc. 2007, 129, 14836–14837; m) T. 
Matsuda, M. Shigeno, M. Murakami, J. Am. Chem. Soc. 2007, 129, 12086–
12087. 
[81] A. D. Aloise, M. E. Layton, M. D. Shair, J. Am. Chem. Soc. 2000, 122, 12610–
12611. 
[82] A. Schweinitz, A. Chtchemelinine, A. Orellana, Org. Lett. 2011, 13, 232–235. 
[83] a) Q. Li, X. Yuan, B. Li, B. Wang, Chem. Commun. 2020, 56, 1835–1838; b) 
Q. Wang, L. Shi, S. Liu, C. Zhi, L.-R. Fu, X.-Q. Hao, M.-P. Song, RSC Adv. 
2020, 10, 10883–10887; c) Q. Wang, C.-L. Zhi, P.-P. Lu, S. Liu, X. Zhu, X. Q. 
Hao, M.-P. Song, Adv. Synth. Catal. 2019, 361, 1253–1258; d) Z. Hu, X.-Q. 
Hu, G. Zhang, L. J. Gooßen, Org. Lett. 2019, 21, 6770–6773; e) Y.-Q. Zhu, Y.-
X. Niu, L.-W. Hui, J.-L. He, K. Zhu, Adv. Synth. Catal. 2019, 361, 2897–2903; 
f) J.-Q. Wu, Z.-P. Qiu, S.-S. Zhang, J.-G. Liu, Y.-X. Lao, L.-Q. Gu, Z.-S. Huang, 
J. Li, H. Wang, Chem. Commun. 2015, 51, 77–80; g) J.-Q. Wu, Z.-P. Qiu, S.-
S. Zhang, J.-G. Liu, Y.-X. Lao, L.-Q. Gu, Z.-S. Huang, J. Li, H. Wang, Chem. 
Commun. 2015, 51, 77–80. 
[84] S. Cui, Y. Zhang, Q. Wu, Chem. Sci. 2013, 4, 3421–3426. 
[85] a) M. Li, F. Y. Kwong, Angew. Chem. Int. Ed. 2018, 57, 6512–6515; b) Q. Lu, 
F. J. R. Klauck, F. Glorius, Chem. Sci. 2017, 8, 3379–3383; c) T. H. Meyer, W. 
Liu, M. Feldt, A. Wuttke, R. A. Mata, L. Ackermann, Chem. Eur. J. 2017, 23, 
5443–5447; d) D. Zell, Q. Bu, M. Feldt, L. Ackermann, Angew. Chem. Int. Ed. 
2016, 55, 7408–7412. 
                     6. References 
197 
 
[86] a) S. Guo, D. I. AbuSalim, S. P. Cook, J. Am. Chem. Soc. 2018, 140, 12378–
12382; b) N. Yoshikai, Isr. J. Chem. 2017, 57, 1117–1130; c) R. P. Yu, D. Hesk, 
N. Rivera, I. Pelczer, P. J. Chirik, Nature 2016, 529, 195–199; d) T. J. Osberger, 
D. C. Rogness, J. T. Kohrt, A. F. Stepan, M. C. White, Nature 2016, 537, 214–
219; e) C. Bornschein, S. Werkmeister, B. Wendt, H. Jiao, E. Alberico, W. 
Baumann, H. Junge, K. Junge, M. Beller, Nat. Commun. 2014, 5, 4111; f) R. V. 
Jagadeesh, A.-E. Surkus, H. Junge, M.-M. Pohl, J. Radnik, J. Rabeah, H. 
Huan, V. Schuenemann, A. Brueckner, M. Beller, Science 2013, 342, 1073–
1076. 
[87] P. Gandeepan, N. Kaplaneris, S. Santoro, L. Vaccaro, L. Ackermann, ACS 
Sustainable Chem. Eng. 2019, 7, 8023–8040. 
[88] a) S. Tang, O. Eisenstein, Y. Nakao, S. Sakaki, Organometallics 2017, 36, 
2761–2771; b) O. Eisenstein, J. Milani, R. N. Perutz, Chem. Rev. 2017, 117, 
8710–8753; c) J. Loup, D. Zell, J. C. A. Oliveira, H. Keil, D. Stalke, L. 
Ackermann, Angew. Chem. Int. Ed. 2017, 56, 14197–14201. 
[89] J. Mo, T. Müller, J. C. A. Oliveira, L. Ackermann, Angew. Chem. Int. Ed. 2018, 
57, 7719–7723. 
[90] a) P. Gütlich, E. Bill, A. X. Trautwein, Mössbauer Spectroscopy and Transition 
Metal Chemistry, Springer, Heidelberg, 2011; b) P. Gütlich, Z. Anorg. Allg. 
Chem. 2012, 638, 15–43. 
[91] S. B. Munoz III, S. L. Daifuku, W. W. Brennessel, M. L. Neidig, J. Am. Chem. 
Soc. 2016, 138, 7492–7495. 
[92] a) M. Callingham, B. M. Partridge, W. Lewis, H. W. Lam, Angew. Chem. Int. 
Ed. 2017, 56, 16352–16356; b) B. M. Partridge, M. Callingham, W. Lewis, H. 
W. Lam, Angew. Chem. Int. Ed. 2017, 56, 7227–7232; c) S. E. Korkis, D. J. 
Burns, H. W. Lam, J. Am. Chem. Soc. 2016, 138, 12252–12257; d) D. J. Burns, 
H. W. Lam, Angew. Chem. Int. Ed. 2014, 53, 9931–9935; e) J. Yan, N. 
Yoshikai, Org. Chem. Front. 2017, 4, 1972–1975; f) J. Yan, N. Yoshikai, ACS 
                     6. References 
198 
 
Catal. 2016, 6, 3738–3742; g) B.-H. Tan, J. Dong, N. Yoshikai, Angew. Chem. 
Int. Ed. 2012, 51, 9610–9614; h) B. Zhou, H. Sato, L. Ilies, E. Nakamura, ACS 
Catal. 2018, 8, 8–11. 
[93] J. Mo, T. Müller, J. C. A. Oliveira, S. Demeshko, F. Meyer, L. Ackermann, 
Angew. Chem. Int. Ed. 2019, 58, 12874–12878. 
[94] T. E. Boddie, S. H. Carpenter, T. M. Baker, J. C. DeMuth, G. Cera, W. W. 
Brennessel, L. Ackermann, M. L. Neidig, J. Am. Chem. Soc. 2019, 141, 12338–
12345. 
[95] E. Bill, E. Mfit Program; Max-Planck Institute for Chemical Energy Conversion: 
Mülheim/Ruhr, Germany, 2008. 
[96] a) W. Li, Z. Lin, L. Chen, X. Tian, Y. Wenig, S.-H. Huang, R. Hong, Tetrahedron 
Lett. 2016, 57, 603–606; b) H. Luo, S. Ma, Eur. J. Org. Chem. 2013, 3041–
3048; c) L. Zhang, X. Li, Y. Liu, D. Zhang, Chem. Commun. 2015, 51, 6633–
6636; d) Q. Li, C. Fu, S. Ma, Angew. Chem. Int. Ed. 2012, 51, 11783–11786. 
[97] G. Winter, D. W. Thompson, J. R. Loehe, Inorg. Synth. 2007, 14, 99–104. 
[98] T. Schwier, M. Rubin, V. Gevorgyan, Org. Lett. 2004, 6, 1999–2001. 
[99] T. Kippo, K. Hamaoka, I. Ryu, J. Am. Chem. Soc. 2013, 135, 632–635. 
[100] Anderson H. W. (1972) PhD Thesis, Massachusetts Institute of Technology, 
Cambridge, Massachusetts. 
[101] a) A. de Meijere, S. I. Kozhushkov, T. Späth, Org. Synth. 2002, 78, 142; b) A. 
de Meijere, S. I. Kozhushkov, N. S. Zefirov, Synthesis 1993, (7), 681–683; c) 
K. A. Lukin, S. I. Kozhushkov, A. A. Andrievsky, B. I. Ugrak, N. S. Zefirov, J. 
Org. Chem. 1991, 56, 6176–6179. 
[102] H.-P. Guan, M. B. Ksebati, Y.-C. Cheng, J. C. Drach, E. R. Kern, J. Zemlicka, 
J. Org. Chem. 2000, 65, 1280–1290. 
[103] K. Miyazawa, D. S. Yufit, J. A. K. Howard, A. de Meijere, Eur. J. Org. Chem. 
2000, 4109–4117. 
                     6. References 
199 
 
[104] O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard, H. Puschmann, 
J. Appl. Cryst. 2009, 42, 339–341. 
[105] G. M. Sheldrick, Acta Cryst. 2015, A71, 3–8. 
[106] G. M. Sheldrick, Acta Cryst. 2008, A64, 112–122. 
  




































































































































































































                     NMR Spectra 
234 
 














































































































                     NMR Spectra 
254 
 





                     NMR Spectra 
256 
 














                     NMR Spectra 
260 
 





















































































































































































































Ich versichere, dass ich die vorliegende Dissertation in dem Zeitraum von 
Oktober 2016 bis Oktober 2020 am Institut für Organische und Biomolekulare 
Chemie der Georg-August-Universität Göttingen 
 
auf Anregung und unter Anleitung von 
 
Herrn Prof. Dr. Lutz Ackermann 
 
selbstständig durchgeführt und keine anderen als die angegebenen Hilfsmittel 
und Quellen verwendet habe. 
 
Göttingen, den 05.11.2020 
___________________ 
 
 
 
 
 
 
 
